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ABSTRACT 
In the course of this study it was established that CtlP associates in vivo with, and 
directly binds to, the DNA damage mediator proteins containing BRCT domains: 
53BP1, MDC1, TopBP1 and NBS1. The binding sites on all of these proteins have 
been mapped establishing which regions of CtlP interact directly with 53BP1, MDC1, 
TopBP1 and NBS1 and vice versa. This implies that CtlP is involved in the DNA 
damage response on many levels interacting with proteins that mediate different 
aspects of DNA damage sensing and signalling.  
CtIP's nuclear localization before and after DNA damage was determined and its co-
localization with the other DNA damage responsive proteins examined. It was  found 
that CtIP associates in vivo with  DNA damage sensor proteins such as the MRN 
complex (Mre11, Rad50 and NBS1) and RPA70, signal transducer proteins such as 
the PIKK kinases ATM, ATR and SMG1 and the mediator proteins 53BP1 and MDC1. 
All of those proteins are involved in detecting and repairing double stranded or single 
stranded lesions.  
Moreover CtIP has a major influence on phosphorylation events induced during 
repair processes and thus could be an inducer of kinase activity. The deletion of CtlP 
causes impairment of phosphorylation of important proteins that take part in the 
DNA damage response pathways such as NBS1, ATM, 53BP1, Chk1 and RPA70. 
However,  impaired phosphorylation only occurs in response to single stranded DNA 
lesions or the collapse of replication forks. This implies that it is the ATR pathway 
that is malfunctioning in CtIP depleted cells.  
CtIP was previously reported to be phosphorylated on Ser664 and Ser745 by the 
ATM kinase in response to the DNA double stranded breaks. I have established two 
possible new phosphorylation sites: Ser506 and Ser555. They could be potentially 
involved in CtlP's redistribution to the DNA damage sites but this remains to be 
elucidated.  
 ‘I was a normal duck once, but YOU KNOW, those scientists…’ 
Andrzej Mleczko 
‘Festina lente!’ 
Julius Caesar 
 
‘Everything should be made as simple as possible, but not one bit 
simpler.’  
 
Albert Einstein 
  
‘For myself I am an optimist - it does not seem to be much use 
being anything else.’  
 
Sir Winston Churchill 
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CHAPTER I 
INTRODUCTION 
 
 2 
1.1. The concept of cancer: a historical perspective. 
Cancer is a Latin word meaning a crab, an invertebrate classified in the Cancridae 
family; with the Greek translation καρκινος /karkinos/. The term was first used by 
Hippocrates (460 b.c.–370 b.c.) to describe hard tumours and was proposed by a 
Persian doctor, Ibn Sina aka Avicenna (980–1037), to describe features of mammary 
carcinoma. A picture of a crab published by the French surgeon Ambroise Paré (1516–
1590) in his works has become the symbol of Oncology. 
 
Figure.1.1. Picture of a crab from Ambroise Paré works, that has become the 
symbol of Oncology. 
A new concept of cancer as a disease was proposed in 1865 by a German surgeon Karl 
Thiersch (1822–1895). While working with a German pathologist Heinrichem 
Wilhelmem von Waldeyer-Hartzem (1836–1921) he established that the solid tumour 
consists of two parts: a malignant part which originates from epithelium and the non-
malignant part that originates from connective tissue. The concept of an incipient 
carcinoma (carcinoma incipiens) was established in 1910 by an American pathologist J. 
C. Rubin who used as an example tissue derived from cervical carcinoma. A modern 
definition of preinvasive carcinoma (carcinoma praeinvasivum) was established in 1928 
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by an Austrian-American gynecologist Walter Schiller (1887-1960) as an atypical 
growth without invasion through epithelial basement membrane, using squamous 
cervical carcinoma as an example. The American pathologist Albert Compton-Broders 
(1885–1964), in 1932, used the term ‘carcinoma in situ’ to describe skin cancers and it 
became the most widely used term in medical publications. It is also known by the 
acronym SIL. However in the TNM Classification of Malignant Tumours (TNM) devised 
by Pierre Denoix between 1943 and 1952, using the size and extension of the primary 
tumour, its lymphatic involvement and the presence of metastases to classify the 
progression of cancer, it is described as "pTis". The TNM was further developed by the 
International Union Against Cancer (UICC) to achieve a consensus in describing the 
extent of the tumour spread.  
Cancer is a genetic disease which is characterized by unrestrained proliferation of a 
body’s own cells. In normal circumstances cell division is a strictly controlled process 
that is governed by homeostasis of multiple signalling pathways. Simplistically, in the 
instance of network failure the cell escapes its normal growth and proliferation control 
and becomes cancerous.  
The multi-stage theory of cancer development and progression was first developed by 
Armitage & Doll in 1954 (Armitage & Doll, 1954). Over the years it has been 
established that cancer is a disease that involves dynamic changes in the genome. A 
key finding was the recognition of tumour suppressor genes, with recessive loss of 
function phenotype, and dominant gain of function by mutations in genes described as 
oncogenes (Weinberg, 2006). Proteins involved in the DNA damage response are 
classed as tumour supressors, as the loss of function gives rise to cancerous growth 
such as in the case of the BRCA1 gene in breast cancer (Fearon, 1999). The current 
view considers cancer as a consequence of multiple genetic alterations that accumulate 
before the actual disease arises.  
 
 4 
The process of changing from normal growth into an oncogenic one involves a number 
of cellular changes. The physiology of the cell has to change and the series of events 
have been divided into six groups: self-sufficiency in growth signals, insensitivity to 
antigrowth signals, bypassing apoptosis, unlimited proliferation potential, sustained 
angiogenesis, and tissue invasion leading to metastasis (Figure.1.2.; Hanahan & 
Weinberg, 2000). The set of changes described above can occur in all tumours cells 
although not all the cells have to undergo all of those changes to become carcinogenic. 
Most tumour tissues are heterogenous in nature such that the individual cells of the 
tumour may have slightly different genotypes due to constant mutations in a rapidly 
proliferating population (Heppner, 1984). From this observation a ‘cancer stem cell’ 
model has been derived whereby a ‘cancer stem cell’ possesses an ability to proliferate 
indefinitely. As cancer stem cells and tissue-specific stem cells share common 
properties such as the capability to self-renew and differentiate, it has been 
hypothesised that cancers are caused by mutations that have occurred in tissue-
specific stem cells (Li et al., 2007; Pohl et al., 2008; Reya et al., 2001). This gives rise 
to a population of cells with an ability to metastasise and perform angiogenesis, and 
each generation may possess different genetic qualities (Martinez-Climent , Andreu & 
Prosper, 2006; Pathak, 2002). 
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Figure.1.2. The six changes in cell’s physiology that occur in the process of 
becoming cancerogenic. The set of changes depicted above can occur in all 
tumours cells; however not all the cells have to undergo all of these changes to 
become carcinogenic. (adapted from Hanahan & Weinberg, 2000). 
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1.2. Genetic disorders involving mutations in proteins taking part in the DNA 
damage response. 
Cancer-prone genetic disorders in DNA damage response pathways mainly involve 
proteins that take part in homologous recombination (HR) such as ATM - Ataxia 
telangiectasia (A-T; Shiloh, 1997), NBS1 - Nijmegen breakage syndrome (NBS; Shiloh, 
1997) and BLM – Bloom syndrome (BS; German, 1993). Other proteins involved in HR 
are connected with tumour suppression like BRCA1 or BRCA2 (Venkitaraman, 2002). 
Seckel’s syndrome patients carry a mutation in the ATR gene (Faivre et al., 2002), the 
product of which is involved in DNA single stranded break (SSB) repair. Ataxia 
telangiectasia-like disorder (ATLD; Taylor et al., 2004) patients carry a mutation in the 
Mre11 gene again involved in HR and DNA damage response. In this section I will 
consider some of those disorders in slightly more detail. 
1.2.1. Ataxia telangiectasia (A-T). 
Ataxia telangiectasia (A-T) was first described over 80 years ago by Syllaba & Henner 
(1926). It falls into the category of autosomal recessive cerebellar ataxias and 50 years 
ago was recognized as a clinical entity (Boder & Sedgwick, 1957). Most ATM mutations 
are unique to single families and founder effects are mostly observed in populations of 
Russians, Poles, Norwegians, Turks, Moroccan Jews and Costa Ricans (Lavin, 2008). A-
T patients first show symptoms at the age of 2 years. The disease manifests with 
ataxia of upper and lower limbs and by puberty most patients require a wheelchair for 
mobility. It is also characterised by eye mobility and speech impairment. Patients show 
increased sensitivity to ionizing irradiation and immunodeficiency. In A-T syndrome 
thymic hypoplastia is also recognized as well as telangiectasia of different body parts 
especially bulbar conjunctiva, growth retardation and high serum alfa-fetoprotein (AFP) 
concentrations. Around 15% of UK A-T patients die of leukemia or lymphoma in 
infancy (Taylor & Byrd, 2005).  
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Gatti et al. (1988) mapped the position of ATM (ataxia telangiectasia-mutated) gene to 
chromosome 11q22–23 and in 1995 the ATM gene was sequenced (Savitsky et al., 
1995a & 1995b). It has been reported to stretch for 160kb, to contain 66 exons and to 
be transcribed to give a 13kb mRNA (Uziel et al., 1996). The ATM protein is 350K and 
consists of 3056 amino acids (Figure.1.3.). In humans over 400 mutations have been 
reported and most patients are heterozygotes, inheriting different mutations from each 
parent. Null alleles predominate with around 85% of all mutations affecting splicing or 
creating nonsense mutations that cause premature termination of translation. The 
mutations are distributed over the whole gene and none of them appears with more 
than 3% frequency (Figure.1.3., Chun & Gatti 2004). 
ATM protein is predominantly nuclear but variable amounts of around 10-20% have 
been found in the cytoplasm (Lim et al., 1998; Watters et al., 1999). ATM's major role 
in the nucleus is in DNA damage sensing and repair (Canman et al., 1998). 
Cytoplasmic ATM is localized in the peroxisomes, cellular organelles that contain 
enzymes for oxidative reactions of very-long-chain fatty acids (β-oxidation) and 
enzymes that neutralize toxic peroxides (Watters et al., 1999).  
ATM is also present in the endosomes which perform endocytosis and intracellular 
routing of receptors and other molecules (Lim, 1998; Watters, 1999). ATM also exists 
in a soluble state in the cytoplasm, where it is suggested to phosphorylate 4E-BP1 
protein in a process that is insulin dependent (Yang & Kastan, 2000). 
ATM is a protein serine/threonine kinase that is a member of the PIKK kinase family  
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Figure.1.3. The ATM protein and the distribution of patients’ mutations along 
the protein. Distribution of ATM domains, autophosphorylation sites (P) and 
adenylation site (A). SBS-substrate binding site; LZ-leucine zipper; PR-proline rich 
motif; FAT-FRAP, ATM, TRRAP; kinase-PI3K-related kinase domain; PRD-PIKK 
regulatory domain; FATC-FAT C-terminus. The arrows indicate some of the mutations 
described in A-T patients and their overall distribution along the whole of the protein. 
HEAT (Huntingtin, Elongation factor 3, A subunit of protein phosphatase 2A and 
TOR1)-repeats. Most important ATM interacting proteins are depicted at the sites 
where they bind to ATM. 
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(phosphoinositide 3-kinase (PI3K) – related kinase) and phosphorylates its substrates 
at a SQ/TQ consensus site. A greater degree of specificity has been suggested with 
ATM preferentially phosphorylating LS/TQE motifs (O’Neill et al., 2000). The presence 
of adjacent positively charged residues inhibits phosphorylation (Kim et al., 1999).  
The members of the PIKK family include: ATR (ATM and Rad3-related), DNA-PKcs 
(DNA-dependent protein kinase catalytic subunit), SMG1 (suppressor with 
morfogenetic effect on genitalia 1, also referred to as ATX), mTOR (mammalian target 
of rapamycin) and TRRAP (transformation/transcription domain-associated protein) 
which does not possess kinase activity (Abraham, 2004). As shown in Figure.1.3. the 
N-terminal region of ATM contains an SBS (substrate binding site), between amino 
acids 82 and 89 which was identified as the binding site for the BLM protein (Beamish 
et al., 2002) and amino acid residues 91-97 which has been shown to be responsible 
for interactions with BRCA1 and p53 (Gatei et al., 2000; Khanna et al., 1998; 
Fernandes et al, 2005). Deletion of this region disables ATM’s p53 activation in 
response to bleomycin (Turrene et al., 2001). The N-terminal region of Tel1/ATM has 
also been reported to be involved in the interaction with Xrs2/NBS1 in S. pombe. (You 
et al. 2005). The N-terminal and middle regions of ATM consist of HEAT (Huntingtin, 
Elongation factor 3, A subunit of protein phosphatase 2A and TOR1) repeats, which, as 
a single unit, are a pair of interacting anti-parallel α-helices linked by a flexible “intra-
unit” loop. They account for 63% of the non-kinase-domain residues. The leucine 
zipper and the proline rich motifs are also located in the middle region of the protein. 
The kinase domain is located in the C-terminal region and is flanked by FAT (FRAP, 
ATM, TRRAP) and FATC (FAT C-terminus) domains which are conserved among the 
PIKK family members. The kinase domain accounts for only 5-10% of the protein 
sequence (Perry & Kleckner, 2003). The FATC domain is a small domain consisting of 
~35 aa and is necessary for the kinase activity although the precise function of FAT 
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domain remains to be elucidated. However, as FAT and FATC domains flank the kinase 
domain, it has been suggested that they may be important as structural scaffolds or as 
protein-protein binding motifs (Bosotti et al, 2000; Lovejoy et al., 2009). The C-
terminus of the ATM kinase also contains the PRD region (PIKK regulatory domain) 
which is responsible for interaction with activating proteins which in the case of ATM is 
the MRN complex (Mre11-Rad50-NBS1; Lee & Paull, 2005). ATM possesses an 
acetylation site, K3016, for Tip60 acetylase and mutations that prevent acetylation 
abrogate ATM’s activation (Sun et al., 2007). After DSBs ATM, from an inactive dimer, 
dissociates into monomers and during activation it also undergoes autophosphorylation 
on S1981 (Bakkenist & Kastan, 2003) and S367 together with S1893 (Kozlov et al, 
2006). ATM’s activation is also orchestrated by its interacting proteins PP5 (protein 
serine–threonine phosphatase 5; Ali et al, 2004) and PP2A (protein phosphatase 2A; 
Goodarzi et al., 2004). 
As ATM is a protein kinase its activation after DSB DNA damage leads to a 
phosphorylation casacade. Its downstream targets include p53 (Banin et al., 1998; 
Canman et al., 1998), BRCA1 (Cortez et al., 1999), NBS1 (Lim et al., 2000; Zhao et al., 
2000), Chk2 (Blasina et al., 1999a & 1999b; Matsuoka et al., 2000), SMC1 (Yazdi et al., 
2002; Kim et al., 2002), BLM (Beamish et al., 2002), FANCD2 (Taniguchi et al., 2002), 
Pin2/TRF1 (Kishi et al., 2001), CtIP (Li et al., 2000) and many more, as shown in 
Figure.1.4. The variety of ATM targets indicates that it is involved in initiating many 
cellular processes after DNA double strand breaks, most of which lead to the cell cycle 
check-point response and DNA repair. Over 700 possible ATM and ATR targets have 
been identified, which form an extensively developed network of response to the DNA 
damage (Matsuoka et al., 2007). 
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Figure.1.4. ATM/ATR mediated response to DSBs. This cartoon illustrates the 
variety of ATM/ATR phosphorylation targets during the cell cycle after DNA damage. It 
also illustrates the checkpoint responses initiated by ATM/ATR kinases. Arrows indicate 
stimulation, blunt T-ends indicate inhibition (adapted from Shiloh, 2003). 
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1.2.2. Nijmegen breakage syndrome (NBS). 
Nijmegen breakage syndrome is a rare autosomal recessive genetic disease that is 
classified as a chromosome instability syndrome. It was first described in two young 
Dutch patients by Weemaes C. M. et al., 1981. However, the majority of patients are 
of Polish or Czech origin (Digweed & Sperling, 2004). NBS patients have prominent 
midface, receding foreheads and receding mandibles followed by long noses, large 
ears and freckles on the nose and cheeks. Not all patients are microcephalic at birth 
but the condition increases with age and by a few months all suffer from severe 
microcephaly. The facial features are described as ‘bird-like’, the body build is retarded 
and the patients show mild to moderate mental deficiency. The chromosome structural 
rearrangements preferentially involve chromosome 7 and 14. The patients have serious 
cellular and humoral immune system defects and most of them suffer from reccurring 
infections of the respiratory tract (Chrzanowska et al., 1995). Chromosome instability 
and immunodeficiency possibly predispose the patients to malignancies and there is a 
tendency to develop lymphomas at a young age and, in a few cases, other types of 
cancer. Radiotherapy is not suitable for NBS patients as they show increased sensitivity 
to γ-irradiation (van der Burgt et al., 1996). Initially NBS patients were treated as a 
subclass of A-T patients until 1998, when the gene mutated in this disease was 
recognized and cloned (Varon et al., 1998; Carney et al., 1998; Matsuura et al.,1998).  
Over 90% of all NBS patients share a homozygous truncating mutation of 5bp, referred 
to as 657del5 in the 6th exon (Varon et al., 1998) and the remainder were found to 
have one of seven other mutations (Figure.1.5.). These are much rarer and occur 
between 657 and 1142 nucleotides and cause, as well as the 657del5 mutation, 
truncation of the protein after the first BRCT domain. The N-terminal 26K fragment of 
NBS1 is present in the patients with the 657del5 mutation, as well as the 70K protein, 
which is produced, by alternative initiation of translation, from a new start codon 
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located upstream from the deletion. However this polypeptide appears at much lower 
concentrations and only in EBV-transformed lymphoblastoid cells (Maser et al., 2001). 
The appearance of NBS1 mutated protein may be necessary to rescue otherwise lethal 
phenotype. It has been shown, that knock-out mice die early in embryonic 
development, and heterozygous knock-out mice develop a range of tumours, 
resembling the NBS phenotype. Thus it has been suggested that the presence of 
truncated NBS1 species partially rescues the phenotype, thus preserving the viability of 
the patient (Figure.1.5.; Dumon-Jones et al., 2003; Zhu et al., 2001). 
NBS1, that encodes the Nibrin or p95 protein, is a 50kb gene containing 16 exons and 
was mapped to the chromosome 8q21–24 (Carney et al., 1998; Matsuura et al., 1998; 
Varon et al., 1998). The 95K protein consists of 754 residues. The N-terminal region 
contains an FHA (fork-head associated) domain stretching from 24–108 aa (Durocher 
& Jackson, 2002) followed by a tandem repeat of the BRCT (BRCA1 C-terminal) 
domains, 108–196 aa and 221-330 aa (Bork et al., 1997; Becker et al., 2006).  
It has been shown that the FHA/BRCT domain is involved in binding to the 
phosphorylated form of H2AX (γ-H2AX) and is responsible for localizing the MRN 
complex in close proximity to the double stranded lesion (Kobayashi et al., 2002; Lee 
et al., 2003; Paull & Gellert, 1999). However the N-terminal region of NBS1 is 
dispensable in ATM signalling cascade but instead is needed in the ATR response to 
DNA damage (Stiff et al., 2008). The middle region contains three ATM 
phosphorylation sites: S278, S343 and S397 and serves in DNA damage signalling as a 
signal transducer in S phase cell cycle check point (Lim et al., 2000; Wu et al., 2000b; 
Zhao et al., 2000). The C-terminal region incorporates an Mre11 binding site (Desai- 
Mehta et al., 2001) and an ATM binding region, that is conserved throughout proteins 
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that bind PIKK kinases, including NBS1, ATRIP and Ku70/80 (Falk et al., 2005).  
NBS1 takes part in cell cycle checkpoint control (Ito et al., 1999; Shiloh, 1997) and 
control of telomere length (Ranganathan et al., 2001) such that patients suffering from 
Nijmegen breakage syndrome have decreased homologous recombination efficiency 
(Tauchi et al., 2002). These features indicate that NBS1 is an important guardian of 
genome stability. When associated with Mre11 and Rad50 in the MRN complex 
(Figure.1.6.) it regulates the nuclear localization, signal transduction ability and the 
catalytic activation of the complex (Mirzoeva & Petrini, 2001; Desai-Mehta, et al., 
2001). In individuals with NBS disorder with the 657del5 mutation the p70 protein is 
localized to the nucleus and is associated with around 50% of the Mre11 protein pool 
present, which would suggest that the p70 protein facilitates the retention of Mre11 in 
the nucleus (Maser et al., 2001). 
During DSB repair the NBS1 subunit of the MRN complex is responsible for direct 
interactions with other proteins that take part in DSB processing such as ATM, γ-H2AX, 
MDC1, BRCA1, SMC1, WRN, Chk2 and FANCD2 (Cheng et al., 2004;Falk et al., 2005; 
Girard et al., 2002; Lane, 2004; Lukas et al., 2004; Nakanishi et al., 2002; Yazdi et al., 
2002).  
The MRN complex is relocalized to sites of DNA damage within minutes of its 
occurrence and is recognized as the first sensor in the DNA damage response 
(Figure.1.13; Williams et al., 2007). Mre11 possesses a nuclease activity, Rad50 is an 
ATPase and NBS1 is responsible for protein-protein interactions. Mre11 gene is 
mutated in ATLD disorder and will be described later in this chapter. The subunit 
Rad50 is a large coiled-coil ATP-binding cassette (ABC) and possesses DNA binding 
activity. Originally, a hypomorphic mutation in Rad50 was recognized in yeast (Alani et 
al., 1990) but later it was found to cause cancer susceptibility and embryonic lethality 
in mice (Bender et al., 2002). Recently a patient with an NBS-like disorder has been 
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reported (Waltes et al., 2009). She was found to be a compound heterozygote for the 
mutations in the Rad50 gene. This mutation is characterized by low and unstable levels 
of Rad50 protein. The cells derived from the patient are radiosensitive, fail to form 
DNA-damage induced MRN foci, are defective in ATM signaling and show chromosomal 
instability. The facial features of the patient resemble of those of NBS syndrome, thus 
the disorder was described as NBSLD – NBS-like disorder (Waltes et al., 2009). Rad50 
belongs to the family of proteins classed as the structural maintenance of chromosome 
(SMC) family. Those proteins act in sister-chromatid cohesion and chromosome 
condensation (Hopfner & Tainer, 2003). The N- and C-terminal regions of Rad50 
contain a Walker motif (A and B respectively; Figure.1.6.a) which resembles motifs 
found in the ATP-binding cassette (ABC) of proteins classed in the transporter family. 
These motifs are required for Rad50 and Mre11 binding (Williams et al., 2007). The 
middle region of Rad50 contains a zinc hook motif (CXXC) which is connected with the 
Walker motifs by the coiled-coil regions (Hopfner & Tainer, 2003). The zinc hook motif 
serves in Rad50’s inter- and intra-molecular interactions which gives the MRN complex 
its flexibility needed for its efficient functioning (Hopfner et al., 2002). 
Mre11 and Rad50 are conserved proteins through evolution (Aravind et al., 1999; 
Blinov et al., 1989; Gorbalenya & Koonin, 1990) and form an ATP-stimulated 3’-5’-
exonuclease which can process most types of DNA ends and hairpins. The conservation 
of the Mre11/Rad50 subunit suggests that they were the primary DNA damage sensing 
proteins and NBS1, as it is only found in eukaryotes, has joined the complex later 
during the evolution (D’Amours & Jackson, 2002). The MRN complex seems to have a 
bipolar structure consisting of a globular head and two tails (Figure.1.6b; Anderson et 
al., 2001; de Jager et al, 2001). The head is formed of one NBS1, two Rad50 ABC 
ATPase domains and two Mre11 molecules and has an ATP-stimulated nuclease  
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a) 
 
b) 
 
Figure.1.6. The MRN complex. a) The members of the MRN complex with 
positioning of known domains and phosphorylation sites. NLS-nuclear localizing signal. 
b) The MRN complex associated with broken DNA ends. 
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activity. The tails consist of 60 nm long antiparallel coiled-coils of the Rad50 ATPase 
and at their apex a zinc-hook is found that serves as a bridging device for Rad50-
Rad50 interaction (Hopfner et al., 2002). Mre11 possesses binding sites for both NBS1 
and Rad50 and all of the components have DNA binding ability (Arthur et al., 2004; de 
Jager et al., 2001; Trujillo et al., 2003). As a biochemical entity the MRN complex is a 
nuclease stimulated by ATP that acts exonucleolytically and endonucleolytically on 
hairpins and ssDNA and possesses exonuclear activity for a variety of dsDNA ends  
(Arthur et al., 2004; Connelly et al., 1997; Hopfner et al., 2000a&b; Paull & Gellert, 
1998; Trujillo et al., 1998). The MRN complex, together with CtIP, plays a major role in 
homologous recombination by resectioning the DNA ends at DSBs prior to rejoining 
(see section 1.4.2.1; Sartori et al., 2007). 
1.2.3. Ataxia telangiectasia-like disorder (ATLD). 
ATLD is a genetic disorder involving mutation in the Mre11 gene. Up to now there have 
only been 16 cases reported, involving four patients from UK, two from Italy and ten 
from Saudi Arabia. Patients show normal eye movement that progresses over time into 
saccadic movement but no head thrusts were observed, unlike in A-T patients. One 
patient showed strabismus at distance. Patients also have their eye convergency 
affected but do not show any telangiectasia (Khan et al., 2008). They are, like A-T 
patients, hypersensitive to ionizing radiation and have chromosome 7/14 
translocations. Their level of serum alfa-fetoprotein (AFP) is normal as are the total 
levels of IgG, IgA and IgM. Patients also show immunodeficiency but predisposition to 
cancer has not been reported (Taylor et al.,2004). 
The Mre11 gene consists of 20 exons and its total size has been determined to be 
~75kb. Two of the British patients and both Italian patients were found to have a the 
same nonsense mutation in exon 15, whilst the other two British patients, who were 
sibs, had a nonsense mutation in exon 17. Both nonsense mutations would have been 
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expected to cause premature termination of translation and truncation of any Mre11 
protein produced. However, truncated Mre11 protein was only evident in the 
individuals with the nonsense mutation in exon 17. The mutation in exon 15 causes the 
transcript to be degraded by NMD (nonsense mediated mRNA decay) thus the 
truncated protein is not detectable in those individuals. However those patients are 
heterozygous thus the other allele, which harbours a missense mutation (117N>S) still 
produces full length Mre11 mutated protein. Whereas the mutation in exon 17 causes 
the appearance of a truncated species detectable as a ~70k protein band on a Western 
blot (Pitts et al., 2001). Ten patients from Saudi Arabia all harbour the same mutation 
in exon 7. It leads to a change of a highly conserved tryptophan residue at position 
210 to cysteine which possibly causes conformational changes within the protein - thus 
affecting its function and causing the ATLD disorder (Fernet et al., 2005). The level of 
expression of Mre11 in ATLD patients is lower than in healthy individuals and varies 
depending on genotype. However, more intriguing is the fact that the level of NBS1 
and Rad50 protein expression is much lower in comparison to healthy individuals. The 
affinity of Mre11 for NBS1 and Rad50 in ATLD patients depends on the type of 
mutation. Proteins in individuals with mutation in exon 15 or 17 both interact with 
NBS1 to the same degree. However the interaction with Rad50 varies, being stronger 
in patients with mutation in exon 17 than in patients with mutation in exon 15 (Taylor 
et al., 2004).  
The Mre11 protein is essential for cell survival and knock-out mice are not viable (Luo 
et al., 1999; Xiao & Weaver, 1997). It is of ~80K molecular weight and the N-terminal 
region contains four phosphodiestrase motifs and a binding site for the C-terminal 
region of NBS1. The N-terminal region is also necessary for nuclear localization of the 
Mre11 protein. The middle and C-terminal region contains a DNA binding motif, and a 
Rad50 binding site is located between them (Figure.1.6.a; Rupnik et al., 2008).  
 
 20 
The phosphodiesterase motif possesses 3’-5’ exonuclease activity which significantly 
increases when it forms the complex with NBS1 and Rad50 (D’Amours & Jackson, 
2002; Trujillo et al., 1998). Mre11 also has endonuclease activity that processes ssDNA 
and dsDNA (Paull & Gellert, 1999). 
The MRN complex (Figure.1.6.b) has been reported to rapidly relocalize to the sites of 
DSBs (Figure.1.13.b; Nelms et al., 1998). Three types of foci have been reported for 
the MRN complex. Type I is recognized in untreated cells and colocalizes with PML 
bodies (Lombard & Guarente, 2000; Mirzoeva & Petrini, 2001; Wu et al., 2000b). In 
cells treated with DNA damage inducing agents within 10 mins and up to 8h post 
induction numerous small foci are seen, which are classed as Type II. Type III foci last 
from 4h up to 24h post irradiation and are described as IRIF (irradiation induced foci, 
Bekker-Jensen et al., 2006) which are large, irregular concentrations of proteins. Cell 
lines derived from patients with NBS and ATLD disorders are unable to form Type III 
foci (Carney et al., 1998; Stewart et al., 1999). Recent reports describe the MRN 
complex as the first sensor of DNA damage. The MRN complex’s first function is to 
tether the broken DNA ends and recruit ATM to initiate the ATM signalling cascade. 
The Mre11 subunit binds to the free DNA ends. Rad50, which is associated with it in 
the MRN complex, binds another Rad50 molecule, on the opposing end of the break, 
forming a clamp which holds the two strands in close proximity for DNA repair to 
proceed (Figure.1.6.b; Bhaskara et al., 2007). The MRN complex partially unwinds the 
DNA to make it accessible for the exo- and endonucleotityc activity of Mre11 which 
resects the 3’ DNA ends. This process as mentioned before requires CtIP which 
promotes Mre11 nucleolytic activity (see section 1.4.2.1; Sartori et al., 2007).  
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1.2.4. Seckel syndrome (SS). 
The Seckel syndrome is a recessive autosomal disorder whose main characteristics 
comprise developmental delay and apparent microcephaly. Features that are used for 
clinical diagnosis include severe pre-birth growth retardation with low birth weight, 
pronounced proportionate short stature, marked microcephaly, mental retardation and 
‘bird-like’ facial features with receding forehead and prominent nose. Five patients 
from two separate consanguineous Pakistani families are all homozygous for the same 
allele which maps to chromosome 3q22.1-3q24 (SCKL1) in which region the ATR (ATM 
and Rad3-related) gene is located (Faivre et al., 2002; Goodship et al., 2000; O'Driscoll 
et al., 2003). In 2001 Borglum et al. reported four more patients with Seckel syndrome 
from a consanguineous Iraqi family but the mutation was mapped to chromosome 
18p11.31-q11.2 (SCKL2). A third locus was mapped by Kilinç et al. to chromosome 
14q23 in 13 Turkish families which were, apart from one, consanguineous. Few 
patients showed linkage to either the SCKL1 or SCKL2 locus (Kilinç et al., 2003). This 
and previous reports suggest that Seckel syndrome is very heterogenous in genetic 
and clinical backgrounds. From over 60 reported cases since 1960 only a third fulfil the 
characteristics set by Seckel (Borglum et al., 2001; Majewski & Goecke, 1982; Seckel, 
1960). However Seckel and Seckel-like syndromes are linked to genes involved in DNA 
repair.  
Genes for two Seckel-like disorders, NBS and LIG4 (mutation in DNA ligase IV gene; 
O’Driscoll et al., 2001) as well as the only gene linked to Seckel syndrome – ATR are 
involved in DNA damage repair (Kilinç et al., 2003; O'Driscoll et al., 2003). A cell line 
derived from a Seckel syndrome patient with SCKL1 locus is not radiosensitive. It also 
shows impairment in phosphorylation of ATR targets following exposure to UV 
irradiation and a standard response to ionizing irradiation carried out by ATM kinase. 
Sequence analysis revealed that a mutation in exon 9 of ATR gene, which is a 
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synonymous one, impairs the gene’s splicing. At the protein level there is a large 
decrease of expression of the ATR kinase. Analysis of cell lines derived from other 
Seckel patients showed, in each case, an impairment of the ATR kinase pathway 
although the defective gene was not always ATR (O’Driscoll et al., 2004).  
The ATR gene has 47 exons and is around 129kb long and located on chromosome 
3q22-q24. Experiments with knock-out mice showed that ATR is necessary for their 
viability as they die in the pre-gastrulation stage of embryonic development and 
heterozygous mice are prone to benign tumours (de Klein et al., 2000). Thus ATR plays 
a major role in prevention of DNA damage in early embryonic stages of development 
(Brown & Baltimore, 2000). 
The ATR protein belongs to the same family of protein kinases as ATM – PIKK kinases. 
The N-terminal region of ATR contains an ATRIP (ATR-interacting protein; Figure.1.7.) 
binding site, the middle region contains HEAT repeats and the C-terminal region 
contains FAT, kinase, PRD and FATC domains which were described previously. The 
FATC domain, in the case of ATR, is essential for even basal ATR kinase activity. 
Activation of ATR following the DNA damage response requires recruitment of ATRIP 
and 9-1-1 complex to the site of lesion. ATRIP brings associated ATR with it and Rad9 
from the 9-1-1 complex brings TopBP1 (Melo et al., 2001; Zou et al., 2002). TopBP1 in 
turn binds to the PDR of ATR and to the middle region of ATRIP stimulating the kinase 
activity of the complex (Figure.1.7; Kumagai et al., 2006; Mordes et al., 2008). ATR as 
a protein kinase phosphorylates its targets at PIKK kinase consensus sites: SQ/TQ. 
Main targets of ATR in response to SSBs are Chk1 (Liu et al., 2000), p53 (Tibbetts et 
al., 1999) and RPA32 (Block et al., 2004; Liu et al., 2006). 
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Figure1.7. The ATR protein. Distribution of ATR domains: ATRIP-ATRIP interacting 
motif; FAT-FRAP, ATM, TRRAP; kinase-PI3K-related kinase domain; PRD-PIKK 
regulatory domain; FATC-FAT C-terminus. HEAT (Huntingtin, Elongation factor 3, A 
subunit of protein phosphatase 2A and TOR1)-repeats. Sites of ATRIP and TopBP1 
interaction are depicted. 
 
 
 
Figure.1.8. The BLM protein. Distribution of BLM domains and motifs: N-terminal 
oligomerization motif, two ATR phosphorylation sites (T99 and T122), in brown – 
conserved acidic patches, helicase domain, RQC – domain conserved in RecQ family 
members, HRDC – (helicase and RNase D C-terminal), NLS – nuclear localizing signal. 
Sites of interaction with TopoIIIα and 53BP1 are depicted. 
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1.2.5. Bloom’s syndrome (BS). 
Bloom’s syndrome was first reported in 1954 (Bloom, 1954). It is a rare recessive 
autosomal genetic dysfunction. Patients with BS share several common clinical features 
such as short posture, immunodeficiency, male sterility, sun sensitivity and 
predisposition to cancer. BS individuals have greater risk of developing tumours 
compared to other disorders with enhanced risk of cancers. Cells derived from patients 
with defective BLM helicase show multiple types of chromosome rearrangements 
including exchanges between sister chromatids (SCE) and homologous chromosomes 
and chromosome breaks and gaps. The genetic instability is also present as mutations 
in a variety of different loci (German, 1993).  
A candidate for BLM was identified by direct selection of a cDNA derived from a 250kb 
segment of the genome to which BLM had been assigned by somatic crossover point 
(SCP) mapping. cDNA analysis of the candidate gene identified a 4437bp cDNA that 
encoded a 1417 amino acid peptide with homology to the RecQ helicases, a subfamily 
of DExH box-containing DNA and RNA helicases (Ellis et al., 1995; German et al., 
1994). Mutations identified in BS patients include frameshits, premature stop codons 
and missense mutations. It is predicted that mutations causing Bloom’s syndrome 
involve loss of function mutations of the BLM helicase. However even homozygous 
patients with a mutated allele are viable, thus it was suggested that BLM is not 
essential for cell survival (Ellis et al., 1995).  
BLM is a member of the RecQ family of helicases together with WRN (Werner’s 
syndrome; Yu et al., 1996), RecQ1 (Seki et al., 1994), RecQ4 (RTS, Rothmnud-
Thompson syndrome; Kitao et al., 1998 and 1999) and RecQ5 (Kitao et al., 1998). All 
members of RecQ family contain a highly conserved helicase region of around 450 aa 
comprising seven motifs including a ‘Walker A-box’ motif, ATP binding motif and a 
DExH box which is typical for this family of proteins (Figure.1.8.). RecQs are all 3’-5’ 
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DNA helicases and WRN also possesses an exonuclease activity. BLM has been found 
to form oligomeric structures, mostly hexamers, of molecular weight of around 850K. 
BLM oligomeric rings can unwind a variety of DNA structures with the exception of fully 
duplexed and blunt-ended DNA molecules (Karow et al., 2000a). BLM’s N- and C-
terminal regions are not conserved in RecQ family members which may contribute to it 
playing a different role in cellular metabolism to other RecQ proteins (Karow et al., 
2000b). Those regions possibly have a role in BLM’s interactions with other proteins, 
such as RPA70 (Brosh Jr. et al., 2000), Topoisomerase III α (Wu et al., 2000a), 53BP1 
(Tripathi et al., 2007) and p53 (Figure.1.8; Wang et al., 2001). BLM also interacts with 
53BP1 and accumulates with it at stalled replication forks caused by HU arrest 
(Sengupta et al., 2004). It is a part of a multiprotein complex (BASC - BRCA1-
associated genome surveillance complex) that is found at stalled replication foci 
together with BRCA1, MRN complex, MLH1, RPA, ATR, and ATM (Wang et al., 2000). 
Following DSBs BLM is phosphorylated by ATM although this phosphorylation is not 
crucial for BLM function in SCE suppression (Sister Chromatide Exchange; Beamish et 
al., 2002). It has also been reported that the phosphorylation of T99 and T122 on BLM 
by ATR is necessary to overcome S-phase arrest (Davies et al., 2004). 
The expression of BLM is cell cycle regulated and reaches its maximum in late S phase 
and G2 (Dutertre et al., 2000) when it colocalizes with PML (Gharibyan & Youssoufian, 
1999). After DNA damage BLM relocalizes to the sites of DSBs and colocalizes with γ-
H2AX (Davalos & Campisi, 2003) RPA and Rad51 at IRIFs (Bischof et al., 2001). BLM 
also colocalizes with Rad51/DMC1 recombination foci mainly during the leptotene stage 
of meiosis (Moens et al., 2000).  
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1.2.6. The tumour suppressors BRCA1 and BRCA2 and Tamoxifen resistence 
in breast cancer. 
In familial cancers mutations in BRCA1 and BRCA2 are found in 80% of the cases. Only 
one mutated BRCA gene in the germline is enough to predispose to breast cancer; 
however, in the tissues isolated from tumours from patients with recognized 
predisposition for breast cancer both of the genes are mutated. Thus BRCA1 and 
BRCA2 fit perfectly as tumour suppressor genes, although mutations in them rarely 
occur in sporadic cancers (Venkitaraman, 2002). BRCA1 mutations also contribute to 
ovarian cancer incidence unlike BRCA2 mutations which have not been linked to that 
disease (Miki et al., 1994). 
In 1990 familial breast cancer was linked with alterations in chromosome 17q21. It has 
been observed that amongst the general population only a small number of the cases 
is connected with familial susceptibility. Thus families with inherited mutations usually 
rarely have sporadic breast cancer cases. On the other hand families with no genetic 
defect can have several cases of sporadic breast cancer. This observations suggest a 
highly heterogenic phenotype of the disease. However it is possible to recognize 
inherited susceptibility from sporadic cases by younger age of the patients, more 
frequent cases amongst men in the family and bilateral form of the disease (Hall et al., 
1990). mRNA levels of BRCA1 are markedly reduced during the transition from 
carcinoma in situ to invasive cancer (Thompson et al., 1995). 
The BRCA1 gene was cloned in 1994 by Miki Y. et al. It was found to have 22 exons 
and span around 100kb of genomic DNA with the transcript length of 7.8kb. Mutations 
identified in that study are located in different exons thus again suggesting 
heterogeneity of the disease (Miki et al., 1994). About 85% of over two hundred 
identified BRCA1 mutations are nonsense or frameshift mutations leading to a 
truncated product and are spread throughout the whole protein. Another 15% are 
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concentrated in the RING domain. However the majority of tumour-associated 
mutations are concentrated in the RING domain and the BRCT domains (Huyton et al., 
2000; Yang & Lippman, 1999). 
BRCA1 has 1863 aa and a molecular weight of 220K. It is shown be a tumour 
suppressor gene as its over expression causes growth retardation of cancer cells in 
nude mice (Holt et al., 1996). As shown in Figure 1.9. at the N-terminus it contains a 
consensus zinc-finger motif (Cys3-His-Cys4) termed a RING-domain and a tandem 
repeat of BRCT domains (BRCA1 C-terminal) in the C-terminal region (Koonin et al., 
1996). The RING-domain was reported to mediate interaction of BRCA1 with BARD1 
(BRCA1 associated Ring Domain; Wu et al., 1996) and BAP1 (BRCA1-associated protein 
1) which is an ubiquitin C-terminal hydrolase (Jensen & Rauscher 3rd, 1999). The 
middle region of BRCA1 interacts with p53 (Figure.1.9.; Zhang et al., 1998), MRN 
complex (Zhong et al., 1999) and further towards C-terminal region a Rad51 binding 
site was reported (Scully et al., 1997b). The BRCT domains have been reported to 
mediate interaction of BRCA1 and RNA polymerase II (Anderson et al., 1998; Scully et 
al., 1997a), CtIP (Wong et al., 1998; Yu et al., 1998), BACH1 (Cantor et al., 2001) and 
BRCA2 (Chen et al., 1998). BRCA1 also forms the BASC complex (Wang et al., 2000). 
ATR phosphorylates BRCA1 on S1423 after DNA damage (Chen, 2000). BRCA1 is also 
phosphorylated by ATM and Chk2 (S988) in response to ionizing irradiation (Cortez et 
al. 1999; Gatei et al., 2000; Lee et al., 2000) and in a cell cycle dependent manner by 
CDK2 and kinases associated with cyclins D and A. This indicates that BRCA1 is 
phosphorylated in mid G1 and stays in a hyperphosphorylated state during S phase 
(Chen et al., 1996). As mentioned before BRCA1 takes an active part in homologous 
recombination as well as being a part of the microhomology-mediated end-joining 
(MMEJ) pathway due to the interaction with the Rad50-Mre11-NBS1 complex
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Figure.1.9. The BRCA1 and BRCA2 proteins. The localization of known domains 
and phosphorylation sites is shown and details of several of the interacting partners of 
BRCA1 are depicted. T-A domain – transcription-activation domain, NLS – nuclear 
localization signal. The eight BRC motifs on BRCA2 are shown with the three ‘OB’ 
(oligonucleotide-binding; binding site for ssDNA) folds. BRCA2 interacting proteins and 
the site where they bind to BRCA2 are depicted. 
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(Moynahan et al., 1999; Zhong et al., 2002). 
BRAC2 was first linked to chromosome 13q12-13 in 1994 in patients with familial 
breast cancer (Wooster et al., 1994). Later it was reported to comprise 27 exons and 
span around 70kb of genomic DNA. In 1995 Wooster R. et al. reported the partial 
sequence of BRCA2 and highlighted six mutations that cause the truncation of the 
protein and subsequently predisposition to cancer (Wooster et al., 1995). The whole 
gene was eventually sequenced by Tavtigian et al., 1996. The mRNA transcript is 
approximately 10-12kb and the BRCA2 protein contains 3418 amino acids. The N-
terminal region contains a transcription-activation domain that has been reported to 
bind RPA and a cancer predisposing mutation, Y42C, abolishes that interaction (Wong 
et al., 2003). The middle region has eight BRC motifs consisting of ~40 amino acid 
residues (Figure.1.9). 
Through its BRC motifs BRCA2 binds directly to RAD51 and regulates its coating of 
ssDNA in preparation for strand exchange of paired DNA molecules in homologous 
recombination (Wong et al., 1997). Towards the C-terminal region three ‘OB’ 
(oligonucleotide-binding) folds were found that allow BRCA2 and ssDNA binding (Yang 
et al., 2002). The pattern of expression of BRCA2 is similar to that of BRCA1 and 
reaches its peak in late G1 and S phase (Yang & Lippman, 1999). 
Estrogen is one of the key factors in initiation and progression of breast cancers and 
therefore the treatment has mainly focused on inhibiting its carcinogenic effects. One 
of the most widely used drugs that inhibits estrogen receptor activity is Tamoxifen. It is 
a nonsteroidal antiestrogen that was the first drug to be approved by the Food and 
Drug Administration in prevention and treatment of estrogen positive breast cancers. 
Nearly 70% of primary breast tumours show expression of estrogen receptor (Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG); 2005). When the disease is in 
its early onset from about 10% of the patients treated with adjuvant systemic 
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tamoxifen therapy can be cured. However, in case of reccurring disease the majority of 
patients will gain tamoxifen resistance and will not respond to treatment (Clarke et al., 
2003; Massarweh & Schiff; 2006). Thus it has been a major concern to uncover the 
pathways of acquired tamoxifen resistance. In one of the studies it has been observed 
that tamoxifen resistant estrogen positive breast cancer cells show a dramatic 
reduction in CtIP expression compared to the parental line. It has been also shown 
that estrogen receptor negative breast cancer cell lines have very low or no CtIP 
expression at all. Apart from that it has been reported that patients with progressive 
disease during the course of treatment show lower levels of CtIP expression. It has 
also been shown that reintroduction of CtIP into tamoxifen resistant cells makes the 
cells vulnerable to tamoxifen treatment again. Thus it has been concluded that CtIP 
expression could be a marker in assessing the treatment for breast cancer patients and 
their clinical management (Wu et al., 2007).  
1.3. The structural and functional characterisation of CtIP. 
CtIP was first reported as a CtBP interacting protein and was named C-terminal 
Binding Protein Interacting Protein. Its cDNA was shown to contain 3247 bp and code 
for a protein of 897 aa with a predicted molecular weight of 125K. The gene is located 
on chromosome 18q11.2 and the amino acid sequence shows homology with yeast 
(Sae2), Xenopus and chicken genes. It is also found to be very conserved in mammals 
(Chinnadurai, 2006; Sartori et al., 2007). The amino acid sequence has a known CtBP-
binding motif, PLDLS (Figure.1.10.; Schaeper et al., 1995). On the basis of this finding 
it was proposed and proven that CtIP binds to CtBP via this motif, that comprises 
amino acids 490 to 494 (Schaeper et al., 1998).  
Following this report another group identified CtIP as an Rb (Retinoblastoma protein)
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Figure.1.10. The CtIP protein. The sites of the interaction with Rb, BRCA1 and CtBP 
are depicted. Coiled-coil motif with zinc-hook like motif, a Cdk phosphorylation site, 
two ATM phosphorylation sites and a C-terminal zink-hook like motif are shown. 
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binding protein and named it Rim (Retinoblastoma interacting myosin-like) and, 
alternatively, RBBP8 (Retinoblastoma Binding Protein 8, HGMW-approved symbol; 
Fusco et al., 1998). There is an Rb-interacting motif (Taya, 1997) in the protein, 
LECEE, which is located between 153 and 157 aa and four nuclear localization signals 
(Fusco et al., 1998). However CtIP has been reported to interact with Rb even in the 
case of Rb mutation in CtIP’s binding site, thus suggesting that there are two binding 
sites on Rb and CtIP (Dick et al., 2000). It is supported by the finding that not all CtIP 
homologues in animals contain that motif. CtIP modulates Rb-dependent G1/S 
transition. Mouse embryo fibroblasts depleted of CtIP would show hypophosphorylation 
of Rb and subsequent cell cycle arrest in G1/S (Chen et al., 2005). 
CtIP has also been reported to contain two zinc-hook motifs (CXXC) at the N-terminal 
(89-92 aa) and C-terminal region (813-816 aa), similar to the ones found in Rad50. 
However, the metal binding ability has not been shown yet (Chinnadurai, 2006). The 
N-terminal fragment of the protein harbours a coiled-coil region which is known to be 
responsible for homodimerisation of CtIP (Dubin et al., 2004). The C-terminal region 
contains two reported ATM phosphorylation sites, S664 and S745 (Li et al., 2000) and 
CtIP has been reported to be hyperphosphorylated in response to ionizing irradiation 
which is dependent upon BRCA1 (Foray et al., 2003; Wu-Baer & Baer, 2001). CtIP has 
also been reported to be a BRCA1 binding protein and the interaction is modulated by 
phosphorylation of CtIP’s S327 by CDK. This association is cell cycle dependent, 
occurring in G2, and is necessary for Chk1 activation after DNA damage. However the 
mechanism of activation is unclear (Yu & Chen, 2004). CtIP interacts with the BRCT 
domains of BRCA1 through a region spanning from 299 to 345 aa (Yu et al., 1998). 
Recently CtIP-BRCA1 interaction has been shown to be responsible for DNA repair 
pathway choice (Yun & Hiom, 2009). In G2/S phase CtIP is phosphorylated on S327 
and subsequently interacts with BRCA1 directing the repair processes towards HR 
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(homologous recombination) and in G1, when S327 is not phosphorylated, the repair 
occurs through MMEJ (microhomology-mediated end-joining; Yun & Hiom, 2009). 
BRCA1 has also been reported to ubiquitynate CtIP which is necessary for its 
redistribution to IRIF in response to γ-irradiation (Yu et al., 2006). 
A screen was performed to reveal CtIP’s homozygous mutations in 89 different tumour 
human cell lines which did not show any homozygous deletions (Wong et al., 1998). 
On the other hand CtIP cDNA’s analysis from those samples showed eleven silent and 
five missense mutations amongst which some were heterozygous and others were 
homozygous. In 11 of those cell lines a silent variation in codon 705 (G2115A) was 
found which may suggest that it is a common polymorphism in the CtIP gene in 
tumour-derived cell lines. More recently one mutation was found in a breast cancer cell 
line and an ovarian cell line which was caused by mutation in codon 589 of CtIP and 
resulted in substitution R=>H (Chinnadurai, 2006). Some colorectal cancers are 
reported to display microsatellite instability (MSI) which results in deletions or 
insertions in the coding region of the genes. This causes frameshift mutations. CtIP 
possesses A9 repeats in the middle of the coding region and has been found to be a 
target for MSI in colorectal cancers. Screen of 109 colorectal tumours revealed 1 bp 
deletion in that region with the frequency of ~22% (Vilkki et al., 2002). This mutation 
would cause the truncation of CtIP protein and expression of an N-terminal 357 aa 
fragment which would still possess the BRCA1 binding site intact but would lose the 
ATM phosphorylation sites and the CtBP binding motif. It is suggested that this 
mutation would contribute to colorectal oncogenesis and it has been reported that 
knock-out homozygous mice die in E4 of embryonic development and heterozygous 
individuals are prone to tumorigenesis. The most common are T and B lymphomas 
possibly because DNA repair is performed there at high rates (Chen et al., 2005; 
Chinnadurai, 2006).  
 
 34 
CtIP has been shown to be involved in the DNA end resectioning after DSBs occurrence 
in G2/S phase (Sartori et al., 2007). It is the first step in HR which prepares the DNA 
strands for exchange. The C-terminal region of CtIP interacts with the MRN complex 
and enhances Mre11’s endonucleolytic activity which generates ssDNA ends for 
efficient RPA-complex coating. The formation of RPA foci in damaged cells is greatly 
impaired in CtIP depleted cells. It has been reported that CtIP is necessary for 
recruitment of ATR to the sites of DNA damage by facilitating the generation of ssDNA 
ends which can be subsequently coated with RPA which in turn recruits ATR. Following 
ATR recruitment the phosphorylation cascade is released resulting in phosphorylation 
of RPA2 and phosphorylation and activation of Chk1 kinase (Sartori et al., 2007). 
1.4. The DNA damage response – a rough guide to the sequence of events. 
Genotoxic stress causes DNA lesions which can occur either in one strand or both at 
the same time. Double stranded breaks (DSBs; Bradley & Kohn, 1979) are the most 
deleterious and can lead to chromosomal rearrangements such as gene deletions or 
duplications, translocations or chromosome loss. They can be caused by γ-irradiation or 
anti-cancer drugs or can be intermediates of normal cellular processes such as meiotic 
recombination (Keeney & Neale, 2006), V(D)J recombination (Franco, Alt & Manis, 
2006), class switch recombination (Chaudhuri et al., 2007) or replication fork collapse 
(Cox et al., 2000). Single stranded breaks (SSBs) on the other hand occur at a rate of 
thousands per day and can be caused by reactive oxygen species (ROS), alkylating 
agents or hydrolysis (Lindahl, 1993). They can also be caused by exogenous agents 
such as UV (Caldecott, 2006). 
UV light that has the most effect on DNA is UVA (320-400nm) and UVB (290-320nm). 
UVA photons are known to penetrate the skin deeply and UVB photons are mostly 
absorbed by the epidermal layer of the skin. Both UVA and UVB generate damage in 
sugars and bases of the DNA molecule (Cadet et al., 2009). 
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UVB has a direct mutagenic effect on DNA causing direct damage to the bases whereas 
UVA causes an indirect damage inflicting oxidative stress towards the bases and 
sugars. UVA apart from mutational changes is also able to introduce strand breaks 
(Pfeifer, You & Besaratinia; 2005). IR (>10pm) introduces DNA strand breaks similarly 
to UVA causing oxidation of the sugar compounds of the DNA molecule (Breen & 
Murphy, 1995). 
Drugs used to induce DNA damage are, amongst others, camptothecin (CPT), a cytotoxic 
quinoline alkaloid that inhibits DNA topoisomerase I (topo I) and causes the collapse of 
the replication fork (Pommier, 2006). Hydroxyurea (HU), an anti neoplastic drug and a 
DNA replication inhibitor that causes ribonucleotide depletion and results in DNA single 
and double strand breaks near the replication forks (Yarbro, 1992). 
There are several different ways in which the cell carries out the DNA damage 
responses. Proteins taking part in them can be classified in two groups, those that 
function as gatekeepers promoting the cell cycle checkpoint arrest and/or apoptosis by 
signal transduction pathways and caretakers, functioning in repairing damaged DNA 
(Kinzler & Vogelstein, 1997). An example of a gatekeeper that is frequently mutated in 
the majority of sporadic tumours is Rb protein (Marshall, 1991; Weinberg, 1995; Sherr, 
1996; Ortega et al., 2002). Rb regulates eukaryotic cell cycle progression at the 
G0/G1-S transition acting as a negative regulator of cellular proliferation and neoplasia 
(Sherr and McCormick, 2002). Caretakers are proteins that are involved in the DNA 
damage response. They recognize the breaks and perform repair, for example the MRN 
complex, RPA complex, ATM, ATR, BRCA1, BRCA2, 53BP1, MDC1, BLM and CtIP. 
Following detection of DNA strand breaks a cell cycle checkpoint is activated. Different 
sets of proteins are utilized depending on the stage of the cell cycle during which the 
damage occurred. In general proteins taking part in the DNA damage response can be 
classed in five groups (Figure.1.11): 
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1. SENSORS which comprise of Mre11-Rad50-NBS1 (MRN) complex, Rad9-Hus1-
Rad1 (9-1-1) PCNA-like sliding clamp and Rad17-RFC clamp loading complex 
(Abraham; 2001; Melo & Toczyski, 2002; Petrini & Stracker, 2003), 
2. MEDIATORS: 53BP1, MDC1, BRCA1, TopBP1 and Claspin (Bartek & Lukas, 
2003; Petrini & Stracker, 2003), 
3. SIGNAL TRANSDUCING KINASES ATM, ATR and DNA-PK (Abraham, 2001; 
Shiloh, 2003), 
4. EFFECTOR KINASES Chk1 and Chk2 (Bartek & Lukas, 2003), 
5. EFFECTOR PROTEINS such as cell cycle regulators (Cdc25), transcription factors 
(p53 or E2F1), DNA repair proteins and several other types of protein (Bartek & 
Lukas, 2003; Donzelli & Draetta, 2003; Shiloh, 2003; Zhou & Elledge, 2000). 
1.4.1. The cell cycle checkpoints. 
The first step in the cellular response to DNA damage is carried out by an instant arrest 
of the progression of the cell cycle. The break in the cycle enables the cell to perform 
any necessary repair to the DNA, or in the case of the damage being too severe, 
undergo apoptosis. The mechanisms that the cell utilizes in order to prevent cell cycle 
progression in the case of acquiring DNA damage are termed ‘the cell cycle 
checkpoints’. In a normal cell they act as a surveillance mechanism to track any 
disruptions to the integrity of the DNA thus they are not physical points at which the 
cell checks the state of its DNA as they are only activated upon DNA damage (van Vugt 
et al., 2005). Each of the checkpoints is termed after the cycle phase at which it can be 
activated upon the DNA damage. 
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Figure.1.11. The classification of proteins taking part in the DNA damage 
response. 
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1.4.1.1. The G1 checkpoint. 
The cell cycle checkpoint disabling entry into S-phase with damaged DNA is the G1 
checkpoint, which inhibits DNA replication initiation. The main players involve ATM/ATR 
and Chk2/Chk1 kinases. They target Cdc25A phosphatase and p53 for phosphorylation. 
Phosphorylation of Cdc25A results in its inactivation. This in turn prevents the 
activation of Cdk2-cyclin E (Bartek & Lukas, 2001). The lack of activation of Cdk2 leads 
to lack of phosphorylation of Cdc45 and its inability to associate with the pre-RC 
complex which ultimately leads to inhibition of the initiation of DNA replication 
(Costanzo et al., 2000). Phosphorylation of p53 acts as a stabilizing modification. In 
this state p53 is able to activate the transcription of its target genes, such as p21 
(Bartek & Lukas, 2001). p21 inhibits both Cdk2-cyclin E and Cdk4-cyclin D (Harper et 
al., 1993). The latter phosphorylates Rb which allows its release from E2F. This in turn 
is required for transcription of the genes needed for S phase progression. As Cdk4-
cyclin D is inhibited by p21, the progression into S phase is also inhibited and the cell 
cycle arrests in G1 until the damage is resolved.  
1.4.1.2. The intra-S checkpoint. 
The intra-S checkpoint causes a slow-down of replication processes by inhibiting the 
assembly of new replicons. Thus it differs from other checkpoints by not being 
permanent and independent of p53 functions (Abraham, 2001; Bartek & Lukas, 2001; 
Shiloh, 2003). It is mainly executed by the Chk1/Chk2-Cdc25A pathway and by ATM 
phoshporylating NBS1 and SMC1. Mediator proteins such as BRCA1, 53BP1; FANCD2 
play a role in it as well (Kim, Xu & Kastan, 2002; Nakanishi et al., 2002; Wang et al., 
2002; Xu, Kim & Kastan, 2001; Yazdi et al., 2002). In general the phosphorylation of 
Cdc25A is performed by checkpoint kinases which prevents Cdc45 loading leading to 
the lack of replication origins firing (Falck et al., 2001). In this pathway, as mentioned 
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before, p53 is not required instead the independent branch of the DNA damage 
response is used utilizing the Chk1/Chk2 kinases as described above.  
1.4.1.3. The G2/M checkpoint. 
The G2/M checkpoint is the final checkpoint beyond which, if the DNA is not repaired, 
the mutations that have arisen will be passed on to progeny cells. The mechanism is 
similar to G1-checkpoint causing cell cycle delay or arrest via post-translational 
modifications of effector proteins and possible alterations in transcriptional 
mechanisms. It has been suggested that the accumulation of cells in G2/M is also 
caused by an additional S/M checkpoint, the so-called DNA replication checkpoint, 
which is very useful in cells with defective G1 or S checkpoints for example in the 
majority of tumours or A-T patient-derived cells (Kastan et al., 1992). The main event 
in the G2/M checkpoint is deactivation of cyclin B/Cdk1 by ATM/ATR and Chk2/Chk1 
and/or inhibition of Cdc25C phosphatase, that would in normal circumstances activate 
Cdk1 before transition from G2 to M phase (Abraham, 2001; Nyberg et al, 2002). 
Additionally, all members of Cdc25 family, namely Cdc25A, Cdc25B and Cdc25C are 
positive regulators of cyclin B/Cdk1 in normal cells (Donzelli & Draetta, 2003; Mailand 
et al., 2002). Thus in response to DNA damage or inaccurately replicated DNA Cdc25A 
is degraded in G2 thus inhibiting activation of cyclin B/Cdk1. This mechanism is shared 
with the G1 and intra-S checkpoints as well (Bartek & Lukas, 2001 & 2003). 
Additionally 53BP1 and BRCA1 take part in the G2/M checkpoint (DiTullio Jr. et al., 
2002; Fernandez-Capetillo et al., 2002; Wang et al., 2002; Xu et al., 2001). A third 
route has also been depicted involving Polo-like kinases Plk1 and Plk3 which seem to 
be upstream regulators of Cdc25C and/or cyclin B/Cdk1 (Nyberg et al., 2002). 
 
 
 
 
 40 
1.4.2. Double-stranded break repair (DSBR). 
The response to DSBs is initiated by the MRN complex that recognizes the break and 
rapidly relocalizes to the site of the lesion (Figure.1.12.; Petrini & Stracker, 2003). 
There are several lines of evidence suggesting that MRN is the initial DNA damage 
sensing agent. Firstly, Rad50 recognizes and binds to broken DNA ends (Moreno-
Herrero et al., 2005), secondly, NBS1 has been found to be necessary for ATM 
recruitment to DSB (Falk et al., 2005; You et al., 2005) and assembly of IRIF 
containing MRN complex has not been reported to depend on any other DNA damage 
response protein (Figure.1.12.b; Bekker-Jensen et al., 2006). The initial association of 
MRN and the double-stranded lesion is only transient; however it is sufficient to recruit 
ATM via direct interaction of NBS1 C-terminal region and HEAT repeats in ATM. It is 
still debatable whether ATM is recruited in its activated state or its autophosphorylation 
is triggered by association with NBS1 (Bakkenist & Kastan, 2003; Cerosaletti et al., 
2006; Falk et al., 2005; You et al., 2005). Nevertheless, autophosphorylation of ATM 
on serine residues 1981, 367 and 1893 activates the kinase which in turn 
phosphorylates histone H2AX, which is referred to as γ-H2AX (Figure.1.12.c; Bakkenist 
& Kastan, 2003; Kozlov et al., 2006; Rogakou et al., 1998). The C-terminal region of γ-
H2AX with the phosphorylated S139 recruits the adaptor-mediator protein MDC1 
through its tandem BRCT domains (Figure.1.12.d; Stucki et al., 2005). MDC1 also 
serves as a stabilizing protein for the MRN-DNA interaction, as it directly binds to NBS1 
(Stucki & Jackson, 2006). This firm scaffold facilitates H2AX phosphorylation spread 
and recruitment of other DNA damage repair proteins (Lukas et al., 2004) which 
include 53BP1, BRCA1 and another set of MRN complexes and the ATM kinase 
(Figure.1.12.e; Bekker-Jensen et al., 2005; Bekker-Jensen et al., 2006). The fact that 
ATM is concentrated in IRIF enhances its phosphorylation potential thus increasing the  
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Figure.1.12. The DSB DNA damage response. The sequence of events during the 
DSB DNA damage response. a) occurrence of DSB, b) detection of the lesion by MRN 
complex (R-Rad50, N-NBS1, M-Mre11), c) recruitment of the transducer ATM kinase to 
the DBS and phosphorylation of the histone H2AX (H2AX-beige, γ-H2AX-green), d) 
MRN and ATM recruit MDC1 mediator, e) amplification of the signal due to recruitment 
of more DNA damage response proteins. 
a) 
b) 
c) 
d) 
e) 
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number of phosphorylation events performed by it in a short space of time. These 
events would include phosphorylation of Chk2 or Kap1 (KRAB-associated protein 1), 
which is involved in global chromatin condensation, thus changing the availability of 
the DNA for repair (Ziv et al., 2006). 
1.4.2.1. The DNA end resectioning. 
The MRN complex together with ATM is also essential for performing DNA end 
resectioning. This process is carried out mainly by Mre11 and creates ssDNA overhangs 
which are rapidly coated by RPA complex (Figure.1.13.). This event is necessary to 
involve ATR in DNA damage signalling and for initiation of homologous recombination 
(Adams et al., 2006; Cuadrado et al., 2006; Jazayeri et al., 2006; Kim et al., 2005; 
Myers & Cortez, 2006). DSB end resectioning, unlike chromatin response (chromatin 
decondensation), requires activation of CDKs and only occurs in S and G2 cell cycle 
phases (Bekker-Jensen et al., 2006; Jazayeri et al., 2006). As mentioned before, 
resected DNA ends are coated with the RPA complex and subsequently recruit ATR-
ATRIP to the sites of damage (Figure.1.13; Zou & Elledge, 2003). ATR for its full 
activation requires binding of TopBP1, which is recruited to the site of repair by an 
independent pathway (Kumagai et al., 2006). Activated ATR phosphorylates its targets 
with the exception of Chk1, which requires recruitment of Claspin before it becomes 
phosphorylated. In turn Claspin assembly on ssDNA requires phosphorylation of Rad17 
by ATR which is stimulated by replication stress (Wang et al., 2006b). 
As mentioned before MDC1 binds to γ-H2AX and this interaction serves as a scaffold 
for further recruitment of other proteins taking part in DSBR. It has been reported that 
MDC1 knock-out mice fail to form foci containing 53BP1, BRCA1, NBS1 and pATM (Lou 
et al., 2006). However Celeste et al. (2003) showed that the initial relocation of 53BP1, 
BRCA1 and NBS1 is not dependent upon H2AX or MDC1. Apart from that it has been 
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Figure.1.13. DNA end resectioning and ATR signalling initiation. a) The MRN 
complex (R-Rad50, N-NBS1, M-Mre11) together with CtIP (yellow circle) performs 
dsDNA ends resectioning, b) ssDNA ends are subsequently coated by the RPA complex 
(red circles), c) ATR/ATRIP/TopBP1 are recruited to ssDNA ends coated by the RPA 
complex.  
 
a) 
b) 
c) 
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reported that 53BP1 can be recruited to the sites of damage by its interaction with 
methylated H3. This association seems to be mediated by the tandem repeat of 
53BP1’s Tudor domains (Huyen et al., 2004). On the other hand, it has been noted 
that the retention of 53BP1, BRCA1 or NBS1 is dependent upon MDC1; thus it is 
suggested that the initial relocation may be due to a different mechanism but the 
stable foci formation is dependent upon MDC1 and its binding to γ-H2AX (Lou et al., 
2006). 
1.4.2.2. MDC1 (Mediator of DNA damage checkpoint protein 1). 
MDC1 is also known as NFBD1 (nuclear factor with BRCT domains 1). It was first 
isolated in a random analysis of a cDNA library obtained from human myeloid cells 
(Nagase et al., 1996). Subsequently it was shown to be a nuclear protein with a 
tandem repeat of BRCT domains in the C-terminal region and to have an in vitro DNA 
binding capability (Ozaki et al., 2000). The N-terminal region possesses an FHA 
domain, which is another typical motif in DNA damage response proteins (Figure.1.14; 
Durocher & Jackson, 2002; Hofmann & Bucher, 1995). It has also been reported that 
MDC1 exists in vivo in at least three variants, which are most likely splice variants. It 
was found to be a member of a cellular protein multicomplex interacting with ATM, 
MRN complex, BRCA1, BARD1, FANCD2, Chk2 and 53BP1 and to regulate ionizing 
irradiation induced foci formation (Eliezer et al., 2009; Goldberg et al., 2003; Lou et al., 
2003a&b; Peng & Chen, 2003; Wu et al., 2008; Xu & Stern, 2003). The middle region 
of MDC1 contains fourteen repeats which are not homologous to protein domains in 
the data base. However this region, the PST domain, has been shown to interact with 
Ku70/Ku80. MDC1 also plays a role in facilitating the autophosphorylation of DNA-PK 
by interaction with it via Ku70/Ku80, thus placing MDC1 in the DNA-PK/Ku70/Ku80 
mediated error-free end-joining pathway (Lou et al., 2004).  
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Figure.1.14. The MDC1 protein. The positioning of known domains and the binding 
sites of several interacting partners are shown. 
 
 
 
 
Figure.1.15. The 53BP1 protein. The positioning of known domains and the 
ATM/ATR phosphorylation sites are shown, as well as the binding sites of several 
interacting partners; GAR – glycine-arginine rich, KBD – kinetochore binding domain, 
NLS – nuclear localization signal. 
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MDC1 is phosphorylated in a cell cycle dependent manner and as a part of the DNA 
damage response pathway. In response to IR MDC1 phosphorylation is ATM-
dependent and NBS1-independent. Approximately twenty potential ATM/ATR 
phosphorylation sites are scattered through the N-terminal region of the protein 
(Stewart et al., 2003).  
Cells depleted of MDC1 are sensitive to IR and have S and G2/M checkpoint deficiency 
(Goldberg et al., 2003; Stewart et al., 2003). MDC1 has also been found to interact 
with Rad51 and prevent its degradation by locating it in the insoluble part of the 
chromatin associated with DNA. Thus MDC1 is thought to facilitate Rad51 binding to 
the chromatin as well as facilitating the formation of Rad51-containing filaments. It is 
suggested that MDC1 maintains a stable level of Rad51 protein in the chromatin and 
makes it readily available for filament formation in response to the DNA damage repair 
performed by HR machinery (Zhang et al., 2005). 
1.4.2.3. 53BP1 (p53 Binding Protein 1). 
53BP1 was first isolated in an yeast two-hybrid screen as an interacting protein of p53 
(Iwabuchi et al., 1994 & 1998). The human protein consists of 1972aa and at the C-
terminal region it contains a tandem repeat of BRCT domains, which have been found 
to directly bind to p53 (Figure.1.15.). As BRCT domains are found in a variety of DNA 
damage response proteins it was suggested that 53BP1 can be considered as one of 
them (Schultz et al., 2000). The N-terminal and middle region contains several 
ATM/ATR phosphorylation sites and the middle region comprises the dimerization 
domain and the glycine-arginine rich region (GAR; Jowsey et al., 2007; Ward et al., 
2003). The C-terminal region contains the BRCT domains and two Tudor domains, 
which, as mentioned before, bind to methylated H3 and H4 in response to DNA 
damage (Huyen et al., 2004; Sanders et al., 2004). The binding to methylated H3 is 
only possible in case of chromatin structural rearrangements, as it is hidden by other 
 
 47 
core histones. Thus 53BP1 is thought to sense chromatin remodelling after DNA 
damage (Huyen et al., 2004). The Tudor domains are also found to bind to γ-H2AX and 
are sufficient to relocalize 53BP1 to IRIF (Ward et al., 2003). 
53BP1 has been reported to bind to RPA70 and RPA32 and the association with the 
latter is disrupted upon campthothecin (CPT) treatment. The interaction occurs 
through the C-terminal region containing the BRCT domains (Yoo et al., 2005). 53BP1 
and BLM also form a complex that is phosphorylation dependent and the association is 
enhanced by 53BP1 phosphorylation by Chk1 in the KBD (kinetochore-binding domain; 
Tripathi et al., 2007). 
53BP1 is also hyperphosphorylated in response to ionizing and UV irradiation by ATM 
and ATR, thus it takes part in DNA damage events stimulated by the PIKK kinases 
(Jowsey et al., 2007). However it has also been shown that it can play a role upstream 
of ATM as cells depleted of 53BP1 showed inefficient p53 accumulation, intra-S-
checkpoint, G2/M checkpoint formation and retained phosphorylation of ATM targets 
such as SMC1, Chk2 or BRCA1 in response to IR (DiTullio Jr. et al., 2002; Fernandez-
Capetillo et al., 2002).  
The Tudor domains of 53BP1 have also been shown to be implicated in NHEJ (Non-
homologous End-joining) by their interaction with DNA ligase IV/XRCC4 (Iwabuchi et 
al., 2003). It is suggested that 53BP1-mediated NHEJ occurs mainly in G1 and S and is 
distinct from the pathways governed by ATM/ARTEMIS and DNA-PK/Ku70-Ku80 
(Iwabuchi et al., 2006). 
Mice deficient of 53BP1 show intact V(D)J recombination but the class switch 
recombination is affected. This result suggests that as class switch recombination takes 
place in G1 it could be possible that 53BP1 takes part in the DNA damage response 
mainly by involvement in class switch recombination (Manis et al., 2004; Ward et al., 
2004). 
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1.4.2.4. Sensing and signalling damage through ATR. 
ATR is thought to be involved in checkpoint signalling in response to a variety of 
agents causing the stalling of the replication forks. It is also known to respond to DNA 
damage caused by other genotoxic insults such as UV or IR. This response enhances 
the G2 arrest (Cortez et al., 2001; Liu et al., 2000). As mentioned before the ATR gene 
is essential for cell viability and its deletion causes embryonic lethality in mice (Brown 
& Baltimore, 2000; de Klein et al., 2000).  
As ATM and ATR are both members of the PIKK family, they share a number of 
structural and functional similarities. However, ATM-depleted cells are viable whereas 
ATR-depleted cells are not. ATM signalling seems to be mainly involved in resolving 
DSBs, that are a rather rare occurence in a normal cell’s life cycle. On the other hand 
ATR is known to be involved in S phase in regulating the firing of replication forks, 
repairing damaged ones and preventing the premature onset of mitosis. This implies 
that ATR takes part in the normal cell cycle unlike ATM, which is activated upon DNA 
damage (Nyberg et al., 2002; Shechter et al., 2004).  
ATR in vivo exists in a complex with ATRIP (ATR interacting protein). The loss of ATRIP 
expression causes loss of ATR expression as well as the disruption of ATR downstream 
signalling. This suggests that ATR and ATRIP are dependent upon each other and 
ATRIP stabilizes ATR (Cortez et al., 2001). ATRIP promotes ATR localization at sites of 
replication stress or DNA damage. Relocation of the ATR-ATRIP complex to the sites of 
DSBs depends upon Mre11’s ability to resect damaged ends and subsequent RPA 
coating of ssDNA (Adams et al., 2006; Cuadrado et al., 2006; Jazayeri et al., 2006; 
Myers & Cortez, 2006). ATRIP binds directly to RPA70 (a large subunit of the RPA 
complex) via a conserved motif (Ball et al., 2007). However this interaction is not 
sufficient for ATR activation. The ATR-ATRIP complex must associate with the Rad9-
Rad1-Hus1 (9-1-1) complex, which in turn recognizes and binds to ssDNA with the 
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adjacent RPA coating (Bermudez et al., 2003; Majka et al., 2006; Zou et al., 2003). 
Thus, in general, for ATR checkpoint activation a structure containing ssDNA coated 
with RPA complex and connected to dsDNA is needed and this conformation can be 
described as a “5’ junction”. This structure in normal circumstances occurs when for 
example DNA polymerase and MCM helicase uncouple during replication which causes 
replication fork stalling and in fact is needed to trigger checkpoint response. It can also 
form upon end resectioning during DSBR and NER (Figue.1.13; Byun et al., 2005; 
Costa et al., 2003; Nedelcheva et al., 2005; Williams et al., 2007).  
The 9-1-1 complex activates ATR by coupling it to its activator protein TopBP1. 
Phosphorylated Rad9 binds to the BRCT domains I and II in TopBP1 and bridges ATR-
TopBP1 binding. The ATR binding site on TopBP1 is located between its VIth and VIIth 
BRCT domains (Delacroix et al., 2007; Kumagai et al., 2006; Lee et al., 2007; St Onge 
et al., 2003). TopBP1 interacts with ATR-ATRIP complex through binding to ATR, in the 
PRD region (Figure 1.7.) and interaction with ATRIP. Mutations in the PRD domain of 
ATR have no effect on its basal activity but they do abolish ATR’s interaction with 
TopBP1 and are found to cause checkpoint defects and mimic complete depletion of 
ATR in somatic cells (Mordes et al., 2008). It is also known that ATM phosphorylates 
TopBP1 on S1131 in response to DSBs and this modification induces interaction 
between TopBP1 and ATR-ATRIP complex. Thus this could be another mechanism for 
enhancing the activation of ATR during DSBR. However, it has been reported that 
TopBP1 S1131 can be phosphorylated by ATR in response to replication stress; thus 
phosphorylation of S1131 seems to be important for DNA repair both during ATM-
initiated and ATR-initiated responses giving the same end result – enhancement of ATR 
activation (Cimprich & Cortez, 2008; Yoo et al., 2007). 
One of the best known ATR targets in the DNA damage response is Chk1 kinase which 
is phosphorylated at S317 and S345. Chk1, as mentioned before, is a signal effector 
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kinase that transduces the signal to the effector proteins. Claspin has been found to be 
a mediator protein in ATR-dependent Chk1 phosphorylation that bridges their 
interaction. After ATR-dependent phosphorylation of Claspin it binds to Chk1 kinase. 
Subsequently Claspin binds to Rad17, which is a component of a clamp loader complex 
Rad17-RFC, that loads the 9-1-1 sliding clamp complex onto DNA lesion. This 
interaction is needed to maintain Chk1 phosphorylation (Kumagai & Dunphy, 2000; 
Wang et al., 2006b). After activation, Chk1 phosphorylates downstream targets such 
as Cdc25. This causes inhibition of Cdc25 phosphatase activity, thus preventing 
activation of CDK and subsequently arresting the cell before entry into mitosis (Furnari 
et al., 1997; Sanchez et al., 1997). The ATR-Chk1 signalling cascade is also crucial in 
regulating the firing of replication origins. This phosphorylation cascade slows down 
DNA replication by slowing down origin firings. This is crucial, when a cell encounters 
DNA damage, while replicating its DNA (Feijoo et al., 2001; Heffernan et al., 2002; 
Tercero & Diffley, 2001).  
Other ATR targets include RPA32 which is phosphorylated after replication fork 
collapse. The RPA complex interacts with the MRN complex at the sites of DNA damage 
and the presence of NBS1 is required for RPA32 phosphorylation (Manthey et al., 
2007; Olson et al., 2006 & 2007; Robison et al., 2004). ATR also phosphorylates 
proteins involved in DNA recombination such as BRCA1, BLM and WRN. They become 
ATR substrates in the vicinity of collapsed replication forks (Davies et al., 2004; 
Pichierri et al., 2003;Tibbetts et al., 2000).  
1.4.2.4.1. RPA (Replication protein A) complex. 
The RPA complex consists of three proteins, named according to their molecular 
weight: RPA70 (RPA1), RPA32 (RPA2) and RPA14 (RPA3, Figure.1.16.a). The RPA 
proteins do not have any enzymatic activity and their main role is to bind to ssDNA and 
orchestrate protein-protein interactions during replication stress and DNA damage 
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(Bochkareva et al., 2002; Mer et al., 2000; Wold, 1997). RPA70 is a 70K protein 
consisting of 616 aa residues. It has four OB (ologonucleotide-binding) folds stretching 
between amino acid residues 1–110 (RPA70N), 181–290 (RPA70A), 300–420 (RPA70B) 
and 436–616 (RPA70C). RPA70C is distinguished by the fact that it also contains a 
zinc-ribbon domain and a three-helix-bundle (3HB) motif, which makes it unique 
amongst the OB folds in RPA complex (Jacobs et al., 1999). RPA32 is a 32K protein 
possessing 270 aa residues. The N-terminal region is unstructured (1-41 aa) and 
contains all of the known RPA32 phosphorylation sites, the central region includes an 
OB fold (43-170 aa) and the C-terminal region is a Helix-turn-Helix (HtH) domain 
(RPA32C, 200-270 aa; Bochkarev et al, 1999). The RPA32 subunit is phosphorylated in 
a cell cycle dependent manner by CDKs on S23 and S29 (Dutta & Stillman, 1992; Fang 
& Newport, 1993). It is also phosphorylated upon DNA damage by the PIKK kinases on 
S4/8, T21, S33 and possibly on S11, S12 or S13 (Manthey et al., 2007; Zernik-Kobak 
M. et al., 1997). RPA14 is a 14K protein comprising of 121 aa residues and the whole 
of it structured into an OB fold. An α-helix is incorporated into the C-terminal region of 
RPA70B, RPA70C, RPA32D and RPA14 and the same α-helix from RPA70C, RPA32D 
and RPA14 is a contact surface in the formation of the RPA complex (Bochkareva et al., 
2002). The RPA complex binds to ssDNA via RPA70A, RPA70B, RPA70C and RPA32D 
(Figure.1.16.b). RPA14 has not been reported to bind to ssDNA. The assembly of the 
RPA complex on ssDNA involves a sequence of events. The RPA70A domain binds first  
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Figure.1.16. The RPA complex. a) the domain structure of the subunits of the RPA 
complex. RPA70 consists of four OB folds: 70N, 70A, 70B and 70C. OB 70C also 
contains a Z-R – zinc-ribbon motif and 3HB – three-helix-bundle motifs. RPA32 
contains N-terminal phosphorylation sites (P), 32D OB fold and 32C Helix-turn-Helix 
motif. OB folds of RPA70 are connected with flexible linkers just like motifs in RPA32. 
RPA14 consists of a single OB fold. The interacting surfaces of each RPA subunit are 
indicated with purple arrows. b) sequential binding of RPA complex OB folds to ssDNA 
in 5’=>3’ direction. 
 
5’ 3’ 
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to the 5’-3’ ssDNA end and subsequently RPA70B, RPA70C and RPA32D bind as well 
(Iftode & Borowiec, 2000).  
The RPA complex has been reported to co-localize and interact with the MRN complex 
and the interaction is not dependent upon DNA damage (Robison et al., 2004). It has 
also been shown to interact with ATR/ATRIP, Rad51, Rad52, BRCA1, BRCA2 and 53BP1 
(Ball et al., 2005; Choudhary & Li, 2002; Park et al., 1996; Wong, Ionescu & Ingles, 
2003; van Komen et al., 2002; Yoo et al., 2005). 
The RPA complex is also involved in base excision repair (BER), nucleotide excision 
repair (NER), mismatch repair (MMR), double-stranded break repair (DSBR) and single-
stranded break repair (SSBR) thus is a crucial component of DNA surveillance 
mechanism (Zou et al., 2006). 
1.4.2.4.2. TopBP1 (Topoisomerase IIβ Binding Protein 1). 
TopBP1 is a 1435 aa nuclear protein. It contains eight BRCT domains and an ATR 
activating domain between the VIth and VIIth BRCT domain (Figure.1.17.). The first two 
BRCT domains are responsible for its interaction with phosphorylated Rad9 protein 
(Delacroix et al., 2007; Kumagai et al., 2006; Lee et al., 2007; St Onge et al., 2003). In 
response to IR it is phosphorylated by ATM on S1131. This modification enhances its 
ability to bind ATR/ATRIP (Cimprich & Cortez, 2008; Yoo et al., 2007). 
TopBP1, together with BRCA1, participates in the G2/M cell cycle checkpoint although 
TopBP1 is thought to take part in it via the ATR route (Yamane et al., 2003). TopBP1 
like BRCA1 forms IRIF and colocalizes with PCNA at the site of stalled replication forks. 
Its expression is shown to be strongly induced in S phase and it also interacts with 
DNA pol-ε which implicates its function in replication (Makiniemi et al., 2001). 
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Figure.1.17. The TopBP1 protein. The domain structure and the distribution of the 
BRCT domains is shown. The ATM phosphorylation and the binding sites for Rad9 and 
ATR/ATRIP complex are depicted. 
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1.4.2.4.3. ATM and ATR – overlapping territories.  
Initially ATM and ATR functions were studied separately. However, the emerging 
evidence suggests that they are components of an integrated circuit, that responds to 
a variety of DNA lesions and enables coordinated execution of checkpoint responses 
(Hurley & Bunz, 2007).  
ATM is best known to respond to DSBs and subsequently initiates the checkpoint 
response and arrest of the cell cycle (Shiloh, 2003). ATR, on the other hand, is known 
to be activated most markedly by agents that cause inhibition of DNA replication such 
as hydroxyurea (HU) or ultraviolet light (UV), both of which block the synthesis of 
nucleotide precursors. In general ATR is activated by DNA replication intermediates 
which means that it monitors the progression of the replication fork (Kumagai & 
Dunphy, 2006; Osborn et al., 2002). 
As mentioned previously ATM is not essential for cell viability which is not the case with 
ATR. This suggests that ATR is essential for a cell’s normal physiology (Brown & 
Baltimore, 2000). The fact that ATM and ATR take part in two distinct DNA damage 
pathways, involving either DSBs or SSBs, respectively, was instinctively directing 
research towards distinguishing two separate cascades of response. However, several 
groups found that ATR is activated by ATM in response to IR (Adams et al., 2006; 
Cuadrado et al., 2006; Jazayeri et al., 2006; Myers & Cortez, 2006). This discovery led 
to the investigation of possible overlaps in ATM and ATR activities. Further findings 
showed that ATR activates ATM in response to DNA damage caused by UV and 
replication fork stalling, thus giving a firm foundation to the concept of ATM and ATR 
pathway cross-talk (Stiff et al., 2006). 
It has also been reported that proteins that are thought to be involved in the ATM 
pathway are phosphorylated and utilized in an ATR-dependent manner. Stiff et al. 
(2008) showed that NBS1 is required for the replication independent G2/M cell cycle 
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checkpoint which is generated by ATR signalling and which also involves 53BP1 and 
MDC1 as mediators in the ATR-dependent phosphorylation cascade (Stiff et al., 2008). 
The same group had previously shown that NBS1 is required for RPA32 phoshorylation 
performed by ATR (Stiff et al., 2005). 
ATM and ATR are known to take part in cell cycle checkpoints and play similar roles in 
triggering the G2/M cell cycle checkpoint and regulation of the progression of firing of 
the origins of replication in S-phase. However ATM at the G1/S stage of the cell cycle 
triggers a checkpoint whereas ATR prevents G1/S stasis and thus pushes the cell to 
continue to reach S phase. ATR is also reported to have some inhibitory effect on ATM 
signalling (Hurley & Bunz, 2007; Hurley et al., 2007). 
1.4.3. Single-stranded break repair (SSBR). 
Single-stranded DNA lesions are first recognized by PARP-1 and PARP-2 (Poly ADP-
ribose polymerase 1 and 2) which are rapidly relocalized to the sites of lesions and 
activated by them (Ame et al., 1999; Benjamin & Gill, 1980). When PARP-1 is activated 
it modifies itself and other proteins by adding negatively charged poly ADP-ribose 
(PAR) chains (D’Amours et al., 1999). Once PARP-1 is modified it quickly dissociates 
from DNA as it has the same, negative charge. After dissociating from DNA, the PAR 
chain is degraded by poly ADP-ribose glycohydrolase and PARP-1 and other proteins 
that had the PAR chain added can be utilized elsewhere to repair another lesion 
(Zahradka & Ebisuzaki, 1982).  
PARP-1 can be also activated by ssDNA that is formed during BER (Base Excision 
Repair; Durkacz et al., 1980). As the ends of DNA are damaged they require 
processing to restore 5’-phosphate and 3’-hydroxyl groups. This step is enzymatically 
very complicated and the nature of the modification requires specific enzymes to 
restore it. For example, to remove 5’-deoxyribose phosphate (dRP) the activity of DNA 
polymerase (Pol) β is needed. After restoring the 5’-phosphate group BER can proceed 
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(Sobol et al., 2000). In the case of modifications of the 3’-terminus, the most common 
modifications that arise from the damage caused by ROS, are 3’-phosphate and 3’-
phosphoglycolate. The 3’-phosphate is a major substrate for polynucleotide kinase 3′-
phosphatase (PNKP, Jilani et al., 1999) and the 3’-phosphoglycolate for apurinic–
apyrimidinic (AP) endonuclease I (APE1; also referred to as APEX1, Winters et al., 
1994).  
Other types of damaged termini include DNA ends that are processed by cellular 
machinery when the processes do not go to completion. For example, when 
Topoisomerase 1 (TOP1) is bound to ssDNA it can collide with RNA polymerase (RNAP) 
or approach a lesion in DNA. These situations create TOP1-linked single-stranded 
breaks (TOP1-SSB) that are repaired by the activity of tyrosyl-DNA phosphodiesterase 
1 (TDP1, Pouliot et al., 1999; Yang et al., 1996). Another example of ssDNA termini 
covalently bound are 5’-phosphate termini linked with AMP which are the result of 
abortive activity of DNA-ligase. These intermediates are fixed by aprataxin (APTX, Ahel 
et al., 2006). When the damaged DNA ends are undergoing repair, XRCC1 directly 
interacts with either PNKP, APTX and Pol β or indirectly with TPD1 via DNA ligase IIIα. 
In the case of PNKP, XRCC1 stimulates both kinase and phosphatase activity. When 
XRCC1 is associated with PNKP, APTX or Pol β it facilitates their accumulation at 
oxidative chromosomal breaks caused by H2O2 or UVA (Clements et al., 2004; Kubota 
et al., 1996; Loizou et al., 2004; Plo et al., 2003; Whitehouse et al., 2001).  
After successful restoration of damaged DNA ends the process of gap filling occurs. 
This can involve filling in just one nucleotide (short-patch repair) or a few nucleotides. 
In this case FEN1 (Flap Endonuclease 1) removes the displaced 5’-residues either one 
at a time or several in one go (long-patch repair). In vitro studies show that Pol β is 
mainly involved in filling in the gaps arising in BER and after oxidative stress, although 
Pol δ and/or Pol ε (Pol δ/ε) can also take part in this process (Caldecott, 2006).  
 
 58 
The next step involves the ligation of the recovered ends. Three human genes have 
been described: LIG1, LIG3 and LIG4. They encode five DNA ligases of which LIG3 
encodes DNA ligase IIIα (LIG3α), DNA ligase IIIβ (LIG3β) and a mitochondrial isoform 
(mtLIG3). Of those ligases, LIG1, LIG3α and mtLIG3 are known to be involved in 
single-stranded break repair. LIG1 seems to be involved in long-patch repair and is 
recruited to the sites of damage by interaction with PCNA (Proliferating Cell Nuclear 
Antigen). LIG3α has been shown to play a role in the short-patch repair and interacts 
with XRCC1 via its C-terminal BRCT domains (Mortusewicz et al., 2006). mtLIG3 has 
been reported to interact with Pol γ and takes part is maintaining mitochondrial 
genome stability (De & Campbell, 2007). 
There are a few genetic disorders that impact SSBR such as mutation in aprataxin gene 
(Ataxia-oculomotor apraxia 1, AOA1, Aicardi et al., 1988) or Spinocerebellar ataxia with 
axonal neuropathy 1 (SCAN1) which is connected with mutation in TDP1 gene 
(Takashima et al., 2002). 
The single stranded DNA damage inflicted, for example by, UV and undergoing repair 
by the NER mechanism can stimulate ATR signaling. This occurs in non-cycling cells in 
the case of insufficient amounts of replication proteins such as Pol δ, Pol ε and/or 
PCNA, and would subsequently activate the ATR-dependent DNA repair. Insufficient 
amounts of replication proteins would cause inefficient filling of the gaps and lead to 
the accumulation of ssDNA intermediates. They are subsequently coated by the RPA 
complex and trigger the ATR-dependent DNA damage response (Matsumoto M. et al., 
2007). 
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1.5. DNA damage repair mechanisms. 
Depending on the nature of the damage, different, but partially overlapping 
mechanisms are employed to deal with it. If the lesion occurs in one of the strands and 
is a small gap (the double helix is not distorted) it can be repaired by base excision 
repair (BER). If the lesion is greater and the structure of the helix is distorted 
nucleotide excision repair (NER) occurs. There are around 30 proteins that take part in 
NER and the process, briefly, is based on damage recognition, opening the double 
helix around the break, excision of around 24-32 nucleotides surrounding the lesion 
and subsequent filling in the gap and ligation (de Boer & Hoeijmakers, 2000).  
When the lesion occurs in both strands, depending on the stage of cell cycle two 
different mechanisms are employed: homologous recombination (HR) in the S and M 
phases, when sister chromatids are available, and non-homologous end-joining (NHEJ) 
in G1 and G2. 
1.5.1. Homologous recombination (HR). 
Homologous recombination is, in general, considered as an ‘error free’ method of 
repairing double-stranded lesions. It is initiated by extensive 5’=>3’ DNA end 
processing performed and regulated by the MRN/MRX complex together with 
CtIP/Sae2, Exo1 and BLM/Sgs1 (Figure.1.13., Figure.1.18.; Mimitou & Symington, 
2008; Sartori et al., 2007). As the result of this process 3’ ssDNA ends are obtained 
which are rapidly coated with RPA. Subsequently, a portion of RPA is exchanged for 
Rad51 and this reaction is catalyzed by Rad52 and Rad51 paralogs (XRCC2, XRCC3, 
Rad51B, Rad51C, and Rad51D). Rad51-coated ssDNA scans for homologous regions 
and once they are found the duplex is aligned and DNA strand exchange begins (Sung 
et al., 2003). Rad52 and RPA together are thought to stimulate Rad51 filament 
formation by securing Rad51’s binding to ssDNA ends. The collaboration of Rad52, RPA 
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Figure.1.18. The two main DBS repair mechanisms: Classical-NHEJ and HR; 
see text for explanation. 
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and Rad51 results in Rad51 mediated DNA strand exchange enhancement (Shinohara 
& Ogawa, 1998). In turn, Rad52 catalyses the annealing of complementary ssDNA 
ends stimulated by RPA. The RPA2 subunit of the RPA complex has been found to bind 
directly to Rad52 and it is suggested that RPA either recruits Rad52 to the ssDNA or 
stabilizes Rad52-ssDNA binding (Mortensen et al., 1996; Park et al., 1996; Shinohara 
et al., 1998). The primary role of RPA binding to ssDNA is removal of its secondary 
structure, which, in turn, facilitates Rad51-ssDNA binding and Rad51 nucleofilament 
formation (Figure.1.18.; Baumann & West, 1997 & 1999). 
It has been proposed that BRCA2 acts as a recombination repair mediator 
(Kowalczykowski, 2002). It binds to Rad51 via its BRC repeats and its C-terminal region 
which possesses three ‘OB’ (oligonucleo-binding, Figure.1.9.) folds. Thus it is proposed, 
that BRCA2 stabilizes Rad51-ssDNA binding (Kowalczykowski, 2002; Yang et al., 2002). 
The association of Rad51 and Rad54 leads to D-loop formation. The energy from ATP 
hydrolysis fuels Rad54/Rad51 movement along the DNA which forms positive 
supercoils at the front of the complex and negative supercoils behind. The remodelling 
of the DNA duplex enables pairing of the homologous regions and strand exchange 
(Figure.1.18.; Symington, 2002).  
As mentioned before BRCA1 and BRCA2 are tumour suppressor genes that play a key 
role in maintaining genome integrity. Cell lines defective for BRCA1 or BRCA2 show 
defects in HR DNA repair systems mediated by Rad51 (Moynahan et al., 1999; 
Moynahan et al., 2001; Sharan et al., 1997). BRCA2 binds directly to RPA (Wong et al., 
2003) and BRCA1 has been shown to colocalize with Rad51 foci together with BRCA2 
(Kowalczykowski, 2002; Scully et al., 1997b; Tarsounas et al., 2003). BRCA2 possibly 
serves as a scaffold for Rad51 and keeps it in an inactive state until DNA damage 
occurs and Rad51 is needed for strand invasion (Figure.1.17; West, 2003). 
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DNA repair mediator proteins containing BRCT domains like MDC1 (Mediator of DNA 
damage checkpoint) or 53BP1 (p53 Binding Protein) are also known to be involved in 
homologous recombination events and in DNA damage sensing and signalling 
pathways, especially in S-phase (Lou et al., 2003; Sengupta et al., 2004). 53BP1 is 
reported to possess antirecombinogenic abilities in HR together with BLM. BLM in turn 
enhances 53BP1-Rad51 interaction. And in this feed-back loop 53BP1 facilitates BLM’s 
accumulation at stalled replication forks (Sengupta et al., 2004; Tripathi et al., 2007). 
Overall 53BP1 suppresses HR and promotes NHEJ (Xie et al., 2007). 
BLM helicase is suggested to act in replication, recombination and DNA damage repair 
events (Hickson, 2003). It may also regulate HR by modulating the functions of its 
interacting proteins, such as Rad51 (Bischof et al., 2001). Cells exposed to replication 
stress or IR show colocalization of BLM and Rad51 in nuclear foci. BLM together with 
p53 affects HR as inactivation of p53 in BS derived cells causes sister chromatid 
exchange (SCE) increase (Sengupta et al., 2003; Wu et al., 2001).  
MDC1 also interacts with Rad51 and the partnership facilitates homologous 
recombination events in response to IR (Zhang et al., 2005). It promotes HR mainly 
through its interaction with γ-H2AX and this route is independent of 53BP1 and BRCA1. 
MDC1 dependent homologous recombination events are mediated via its FHA and PST 
domains (Xie et al., 2007). On the other hand the central region of MDC1 contains a 
DNA-PK binding region and is required for DNA-PK’s phosphorylation after DNA 
damage and subsequent repair processes stimulated by DNA-PK (Stucki & Jackson, 
2004). 
1.5.2. Non-homologous End-joining (NHEJ). 
Non-homologous End-joining accounts for around 50-70% of repair processes  
performed in mammalian cells in which the DSBs were caused by the I-SceI 
endonuclease. The rest of them are repaired by HR (Liang et al., 1998). 
 
 63 
Non-homologous End-joining comprises two main routes: classical-NHEJ and 
alternative-NHEJ (alt-NHEJ) none of which rely on the template to reseal the DNA 
ends. Classical-NHEJ in mammalian cells involves mainly the DNA-PK kinase with its 
interacting partner the Ku70/Ku80 heterodimer, which binds to broken DNA ends and 
DNA ligase IV with its interacting partner, XRCC4 (Figure.1.18.). In budding yeast the 
MRX complex is also utilized to resolve DSBs (Chen & Kolodner, 1999; Haber, 2000). 
Classical-NHEJ is also regarded as requiring the minimal amount of end processing. In 
general it involves DNA end processing to reveal only short, complementary (1-4nt) 
sequences on either side of the break. They serve in the alignment of the DNA 
molecule and excess nucleotides are either trimmed or if a gap is produced, it is filled 
in. Those processes result either in deletions or insertions, thus classical-NHEJ is 
regarded as error-prone method of repairing the DSBs (Figure.1.18.; Burma et al., 
2006; Guirouilh-Barbat et al., 2004). The alt-NHEJ is independent of DNA-PK and its 
mechanism is not clearly understood (DiBiase et al., 2000).  
The first step of classical-NHEJ involves the heterodimer Ku70/Ku80 binding to the 
broken ends and recruiting the DNA-PK kinase. DNA-PK in turn recruits Artemis and 
this complex possesses an endonuclease activity that cleaves 5’- or 3’-overhangs. The 
ligation of DNA ends is performed by XRCC4/ligase IV complex (Grawunder et al., 
1997). Recently another protein, XLF/Cernunnos, has been recognized as stimulating 
the XRCC4/ligase IV activity and promoting NHEJ (Ahnesorg et al., 2006). The gaps 
created during the classical-NHEJ are filled in by DNA polymerases Pol µ and Pol γ. 
Classical-NHEJ operates in G0/G1 and the majority of DSBs are repaired within minutes 
after they occur (Lee et al., 2004; Ma et al., 2004) 
The alt-NHEJ recently described as MMEJ (Microhomology-mediated End-joining; 
Figure.1.19.) is a DNA-PK-independent pathway that operates even in cells with 
malfunctioning DNA-PK, mainly in G1 but also in the S and G2 phases of the cell cycle. 
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Its kinetics are 20- 30-fold slower than those of classical NHEJ and it requires four or 
more nucleotides for microhomology. It is recognized as error-prone as fairly large 
deletions may occur during its course (McVey & Lee, 2008; Yun & Hiom, 2009). MMEJ 
requires other proteins which are normally involved in different pathways, such as the 
MRN complex, CtIP, BRCA1, DNA ligase I and III, ERCC1/XPF (excision repair cross 
complementation group 1/xeroderma pigmentosum complementation group F) 
endonuclease and PARP-1 (poly(ADP-ribose) polymerase 1) and recently a possible role 
for NBS1 was revealed in this process (Ahmad et al., 2008; Audebert et al., 2004; 
Bennardo et al., 2008; Deriano et al., 2009; Liang et al., 2005; Yun & Hiom, 2009). 
There are reports that suggest that MMEJ is inhibited by Rad51, Ku70/Ku80 dimer and 
DNA-PK (Decottignies, 2007; McVey & Lee, 2008; Perrault et al., 2004). Additionally, 
PARP-1 competes with Ku70/Ku80 for binding to the DNA ends thus directing the 
repair towards MMEJ (Wang et al., 2006a).  
MMEJ is thought to be initiated by the DNA end resectioning by the MRN complex, 
supported by CtIP and Exo1 nuclease. The microhomologies exposed during the 
resectioning are annealed in a way that provides stability. After the annealing the 
remaining non-complementary 3’-flaps are removed by ERCC1/XPF endonuclease 
complex (Ahmad et al., 2008). The insertion of additional nucleotides at many MMEJ 
sites suggests that the polymerases that fill the gaps are error-prone. The ligation step 
is performed by either DNA ligase I or IIIα/XRCC1 and PARP-1 (Audebert et al., 2004; 
Liang et al., 2008). 
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Figure.1.19. The microhomology-mediated end-joining (MMEJ); see text for 
explanation. 
 
 66 
1.6. Ubiquitylation in DNA damage signaling. 
As discussed previously and in section 5.1. phosphorylation plays a key role in the 
regulation of DNA damage responses as well as in a variety of other cellular signalling 
processes (Stryer, 1995). The FHA domain and the BRCT domains are only two 
examples of phosphopeptide binding domains (Durocher & Jackson, 2002; Manke et 
al., 2003) that are present in proteins taking part in DNA damage responses. Recently 
ubiquitination and deubiquitination have been recognized as additional ways of 
regulating DNA damage signalling. It has also emerged that the PIKK kinases 
phosphorylation cascade mediates the assembly of E3 ligase complexes at the sites of 
DSBs (Messick & Greenberg, 2009). 
Ubiquitination regulates several cellular processes such as protein degradation, 
transcription, endocytosis, cell cycle and DNA damage response (Di Fiore et al., 2003). 
It is performed by the cooperative action of three groups of enzymes: E1, E2 and E3 
and results in covalently linked mono- or polyubiquitin in several different 
conformations. E1 is an ubiquitin-activating enzyme which activates the ubiquitin 
polypeptide and transfers it to E2 – the ubiquitin-conjugating enzyme. E2 together with 
E3 (ubiquitin ligase) links the ubiquitin chain to the target protein (Hershko et al., 
2000; Pickart, 2001). Typically, ubiquitin molecules are linked together via K48 and this 
modification directs the target protein for degradation (Pickart and Cohen, 2004). If 
ubiquitin particles are linked via K63 this serves for localizing or signalling events (Chen 
& Sun, 2009). Ubiquitins can also be linked via K6 as in the case of autoubiquitination 
of BRCA1/BARD heterodimer (Wu-Baer et al., 2003). On the other hand, ubiquitin 
chains can be linked together via one residue forming homogenous chains, as 
described above or via multiple residues forming branched chains, which broadens the 
spectrum of posttranslational modifications (Kim et al., 2007b). 
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As mentioned above phosphorylation and ubiquitination in response to DNA damage is 
coordinated. It has been shown that FANCD2 is phosphorylated by ATR in S phase 
which is subsequently followed by its monoubiquitination that is required for FANCD2 
localization at the DSB and its chromatin association (Andreassen et al., 2004; Wang et 
al., 2004). Another example includes ATM/ATR dependent phosphorylation of 
BRCA1/BARD complex, an E3 ubiquitin ligase. After its activation by ATM/ATR it 
performs autoubiquitination together with the E2 (ubiquitin-conjugating enzyme) 
Ubch5c linking a K6 ubiquitin chain (Wu-Baer et al., 2003; Nishikawa et al., 2004). 
Furthermore the BRCA1/BARD complex links K6 ubiquitin chain to CtIP, this has been 
reported to be required for CtIP localization at DSB sites although the mechanism of 
CtIP-Ub foci formation awaits further understanding (Figure.1.19; Yu et al., 2006). 
BRCA1 is targeted to the DSBs via interaction with a multicomplex encompassing 
RAP80, BRCC36, BRCC45, Abraxas, and MERIT40/NBA1 (Feng et al., 2009; Shao et al., 
2009b; Wang et al., 2009). RAP80 is known to specifically recognize K6 and K63 
polyubiquitin chains and bind them via its Ub-interacting motifs (UIMs; Sobhian et al., 
2007). It has also been shown to interact with ubiquitylated γ-H2AX. BRCC36 is a 
member of the JAMM family of metalloprotease DUB (deubiquitynase) enzymes which 
deubiquitynates specifically K63-linked chains (Cooper et al., 2009; Shao et al., 2009a). 
BRCA1 has been reported to interact with the coiled-coil domain-containing 98 
(CCDC98)/Abraxas mediator protein that is a part of the multicomplex formed by 
RAP80 (Kim et al., 2007a). It is also suggested that ubiquitynated γ-H2AX binds to 
RAP80 UMIs and this relocalizes the whole complex together with BRCA1 to DSBs 
(Mailand et al., 2007). Thus the initial sequence of events after DSB occurrence 
involves recognition of the break by MRN/CtIP complex, activation of ATM and 
subsequent phosphorylation of H2AX (Yuan & Chen, 2009). Secondly MDC1 is recruited 
to associate with γ-H2AX (Stucki et al., 2005). MDC1 is also known to recruit other DNA 
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damage response proteins such as 53BP1, BRCA1 and another set of MRN complexes 
and the ATM kinase (Figure.1.12.e; Bekker-Jensen et al., 2005; Bekker-Jensen et al., 
2006). Apart from that it binds to RNF8, which is an E3 Ub-protein ligase, which 
ubiquitynates H2A, H2AX and γ-H2AX, together with E2 Ub-conjugating enzyme 
UBC13, in response to IR. Subsequently, ubiquitynated γ-H2AX recruits the RAP80 
complex together with BRCA1 to IRIF (Figure.1.20.; Huen et al., 2007; Kolas et al., 
2007; Mailand et al., 2007). Another protein that recognizes the Ub-chains synthesized 
by RNF8 is E3 Ub-protein ligase RNF168, mutated in the RIDDLE syndrome. RNF168, 
similarly to RNF8, associates with UBC13 to orchestrate ubiquitynation of H2A histone 
variants and synthesis of K63 Ub-chains at DSBs (Doil et al., 2009; Stewart et al., 
2009). 
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Figure.1.20. Ubiquitylation in early DNA damage response. For Figure 
description refer to the text. Orange arrow – detection of DSB by MRN/CtIP and 
BRCA1; red arrow – BRCC36 performing deubiquitylation, pink cylinder – H2AX, green 
cylinder - γ-H2AX (adapted form Messick & Greenberg, 2009).  
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1.7. Aims. 
When this studentship began the major interest in CtIP was its proposed ability to 
modulate the activity of the transcriptional co-repressors Rb and CtBP. However, in 
view of CtIP’s interaction with BRCA1 a study of its role in the DNA damage response 
was undertaken. 
Specifically, the aims of this project were: 
1. Determine CtIP’s direct interaction with proteins containing BRCT domains such 
as 53BP1, MDC1, TopBP1 and NBS1. 
2. Establish CtIP’s nuclear localization before and after DNA damage and its co-
localization wth damage response proteins. 
3. Investigate CtIP’s involvement in phosphorylation cascades that follow DNA 
damage caused by IR, UV and CPT. 
4. Study CtIP’s in vivo complex formation. 
5. Determine novel phosphorylation sites on CtIP. 
It should be noted that whilst my study was underway results similar to my own were 
published by Sartori et al., (2007). 
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CHAPTER II 
MATERIALS AND METHODS 
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2.1. Cell biology techniques. 
2.1.1. Cell lines. 
Cells used during the course of this study were all of human origin, and individual lines 
are listed in Table 2.1. 
Table.2.1. Cell lines used in this study. 
Cell Line Cell Type Source Culture Media 
Normal LCL B cell Lymphoid tissue RPMI 
ATLD LCL B cell Lymphoid tissue RPMI 
A-T LCL B cell Lymphoid tissue RPMI 
HeLa Epithelial Cervical carcinoma RPMI 
HeLa shATM Epithelial Cervical carcinoma RPMI 
NBS LCL B cell Lymphoid tissue RPMI 
 
2.1.2. Cell culture media. 
Cell lines were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
(Invitrogen) which was supplemented with 8% foetal calf serum (FCS; Invitrogen). 
Antibiotics were not used. Media were stored at 4˚C for up to three months. 
2.1.3. Maintenance and passage of cell lines. 
All cells were cultured at 37˚C in humidified incubators supplied with 5% CO2. The 
HeLa cell line was grown in monolayer and LCL cell lines were grown in suspension. 
HeLa cells during passage, after removal of medium, were washed twice with PBS, pre-
warmed to 37˚C. Trypsin (Invitrogen) was added (1 ml/10cm dish) and incubated at 
37˚C until cells had detached. Fresh medium was added to quench the trypsin, and 
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cells were pelleted by centrifugation at 1500 rpm for 5 min. Pellets were resuspended 
in medium, and re-plated at appropriate dilution. While passaging LCLs medium was 
removed, cells were resuspended in fresh medium and divided into fresh flasks at 
appropriate dilution.  
2.1.4. Cryopreservation of cell lines. 
HeLa cells were trypsinized and pelleted as above, but resuspended in 10% DMSO in 
FCS. LCL cells were pelleted and resuspended in 10% DMSO in FCS. Aliquots of 1ml 
were cooled to -80˚C at a controlled rate of 1˚C/min in isopropanol. Frozen samples 
were then transferred to liquid nitrogen storage tanks, to be kept long term at -180˚C. 
When required, cells were rapidly thawed in medium at 37˚C, pelleted by 
centrifugation, and resuspended in fresh medium before plating. 
2.1.5. Drug treatments. 
2.1.5.1. HeLa cells drug treatments. 
Cells were treated with camptothecin (CPT), a cytotoxic quinoline alkaloid, at a final 
concentration of 1µM to inhibit DNA topoisomerase I (topo I). The drug was left in 
medium for 1h. After that time medium was removed, cells were washed twice with 
PBS, fresh medium was added and cells were harvested at the appropriate time points. 
Cells were treated for 16h with 1mM hydroxyurea (HU), an anti neoplastic drug and 
DNA replication inhibitor that causes ribonucleotide depletion and results in DNA 
double strand breaks near replication forks. After treatment cells were harvested to 
perform the appropriate experiments. 
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2.1.5.2. LCL cells drug treatment. 
Cells were treated for 1h with caffeine, a xanthine alkaloid compound, at a final 
concentration of 5mM to inhibit caffeine-sensitive kinases. After treatment cells were 
harvested and used to perform kinase assays. 
2.1.6. IR and UV irradiation. 
2.1.6.1. HeLa cells. 
Subconfluent cells were mock-treated or treated with ionizing γ-rays from a 137Cs 
source at an appropriate dose. Prior to UV irradiation, medium was removed from 
exponentially growing cells and stored at 37˚C. Cells were washed with PBS and mock-
irradiated or irradiated with the appropriate dose of UV light, after which the cells’ 
original medium was replaced. UV radiation with a wavelength of 254nm was delivered 
in a single pulse using a Stratalinker UV crosslinker 1800 (Stratagene). 
2.1.6.2. LCL cells. 
Confluent cells were treated with ionizing γ-rays from a 137Cs source at a dose rate of 5 
Gy and left for 30 min at 37˚C for full activation of ATM kinase, then harvested to 
perform kinase assays. 
2.1.7. RNA interference (RNAi). 
Control small interfering RNAs (siRNA) and siRNAs targeting CtIP or Mre11 are shown 
in Table 2.2. 
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Table 2.2. siRNA sequences used in this study. 
Target siRNA Sense sequence Company 
None AllStars Proprietary Qiagen 
CtIP CtIP4 5’-CUG CUU GGG CAC ACG UGU A-3’ Qiagen 
Mre11 Mre11 5’-GCU AAU GAC UCU GAU GAU A -3’ Ambion 
 
RNAi was carried out using different protocols, depending on the target protein. In 
each case HeLa cells were plated into 6 cm dishes 24h prior to transfection, so as to be 
50-70% confluent the following day. Oligofectamine (OF) reagent (Invitrogen) was 
used to deliver siRNA duplexes into cells. To target CtIP 10 µl of OF was diluted to 500 
µl with RPMI, and left for 5 min. 20 µl of CtIP siRNA (20 mM) was then diluted to 500 
µl with RPMI, and added to the OF mix. OF-siRNA complexes were left to form for 20 
min. After that time the mix was added to the appropriate dishes and left for 3 days 
before utilising them in an experiment. To target Mre11 a similar protocol was used 
except that 20 µl of OF was used for each knock-down and the transfection was 
repeated 24h after the initial treatment. Cells were harvested and used for experiments 
96h after the first transfection. 
2.2. Molecular biology techniques. 
2.2.1. Preparation of media and plates. 
Luria broth (LB) was made with 10 g/l NaCl (Sigma), 10 g/l bacto-tryptone (BD) and 5 
g/l yeast extract (BD) in water, and sterilized by autoclaving at 120˚C and 100 kPa for 
30 min. LB-agar was made by adding 15 g/l agar (BD) to LB, and sterilizing the 
solution by autoclaving as above. After cooling, ampicillin was added to a final 
concentration of 100 µg/ml. Before solidifying, aliquots of LB-agar were poured into 
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plates and left to cool. LB-agar plates were stored at 4˚C until used for bacterial 
transformations. 
2.2.2. Bacterial transformations. 
Bacterial transformations were carried out in competent Escherichia coli cells. The NEB 
1-beta DH5α strain (New England BioLabs) was used for recombinant plasmid 
production and propagation, XL10-Gold Ultracompetent cells (Stratagene) were used 
for directed site mutagenesis and BL21-CodonPlus (DE3)-RIL bacteria were used to 
generate recombinant proteins. For each transformation, a 25 µl aliquot of competent 
cells was thawed on ice before addition of up to 100 ng of DNA or ligation mixture; in 
the case of XL-10-Gold, cells were incubated with 1 µl of β-mercaptoethanol for 10 min 
before addition of plasmid DNA. Bacteria were incubated on ice for 30 min, before 
being heat-shocked at 42˚C for 30 sec. They were placed back on ice for 5 min, before 
addition of 300 µl of LB medium described above, pre-warmed to 37˚C. Cultures were 
placed in an incubator at 37˚C with shaking at 200 rpm for 1h. Bacteria were then 
spread onto LB-agar plates containing ampicillin, and incubated at 37˚C overnight. 
2.2.3. Preparation of plasmid DNA. 
Plasmids used in this study and the proteins they encode are detailed in Table 2.3. 
Table 2.3. Plasmids used in this study. 
Vector Product Tag Amino acids Origin 
pGEX-4T-1 53BP1 GST 1-356 G. Stewart 
pGEX-4T-1 53BP1 GST 333-759 G. Stewart 
pGEX-4T-1 53BP1 GST 722-1039 G. Stewart 
pGEX-4T-1 53BP1 GST 992-1331 G. Stewart 
pGEX-4T-1 53BP1 GST 1309-1620 G. Stewart 
pGEX-4T-1 53BP1 GST 1584-1972 G. Stewart 
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pcDNA4/His 53BP1 His 1584-1972 In-house 
pcDNA3 CtIP none Full length - 1-897 In-house 
pGEX-4T-1 CtIP GST Full length – 1-897 J. Last 
pGEX-4T-1 CtIP GST 324-897 J. Last 
pGEX-4T-1 CtIP GST 42-132 R. Baer 
pGEX-4T-1 CtIP GST 45-620 R. Baer 
pGEX-4T-1 CtIP GST 133-462 R. Baer 
pGEX-4T-1 CtIP GST 371-620 R. Baer 
pGEX-4T-1 CtIP GST 620-897 R. Baer 
pGEX-4T-1 CtIP GST 775-897 R. Baer 
pGEX-4T-1 MDC1 GST 1-380 G. Stewart 
pGEX-4T-1 MDC1 GST 341-724 G. Stewart 
pGEX-4T-1 MDC1 GST 791-1118 G. Stewart 
pGEX-4T-1 MDC1 GST 1052-1720 G. Stewart 
pGEX-4T-1 MDC1 GST 1686-2090 G. Stewart 
pcDNA4/His MDC1 His 1686-2090 In-house 
pRS314 Mre11 none Full length – 1-708 J. Petrini 
pcDNA3β NBS1 myc Full length – 1-754 X. Wu 
pcDNA3β NBS1 myc 1-116 X. Wu 
pcDNA3β NBS1 myc 92-246 X. Wu 
pcDNA3β NBS1 myc 209-363 X. Wu 
pcDNA3β NBS1 myc 343-501 X. Wu 
pcDNA3β NBS1 myc 475-634 X. Wu 
pcDNA3β NBS1 myc 613-754 X. Wu 
pGEX-4T-1 p53 GST 1-72aa J. Last 
pRS314 Rad50 none Full length - 1-1312 J. Petrini 
pGEX-4T-1 RPA32 GST Full length – 1-270 J. Last 
p-BIND TopBP1 GAL4 Full length – 1-1435 M. Morgan 
p-BIND TopBP1 GAL4 2-591 M. Morgan 
p-BIND TopBP1 GAL4 253-914 M. Morgan 
p-BIND TopBP1 GAL4 789-1435 M. Morgan 
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2.2.3.1 Large scale preparation. 
Single colonies from plates containing successful transformants were picked and used 
to inoculate 5 ml cultures of LB containing 100 µg/ml ampicillin. Minicultures were 
incubated at 37˚C with shaking at 200 rpm. After 6-8h the 5 ml cultures were added to 
flasks containing 500ml LB supplemented with 100 µg/ml ampicillin, and left to grow 
overnight at 37˚C with shaking at 200 rpm. The following day, cells were pelleted by 
centrifugation at 6000 rpm for 15 min at 4˚C. Plasmid DNA was extracted from 
bacterial pellets using a PureLink HiPure Plasmid Maxiprep Kit (Invitrogen), according 
to the manufacturer’s instructions. DNA was concentrated with 2 volumes of 
isopropanol and pelleted by centrifugation at 6000 rpm for 1h at 4˚C. Pellets were 
washed with 1.5 ml of ethanol, centrifuged as before and air dried under sterile 
conditions. DNA was resuspended in 400 µl of nuclease-free water (Ambion) and the 
concentration was measured using a NanoDrop spectrophotometer (Thermo Scientific). 
2.2.3.2. Small scale preparation. 
Single colonies from plates containing successful transformants were picked and used 
to inoculate 15 ml cultures of LB containing 100 µg/ml ampicillin. Minicultures were 
incubated at 37˚C with shaking at 200 rpm overnight. The following day cultures were 
pelleted at 3000 rpm for 15 min at 4˚C. Plasmid DNA was extracted from bacterial 
pellets using a QIAprep Spin Miniprep Kit (QIAGEN) according to the manufacturer’s 
instructions and eluted in 30 µl of nuclease-free water (Ambion) and the concentration 
was measured using a NanoDrop spectrophotometer (Thermo Scientific). 
2.2.4. Agarose gel electrophoresis. 
Agarose gels were prepared by dissolving agarose (Invitrogen) in TBE (100 mM Tris-
HCl, 100 mM boric acid, 2 mM EDTA, pH 8.0) buffer to a final concentration of 0.8%. 
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The resultant slurry was boiled in order to dissolve the agarose and allowed to cool 
before the addition of SybrSafe stain in DMSO solution (Invitrogen) at a 1:10 000 
dilution and poured into the casting tray. Gels were allowed to set at room 
temperature. Samples were diluted with 6x loading buffer (0.25% bromophenol blue, 
50% glycerol in a 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 solution). Electrophoresis was 
carried out at 50V in TBE buffer for 30 min. DNA was visualized with a Safe Imager 
(Invitrogen). 
2.2.5. Restriction enzyme digestion and insert purification by gel extraction. 
Restriction enzymes: BamHI and Not1 were obtained from Roche and stored at -20˚C. 
Restriction enzyme digestion of GST-53BP1 1584-1972 aa, GST-MDC1 1686-2090 aa or 
pcDNA4/His C (Invitrogen) was carried out in a total volume of 50 µl at 37˚C for 3h in 
buffer 3 (NEB) with addition of Bovine Serum Albumin (BSA, NEB). Digestion products 
were separated by agarose gel electrophoresis and appropriate bands cut out from the 
gel. The gel extraction procedures were performed using QIAquick Spin Columns in 
accordance with manufacturer’s instructions (QIAGEN). Briefly, bands of the expected 
size were excised from the gel and placed in a microfuge tube which was weighed. 
Three times the volume of the slice of QG buffer was added and mixtures were 
incubated at 50˚C until the slices dissolved. Mixtures were applied onto the column 
and centrifugated at 13000 rpm for 1 min. Columns were washed with PE buffer and 
bound DNA eluted in 30 µl of sterile distilled water by centrifugation at 13000 rpm for 
1 min. 
2.2.6. Ligations. 
A vector:insert ratio of 1:5 was prepared in a total volume of 12µl that also contained 
1µl (400 cohesive end units) of T4 DNA ligase and 1.2µl of ligase buffer as supplied by 
the manufacturer (NEB). The reaction was incubated at 16˚C overnight. 
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2.2.7. GST fusion protein expression and purification. 
Plasmids encoding glutathione S-transferase (GST)–tagged proteins were used to 
transform BL21 bacteria as described above. Colonies from successful transformations 
were picked and used to inoculate 20ml LB media containing 100 µg/ml ampicillin. 
Cultures were incubated overnight at 37˚C with shaking at 200 rpm. The following 
day, 15ml of the overnight cultures were added to flasks containing 500ml LB with 
100µg/ml ampicillin (the remainder of the overnight cultures was aliquoted, prepared 
for long-term storage by addition of sterile glycerol to final concentration of 50%, and 
kept at -80˚C). The flasks of bacterial cultures were incubated at 37˚C with shaking at 
200 rpm. Once the cultures had reached an optical density of A600 ≅ 0.6-0.7, protein 
production was induced by addition of isopropyl-β-thiogalactopyranoside (IPTG) to a 
final concentration of 1 mM. The cultures were then transferred to an orbital incubator 
set at 30˚C and shaken at 200rpm for 4h, before centrifuging bacteria at 6000rpm for 
10 min at 4˚C. Pellets were stored at -80˚C until used for protein purification. 
To purify tagged proteins bacterial pellets were thawed and resuspended in ice-cold 
bufferA (1% Triton X-100, 2mM EDTA in PBS). Lysates were sonicated (3 x 30s) and 
centrifuged at 18,000 rpm for 20min at 4˚C to remove insoluble material. Supernatants 
were incubated twice with glutathione-agarose beads (Sigma-Aldrich) for 90 min with 
rotation at 4˚C. Beads were collected by centrifugation at 3000 rpm for 5 mins at 4˚C. 
Complexes were washed three times in buffer A and twice in buffer B (2mM EDTA in 
PBS). GST-fusion proteins were released by addition of GST elution buffer (25 mM 
glutathione, 50 mM Tris-HCl, pH 8.0). Beads were removed by centrifugation at 3000 
rpm for 5 min at 4˚C, and supernatants were dialysed overnight at 4˚C against a 
solution of 10% glycerol, 150 mM NaCl, 1mM DTT, 50 mM Tris-HCl, pH 7.2. The 
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following day dialysis was repeated for 3 h in fresh buffer and GST-fusion proteins 
were collected, aliquoted and stored at -80˚C until further use. 
Table 2.4. GST-tagged proteins used in this study. 
Vector Product Tag Amino acids Origin 
pGEX-4T-1 53BP1 GST 1-356 G. Stewart 
pGEX-4T-1 53BP1 GST 333-759 G. Stewart 
pGEX-4T-1 53BP1 GST 722-1039 G. Stewart 
pGEX-4T-1 53BP1 GST 992-1331 G. Stewart 
pGEX-4T-1 53BP1 GST 1309-1620 G. Stewart 
pGEX-4T-1 53BP1 GST 1584-1972 G. Stewart 
pGEX-4T-1 CtIP GST Full length – 1-897 J. Last 
pGEX-4T-1 CtIP GST 324-897 J. Last 
pGEX-4T-1 CtIP GST 42-132 R. Baer 
pGEX-4T-1 CtIP GST 45-620 R. Baer 
pGEX-4T-1 CtIP GST 133-462 R. Baer 
pGEX-4T-1 CtIP GST 371-620 R. Baer 
pGEX-4T-1 CtIP GST 620-897 R. Baer 
pGEX-4T-1 CtIP GST 775-897 R. Baer 
pGEX-4T-1 MDC1 GST 1-380 G. Stewart 
pGEX-4T-1 MDC1 GST 341-724 G. Stewart 
pGEX-4T-1 MDC1 GST 791-1118 G. Stewart 
pGEX-4T-1 MDC1 GST 1052-1720 G. Stewart 
pGEX-4T-1 MDC1 GST 1686-2090 G. Stewart 
pGEX-4T-1 p53 GST 1-72 J. Last 
pGEX-4T-1 RPA32 GST 1-270 J. Last 
 
2.2.8. In vitro transcription/translation. 
Eukaryotic in vitro transcription and translation was carried out using the TNT T7/T3 
Coupled Rabbit Reticulocyte Lysate System, according to the manufacturer’s 
instructions (Promega). Briefly, a reaction was assembled using 25µl rabbit reticulocyte 
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lysate, 2 µl TNT reaction buffer, 1 µl T7 polymerase or SP6 polymerase in case of 
pcDNA3-CtIP construct, 1 µl 1mM amino acid mixture minus methionine, 2 µl [35S]-
methionine (1000 Ci/mmol at 10 mCi/ml), 1 µl Protector RNase Inhibitor (Roche), 2 µg 
DNA template and nuclease-free water (Ambion) to a final volume of 50 µl. Reactions 
were incubated at 30˚C for 90 min. The resultant protein was stored at -80˚C until 
required. All plasmids use to produce labelled proteins and polypeptides are listed in 
Table 2.5. 
Table 2.5. Plasmids use to produce labelled proteins and polypeptides. 
Vector Product Tag Amino acids Origin 
pcDNA4/His 53BP1 His 1584-1972 In-house 
pcDNA3 CtIP none Full length - 1-897 In-house 
pcDNA4/His MDC1 His 1686-2090 In-house 
pRS314 Mre11 none Full length – 1-708 J. Petrini 
pcDNA3β NBS1 myc Full length – 1-754 X. Wu 
pcDNA3β NBS1 myc 1-116 X. Wu 
pcDNA3β NBS1 myc 92-246 X. Wu 
pcDNA3β NBS1 myc 209-363 X. Wu 
pcDNA3β NBS1 myc 343-501 X. Wu 
pcDNA3β NBS1 myc 475-634 X. Wu 
pcDNA3β NBS1 myc 613-754 X. Wu 
pRS314 Rad50 none Full length J. Petrini 
p-BIND TopBP1 GAL4 Full length – 1-1435 M. Morgan 
p-BIND TopBP1 GAL4 2-591 M. Morgan 
p-BIND TopBP1 GAL4 253-914 M. Morgan 
p-BIND TopBP1 GAL4 789-1435 M. Morgan 
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2.2.9 Polymerase Chain Reaction (PCR) based techniques. 
2.2.9.1 Site directed mutagenesis. 
Primers used to generate mutated forms of GST-CtIP fragments are detailed in Table 
2.6. 
Table 2.6. Primer sequences used to generate mutated forms of GST-CtIP 
fragments. 
 
GST-CtIP target 
fragment and 
mutated residues 
 
Primer sequence 
 
Company 
 
371-620 aa, 
506 S > A 
FWD: 5’ CGT CAA GAG AAA 
GCC CAA GGA AGT GAG ACT 3’ 
REV: 5’ AGT CTC ACT TCC 
TTG GGC TTT CTC TTG ACG 3’ 
 
AltaBiosciences 
 
371-620 aa, 
555 S > A 
FWD: 5’ GGG GAG CCC TGT 
GCA CAG GAA TGC ATC ATC 3’ 
REV: 5’ GAT GAT GCA TTC 
CTG TGC ACA GGG CTC CCC 3’ 
 
AltaBiosciences 
 
324-897 aa, 
506 S > A 
FWD: 5’ CGT CAA GAG AAA 
GCC CAA GGA AGT GAG ACT 3’ 
REV: 5’ AGT CTC ACT TCC 
TTG GGC TTT CTC TTG ACG 3’ 
 
AltaBiosciences 
 
324-897 aa, 
555 S > A 
FWD: 5’ GGG GAG CCC TGT 
GCA CAG GAA TGC ATC ATC 3’ 
REV: 5’ GAT GAT GCA TTC 
CTG TGC ACA GGG CTC CCC 3’ 
 
AltaBiosciences 
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324-897 aa, 
664 S > A 
FWD: 5’ GGA GCA GAC CTT 
GCT CAG TAT AAA ATG GAT 3’ 
REV: 5’ ATC CAT TTT ATA 
CTG AGC AAG GTC TGC TCC 3’ 
 
AltaBiosciences 
 
324-897 aa, 
679 S > A 
FWD: 5’ ACA AAG GAT GGC 
GCT CAG TCA AAA TTA GGA 3’ 
REV: 5’ TCC TAA TTT TGA 
CTG AGC GCC ATC CTT TGT 3’ 
 
AltaBiosciences 
 
324-897 aa, 
745 S > A 
FWD: 5’ GCA GAC AGT TTC 
GCC CAA GCA GCA GAT GAA 3’ 
REV: 5’ TTC ATC TGC TGC 
TTG GGC GAA ACT GTC 3’ 
 
AltaBiosciences 
 
324-897 aa, 
859 T > A 
FWD: 5’ GGT TTT CCT TCC 
GCT CAG ACT TGT ATG GAA 3’ 
REV: 5’ TTC CAT ACA AGT 
CTG AGC GGA AGG AAA ACC 3’ 
 
AltaBiosciences 
 
Site directed mutagenesis was carried out using reagents from Promega unless 
otherwise stated. Briefly, the reaction mix was assembled as follows: 5 µl of 10x Buffer 
containing 20mM MgSO4, 50 ng of plasmid DNA template, 1 µl of appropriate primer 
set, 1 µl deoxynucleotide triphosphate (dNTP) mix (10 mM), 1 µl Pfu DNA Polymerase 
all made up to 50 µl with nuclease-free water (Ambion). The reaction was performed in 
a thermocycler (Applied Biosystems) according to the below protocol: 
95˚C => 30 s 
16 cycles 
95˚C => 30 s 
55˚C => 1 min 
 68˚C => 13 min for GST-CtIP 324-897aa or 11 min for GST-CtIP 371-620 
4˚C =>  ∞ 
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To remove the parental unmutated plasmid DNA after PCR, 1 µl of DpnI enzyme was 
added and the mix was incubated for 3h at 37˚C. Following the digestion, mutated 
plasmid DNA was transformed into XL10 Gold bacteria as described above. Successful 
transformants were picked for small scale plasmid DNA purification. Purified DNA was 
used to transform BL21 bacteria to produce mutated GST-CtIP proteins. 
2.2.9.2. DNA sequencing. 
Site-directed mutagenesis products and pcDNA4/His-53BP1 and pcDNA4/His-MDC1 
constructs were purified and sequenced in 20 µl reactions containing 1 µl ABI Prism Big 
Dye Terminator (Applied Biosystems), 4 µl 5x buffer (Applied Biosystems), 250 ng 
plasmid DNA, 5 pmol sequencing primer. PCR conditions were as follows:  
29 cycles 
4˚C =>  ∞ 
 
Sequencing reactions were subsequently isopropanol precipitated and resuspended in 
10 µl Hi-Di Formamide for use with the ABI Prism 3130xl Genetic Analyser DNA 
Sequencer (Applied Biosystems). 
2.3. Protein biochemistry techniques. 
2.3.1. Preparation of total cell lysates. 
Cell culture medium was removed and cells were washed twice in PBS. Samples were 
lysed and harvested by addition of denaturing buffer (9 M urea, 150 mM β-
96˚C => 10 s 
50˚C => 5 s 
60˚C => 4 min 
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mercaptoethanol, 50 mM Tris-HCl, pH 7.3). Cells were sonicated for 15 s on ice and 
samples were used immiediately or stored at -80˚C. 
2.3.2. Determination of protein concentration. 
Protein concentrations were determined by Bradford assay. A small volume (1 – 2 µl) 
of lysate was mixed with 1 ml of Bradford reagent (BioRad) diluted 1:4 with deionised 
water. The same procedure was applied to BSA to obtain concentrations ranging from 
0 – 10 µg/ml to generate a standard curve for comparison purposes on a 
spectrophotometer (Cecil, CE9200) at a wavelength of 595 nm against a blank of 
deionised water. 
2.3.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein samples were separated by SDS-PAGE. Polyacrylamide gels were made using 
30% Acrylamide/Bis Solution (Severn Biotech) diluted with deionised water to give the 
appropriate percentage. Generally, gels used to separate molecules of around 200 – 
350 kDa contained 8% acrylamide and 11% for separation of lower molecular weight 
proteins. Gel solutions also contained 100 mM Tris, 100mM Bicine, 0.1% SDS and 
0.25% TEMED. Acrylamide polymerisation was initiated by addition of ammonium 
persulfate (APS) to a final concentration of 0.05%. Gels were assembled using Hoeffer 
Scientific apparatus according to the supplied instructions and electrophoresis was 
carried out in buffer containing 100 mM Tris, 100mM Bicine and 0.1% SDS. Protein 
samples were prepared for SDS-PAGE by addition of Laemmli Sample Buffer (BioRad), 
before being heated at 90˚C for 5 min. Pre-stained protein molecular weight markers 
were used to identify analysed proteins. After loading samples onto the gel the 
electrophoresis was generally run overnight at constant current depending on the size 
of the proteins of interest. 
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2.3.4. Protein visualization in polyacrylamide gels. 
After electrophoresis, gels were stained with 0.1% Coommassie Brilliant Blue R-250 
(Sigma-Aldrich), 10% glacial acetic acid, 20% methanol in deionised water and left at 
room temperature for 30 min with agitation. To visualise protein bands gels were 
destained in 10% glacial acetic acid, 20% methanol in deionised water until the bands 
were clearly visible. 
2.3.5. GST-pull down assays with radioactive proteins. 
GST-fusion proteins and [35S]-labelled proteins were produced as described above. 
Typically, 30 µg of GST-fusion protein diluted in 150 µl of buffer A, described above, 
supplemented with 1% BSA was mixed with 10 µl of [35S]-labelled protein reaction 
mixture and incubated on ice for 1.5 h. Protein complexes were isolated by incubation 
with glutathione-agarose beads for 1h with rotation. Beads were washed three times in 
buffer A and twice in buffer B described above. Samples were analyzed by SDS-PAGE, 
followed by fluorography and autoradiography. 
2.3.6. Detection of radioactive proteins by fluorography and 
autoradiography. 
Gels were incubated twice in DMSO for 30 min each time and subsequently in 23% 
2,5-Diphenyloxazole solution in DMSO for 3 h. Gels were rehydrated for 1h in deionised 
water and dried for 2h under vacuum at 80˚C. Dried gels were exposed for 
autoradiography at -20˚C using KODAK Medical X-ray film. Alternatively gels were 
agitated in Amplify (GE Healthcare) for 30 min and then dried. 
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2.4. Immunocytochemistry techniques. 
2.4.1. Antibodies. 
All antibodies used in this study and their origins are shown in Table 2.7. 
Table 2.7. Primary antibodies used in this study. 
 
Antigen Antibody Source Use Dilution Origin 
53BP1 3661 Rabbit IF, WB 1/500 G. Stewart 
53BP1 3662 Rabbit IP 1/100 G. Stewart 
53BP1-
pS1778 
2675 
 
Rabbit WB 1/1000 Cell signalling 
β-actin AC-74 Mouse WB 1/50000 Sigma-Aldrich 
ATR 2B5 Mouse IP, WB 1/200;1/1000 Abcam 
ATM 11G12 Mouse IP, WB 1/100; 1/500 J. Last 
ATM-pS1981 1655 Rabbit WB 1/500 R&D Systems 
BLM C-18 Goat IP, WB 1/50; 1/500 Santa Cruz 
BRCA1 D-9 Mouse IF 1/10 Santa Cruz 
CtIP 14-1 Mouse IF, WB 1/20; 1/250 R. Baer 
CtIP 222 Rabbit IP 1/100 In-house 
H2AX 07-627 Rabbit WB 1/1000 Upstate 
γ-H2AX JBW301 Mouse IF, WB 1/1000 Upstate 
MDC1 12/13 Rabbit IF, WB 1/100; 1/500 G. Stewart 
MDC1 40/41 Rabbit IP 1/100 G. Stewart 
MDC1 M2444 Mouse WB 1/1000 Sigma-Aldrich 
Mre11 12D7 Mouse WB 1/1000 Gene Tex 
NBS1 1C3 Mouse WB 1/1000 Gene Tex 
NBS1-S343 12297 Rabbit WB 1/500 Abcam 
Rad50 13B3/2C6 Mouse WB 1/1000 Ambion 
RPA70 Ab-1 Mouse WB 1/1000 Calbiochem 
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SMC1 A300-055A Rabbit WB 1/500 Bethyl Laboratories 
SMC1-pS966 A300-050A Rabbit WB 1/500 Bethyl Laboratories 
SMG1 A300-393A Rabbit WB 1/500 Bethyl Laboratories 
SMG1 A300-394A Rabbit IP 1/100 Bethyl Laboratories 
 
 
Table 2.8. Secondary antibodies used in this study. 
Antigen Antibody Source Use Dilution Origin 
Goat IgG P0449 Rabbit WB 1/2000 DAKO 
Goat IgG AlexaFluor488 Donkey IF 1/1000 Molecular Probes 
Goat IgG AlexaFluor594 Donkey IF 1/1000 Molecular Probes 
Mouse IgG P0447 Goat WB 1/2000 DAKO 
Mouse IgG AlexaFluor488 Donkey IF 1/1000 Molecular Probes 
Mouse IgG AlexaFluor594 Donkey IF 1/1000 Molecular Probes 
Rabbit IgG P0399 Swine WB 1/3000 DAKO 
Rabbit IgG AlexaFluor488 Donkey IF 1/1000 Molecular Probes 
Rabbit IgG AlexaFluor594 Donkey IF 1/1000 Molecular Probes 
 
 
2.4.2. Immunoprecipitations. 
Cell lysates were prepared by washing dividing cells twice in PBS followed by addition 
ice-cold immunoprecipitation (IP) buffer containing 1% Nonidet P-40, 150 mM NaCl, 1 
mM EDTA, 50 mM Tris-HCl (pH 7.3). Cell lysates were homogenized using a Wheaton-
Dounce glass homogeniser and centrifuged at 40,000 rpm for 30 min at 4˚C to remove 
insoluble material. Antibodies were added to cleared lysates and antibody-antigen 
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complexes were left to form overnight at 4˚C. The following day Protein G-Sepharose 
beads (Sigma-Aldrich) were added to the samples for 1 h at 4˚C with rotation. The 
sepharose beads were centrifuged and washed four times in ice-cold IP buffer, before 
addition of 30 µl Laemmli Sample Buffer (BioRad) to elute proteins. Samples were 
boiled and centrifuged in preparation for SDS-PAGE and Western blotting. 
2.4.3. Western blotting. 
After SDS-PAGE, separated proteins were transferred onto a nitrocellulose membrane 
using a Hoeffer Scientific transfer system. Briefly, gels and nitrocellulose membranes 
were soaked for 5 min in blotting buffer (50 mM Tris, 190 mM glycine, 20% methanol). 
Individual gels were laid onto a nitrocellulose membrane of similar size, sandwiched 
between two pieces of pre-soaked Whatman 3 MM blotting filter paper and two 
blotting pads, and placed in plastic cassettes. These were then put into the blotting 
tank and electro-transfer was carried out for 6–8 h at 300 mA. After the transfer 
membranes were stained with a solution containing 0.1% Ponceau S (Sigma-Aldrich), 
3% trichloroacetic acid for 3 min. To visualize the proteins membranes were washed in 
water and in 0.1% Tween 20, 150 mM NaCl, 20 mM Tris-HCl, pH 7.3 (TBST) to remove 
protein staining. 
Nitrocellulose membranes were blocked in 5% skimmed dried milk powder in PBS for 
1h at room temperature with agitation, followed by washing in TBST. Blots were 
shaken overnight at 4˚C with antibodies at the appropriate dilution in TBST containing 
5% milk. The following day, blots were washed six times in TBST, before incubation at 
room temperature with the appropriate horseradish peroxidise-conjugated (HRP) 
secondary antibodies in TBST containing 5% milk with agitation. After 2 h blots were 
again washed six times in TBST. Specific antigens were detected using ECL reagent 
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(GE Healthcare) or Immobilon Western HRP Substrate (Millipore) and KODAK Medical 
X-ray film. 
2.4.4. Kinase assay. 
Cell lysates were prepared in several ways. For the ATM kinase assay dividing LCLs 
were irradiated with 5Gy and harvested 30 min post-irradiation. For the ATR kinase 
assay dividing LCLs were harvested without previous irradiation . For the SMG1 kinase 
assay dividing LCLs were mock-treated or treated with 5mM caffeine and harvested 1 h 
post-treatment. For the CtIP kinase assay HeLa cells depleted of ATM we irradiated 
with 5Gy and harvested 30 min post treatment or LCLs were mock-treated or treated 
with 5mM caffeine for 30 min and subsequently irradiated with 5Gy and harvested 30 
min post-irradiation. After harvesting, the cells were washed twice in PBS and 
subsequently lysed in ice-cold immunoprecipitation buffer (TGN) containing 50mM Tris 
pH7.5, 150mM NaCl, 10% Glycerol, 50mM β-Glycerophosphate, 1% Tween-20, 0.2% 
Nonidet P40 supplemented before use with 10mM NaF. Cell lysates were homogenized 
using a Wheaton-Dounce glass homogeniser and centrifuged at 40,000 rpm for 30 min 
at 4˚C to remove insoluble material. Antibodies were added to cleared lysates and 
antibody-antigen complexes were left to form for 3 h on ice. Following the incubation 
Protein G-Sepharose beads (Sigma-Aldrich) were added to the samples for 1 h at 4˚C 
with rotation. Sepharose beads were centrifuged and washed three times in ice-cold 
TGN buffer, once in TGN buffer supplemented with 0.5M LiCl and twice in kinase buffer 
containing 20mM HEPES pH 7.5, 50mM MgCl2, 10mM MnCl2 and supplemented before 
use with 1mM NaF and 0.5mM DTT. After the last wash 30µl of kinase buffer, 10µg of 
GST-CtIP protein or 10µg of GST alone or 20µg GST-53BP1 protein or 20µg of GST 
alone and 1µl of [32P]γ-ATP (PerkinElmer) were added to each sample. Kinase assays 
were performed at 37˚C for 5 min for the phosphorylation of GST-CtIP fragments and 
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for 10 min for the phosphorylation of the GST-53BP1 fragment. To stop the reaction 
Laemmli Sample Buffer was added and samples were heated to 95˚C for 5 mins and 
separated over night in 11% SDS-PAGE gels. The following day gels were 
Coommassie-stained, dried and radioactive signals detected by autoradiography. 
2.4.5. Immunofluorescence. 
Hela cells were seeded on 12-well glass slides to densities of around 1-2 x 104cell/well. 
The following day the slides were mock irradiated or irradiated with 9Gy and incubated 
for 1 h. Cells were then washed twice in PBS, fixed in 4% w/v paraformaldehyde in 
PBS for 10 min and washed again in PBS. Methanol extraction was carried out for 15 
min at -20˚C. Cells were rehydrated in PBS and blocked in PBS for 1 h. Primary 
antibodies were diluted to appropriate concentration in 0.1% FCS in PBS, and were 
incubated with the cells for 1 h in light-proof container. After the incubation cells were 
washed five times in PBS and incubated with secondary antibodies diluted in 0.1% FCS 
in PBS for 1 h in the same container. Slides then were washed five times in PBS, air-
dried and mounted in Vectashield Mounting Medium (Vector Laboratories) containing 
4’,6-diamidino-2-phenylindole (DAPI), and protected with glass coverslips. Cells were 
viewed on a Zeiss Axioskop microscope, and z-Layer images (0.1 µm horizontal 
sections) were recorded with Openlab v3.0.9 Biovision software package (Improvision). 
Single, deconvoluted z-Layers were merged to show colocalizations. 
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CHAPTER III 
RESULTS 
 
 
 
CtIP interacts with the DNA damage response 
proteins containing BRCT domains. 
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3.1. CtIP associates with proteins containing BRCT domains. 
3.1.1. Introduction. 
BRCT domains are found in a large number of proteins and as an evolutionarily 
conserved module they exist in a wide range of organisms from prokaryotes to 
eukaryotes. It was first identified as a 90-100 amino acid tandem repeat at the C-
terminus of the BRCA1 gene product. It can appear as a single or multiple motif 
comprising several characteristic clusters of conserved hydrophobic residues that form 
the core of the BRCT fold. It is found in many proteins that are involved in DNA-
damage check point control and DNA repair (Bork et al., 1997; Callebaut & Mornon, 
1997). It has been shown that the tandem BRCT repeats of BRCA1 function as a 
phosphopeptide binding module, although, the isolated individual repeat does not 
(Manke et al., 2003; Rodriguez et al., 2003; Yu et al., 2003). The binding of BRCT 
domains to phosphorylated peptide targets has been reported for other proteins 
involved in the DNA damage response, thus it could be concluded that it may be a 
common property of the BRCT-containing proteins. The BRCT domain of BRCA1 binds 
with higher affinity to serine-phosphorylated peptides that contain phenylalanine three 
residues downstream of phosphoserine (pSer-X-X-Phe), than to unphosphorylated 
peptides (Manke et al., 2003; Yu et al., 2003). This may represent a general rule of 
how BRCT domains of BRCA1, as well as BRCT domains in other proteins, interact with 
their binding partners in response to the DNA damage-induced cellular signalling 
cascade. 
In previous studies BRCA1 was shown to interact with CtIP via its BRCT domains; 
tumour-associated mutations in the BRCT domains abolished that interaction. (Li et al., 
1999; Wong et al., 1998; Yu et al., 1998). This indicates the importance of this 
association and places CtIP as a possible tumour suppressor protein (Chinnadurai, 
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2006; Wu & Lee, 2006). Recently it has also been shown that the choice of DNA repair 
pathway depends on the phosphorylation status of CtIP’s Ser327 and its subsequent 
interaction with the BRCT domains of BRCA1. Thus CtIP is not only required for repair 
of DSBs by homologous recombination together with BRCA1 in S/G2 phase but also for 
MMEJ (microhomology-mediated end-joining) in G1 (Yun & Hiom, 2009). These 
findings suggest that CtIP’s interaction with the BRCT domains of BRCA1 is crucial for 
the cell’s survival. Thus, one can hypothesise that CtIP would interact with the BRCT 
domains present in other proteins. As most BRCT domain-containing proteins are 
involved in crucial stages of cell survival and cell cycle, CtIP could be found as an 
adaptor protein that modulates the transitions into different repair pathways, 
depending on the stage of the cell cycle. Thus it was interesting to see which of the 
BRCT domain-containing proteins interact with CtIP and via which region that 
interaction occurred. It was decided to investigate possible interactions with four of 
those proteins namely 53BP1, MDC1, TopBP1 and NBS1. 53BP1 has been shown to be 
mainly involved in an XRCC4-dependent NHEJ as it interacts with dimethylated K20 of 
H4 and this DNA repair process is γ-H2AX independent. MDC1 has been reported to 
function primarily in HR in a γ-H2AX-dependent manner (Kotnis et al., 2009; Xie at el., 
2007). NBS1, like MDC1, is involved in HR and recently has been shown to take part in 
MMEJ (Deriano et al., 2009; Tauchi et al., 2002). TopBP1 is involved in the DNA 
damage response via its interaction with ATR and ATRIP and subsequent activation of 
ATR (Kumagai et al., 2006). 
3.1.2. Results. 
3.1.2.1. The interaction of CtIP with 53BP1. 
53BP1 is a DNA damage mediator protein containing several ATM/ATR phosphorylation 
sites, a dimerization motif followed by G-A (glycine-alanine) rich region, the tandem 
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Tudor domain (methylated protein binding domain), NLS (nuclear localization signal) 
and the tandem repeat of BRCT domain at the C-terminus. The dimerization motif, 
GAR and Tudor domain form a kinetochore-binding domain (KBD; Jullien et al., 2002; 
Figure.3.1.). Human 53BP1 protein was arbitrarily divided into six fragments and the 
corresponding cDNA was cloned into a pGEX vector. The GST-tagged proteins were 
expressed and purified as described in section 2.2.7. Figure.3.1. shows the domain 
localization and the distribution of amino acids in the GST-53BP1 fragments. 
 
 
Figure.3.1. The amino acid distribution in the GST-53BP1 fragments, the 
domain structure and ATM/ATR phosphorylation sites of human 53BP1 
protein. GAR – glycine-arginine rich, KBD – kinetochore binding domain, NLS – 
nuclear localization signal 
 
To establish whether CtIP associates with 53BP1 a co-immunoprecipitation assay was 
performed. A rabbit antibody against 53BP1 was used and immunoprecipitated 
complexes were isolated with protein G-Sepharose beads as described in the section 
2.4.2. Interacting CtIP was visualised by Western blotting as shown in Figure.3.2.a. 
To determine direct interaction and the binding sites for CtIP on 53BP1 a GST-pull 
down assay was performed as described in the section 2.3.5. The equivalent of 10 µg 
of non-degraded GST-tagged 53BP1 fragments, assessed on the basis of previously 
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a)      
 
 
b)       c) 
           
Figure.3.2. CtIP associates with 53BP1 in vivo and directly binds to 53BP1. 
a), HeLa cell lysates were immunoprecipitated with an antibody against 53BP1 and 
coimmunoprecipitating CtIP was identified by Western blotting. b), GST-53BP1 
polypeptides were incubated with [35S]CtIP, and complexes isolated with glutathione-
agarose beads. Bound proteins were visualised by SDS-PAGE and audioradiography, c) 
Coomassie Brilliant Blue stained gel representing the GST-53BP1 fragments used in the 
experiment. This figure is representative of three independent experiments. 
 
77kDa 
66kDa 
45kDa 
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a) 
 
 
 
b) 
 
 
 
Figure.3.3. The possible interaction sites of CtIP with 53BP1. a) CtIP interacts 
with 53BP1 via its Tudor domain and the tandem repeat of the BRCT domains, b) CtIP 
interacts with 53BP1 via a polypeptide fragment that is located in the region where the 
two GST-53BP1 fragments, that bind to CtIP, overlap. 
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stained Coomassie Brilliant Blue stained gel was used in each reaction. Six different 
GST-53BP1 fragments, covering the whole of 53BP1 (Figure.3.1.) were incubated with 
full length [35S]CtIP. Radioactively labelled CtIP was synthesized using full length CtIP 
cDNA cloned into a pcDNA3 vector, which has a SP6 promoter site for an in vitro 
transcription/translation reaction as described in section 2.2.8. Complexes were 
isolated with glutathione-agarose beads and fractionated by SDS-PAGE. The 
autoradiograph shows CtIP binding to two GST-53BP1 fragments stretching from 1309-
1620aa and including the Tudor domain and 1584-1972aa including tandem repeats of 
the BRCT domain (Figure.3.2.b). This result suggests that there could be a binding site 
in each of the fragments or one binding site in the region where the two fragments 
overlap (amino acids 1584-1620, Figure.3.3.). 
3.1.2.2. The interaction of CtIP with MDC1. 
Following the demonstration that CtIP binds to 53BP1 a second novel associated 
protein was identified as MDC1. MDC1 is a DNA damage response mediator protein 
found to contain an FHA domain (phosphothreonine recognition domain, Durocher D. 
& Jackson S. P., 2002) at the N-terminus, a PST domain localized in the centre of the 
protein and tandem repeats of the BRCT domains at the C-terminus (Figure.3.4). 
Human MDC1 cDNA was arbitrarily divided into five fragments and the corresponding 
fragments were cloned into a pGEX vector. The equivalent of 10 µg of non-degraded 
GST-tagged MDC1 fragments, assessed on the basis of previously stained Coomassie 
Brilliant Blue stained gel was used in each reaction. The GST-tagged proteins were 
expressed and purified as described in section 2.2.7. Figure.3.4. shows the domain 
localization and the distribution of amino acids in GST-MDC1 fragments. 
An immunoprecipitation experiment, as described in section 2.4.2, was performed to 
investigate the in vivo association of CtIP and MDC1. An MDC1 rabbit antibody was 
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used to immunopreciptate MDC1 and associated proteins from HeLa cell lysates. 
Complexes were isolated with protein G-Sepharose beads and associated CtIP was 
visualized by Western Blotting as shown in Figure.3.5.a.  
 
Figure.3.4. Cartoon of the amino acid distribution in the GST-MDC1 
fragments and the domain structure of human MDC1. 
 
To establish binding sites for CtIP on MDC1 a GST-pull down assay was performed (see 
section 2.3.5). Full length [35S]CtIP, generated using full length CtIP cDNA cloned into 
a pcDNA3 vector and translated in vitro (see section 2.2.8.), was incubated with five 
GST-MDC1 fragments covering the whole of MDC1 (Figure.3.4.). Complexes were 
isolated with glutathione-agarose beads, fractionated by SDS-PAGE and visualised by 
autoradiography. A GST-MDC1 fragment which is composed of amino acid residues 
1052-1720 and includes the PST domain and a fragment comprising 1686-2090aa 
including tandem repeat of the BRCT domain bind to full length [35S]CtIP, Figure.3.5.b. 
This result suggests two CtIP binding sites on MDC1 or one binding site in the region 
where the two GST-MDC1 fragments overlap (amino acid residues 1686-1720, 
Figure.3.6.).  
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Figure.3.5. CtIP associates with MDC1 in vivo and directly binds to MDC1
Hela cell lysates were immunoprecipitated with an antibody against M
Coimmunoprecipitating CtIP was identified by Western blotting. b), GST-M
polypeptide fragments were incubated with [35S]CtIP, and complexes isolated 
glutathione-agarose beads. Bound proteins were visualised by SDS-PAGE 
audioradiography, c) Coomassie Brilliant Blue stained gel representing the GST-M
fragments used in the experiment. This figure is representative of three indepen
experiments. 
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Figure.3.6. The possible interaction sites of CtIP with MDC1. a) CtIP interacts 
with MDC1 via its PST domain and the tandem repeat of the BRCT domains, b) CtIP 
interacts with MDC1 via a polypeptide fragment that is located in the region where the 
two GST-MDC1, that bind to CtIP, overlap. 
 
 3.1.2.3. The interaction of CtIP with TopBP1. 
TopBP1, like 53BP1 and MDC1, falls into the DNA damage response mediator protein 
category. It contains eight BRCT domains which are spread throughout the whole of 
the protein. Human TopBP1 protein was arbitrarily divided into three fragments and 
the corresponding cDNAs, as well as the full length cDNA, were cloned into a pBIND 
vector (Wright et al., 2006), which has a T7 promoter site for in vitro 
transcription/translation as described in the section 2.2.8. Figure.3.7. shows the ATR 
activation domain and the BRCT domain localization and the distribution of amino acids 
in the pBIND-TopBP1 fragments.  
 
Figure.3.7. The amino acid distribution in the pBIND-TopBP1
the domain structure of human TopBP1 with the ATM phosph
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[35S]TopBP1 fragments covering the whole of the protein were incubated with three 
GST-CtIP fragments. The equivalent of 10 µg of non-degraded GST-tagged CtIP 
fragments, assessed on the basis of previously stained Coomassie Brilliant Blue stained 
gel was used in each reaction. Complexes were isolated with glutathione-agarose 
beads, fractionated by SDS-PAGE and detected by autoradiography. As shown in 
Figure.3.8.b.&c. full length [35S]TopBP1 and a fragment composed of amino acid 
residues 2-591 bind to all three GST-CtIP fragments. As the fragment composed of 
residues 253-914 does not bind to CtIP we hypothesise that CtIP binds directly to 
TopBP1 via its first two BRCT domains (Figure.3.10.a).  
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination, Figure.3.8.c. 
To investigate further the direct interaction of these two proteins and establish CtIP 
binding sites for TopBP1, another GST-pull down assay was performed. In this 
experiment full length TopBP1 and the 2-591aa fragment were incubated with five 
different overlapping GST-CtIP fragments covering different regions of CtIP. The 
equivalent of 10 µg of non-degraded GST-tagged CtIP fragments, assessed on the 
basis of previously stained Coomassie Brilliant Blue stained gel was used in each 
reaction. Complexes were isolated with glutathione-agarose beads, fractionated by 
SDS-PAGE and bound full length and 2-591aa fragment of [35S]TopBP1 were visualized 
by autoradiography. As shown in Figure.3.9. full length [35S]TopBP1 (Figure.3.9.a.) and 
the 2-591aa fragment (Figure.3.9.b.) each bind to four GST-CtIP fragments. On the 
basis of the GST-CtIP fragments composition it was concluded that TopBP1 has 
probably two binding sites on CtIP, within peptides encompassing residues 133-371aa 
and 620-775aa (Figure.3.10.b). The first of the CtIP regions contains  
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Figure.3.8. CtIP associates with TopBP1 in vivo and directly binds to 
TopBP1. a), Hela cell lysates were immunoprecipitated with an antibody against 
TopBP1. Coimmunoprecipitating CtIP was identified by Western blotting. b), 
[35S]TopBP1 full length fragment was incubated with various GST-CtIP polypeptide 
fragments, and complexes isolated with glutathione-agarose beads. Bound proteins 
were visualised by SDS-PAGE and audioradiography; c), Coomassie Brilliant Blue 
stained gel representing GST-CtIP fragments used in the experiment, 
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Figure.3.8. CtIP associates with TopBP1 in vivo and directly binds to 
TopBP1. d) three [35S]TopBP1 polypeptide fragments and [35S]p-BIND vector were 
incubated with various GST-CtIP polypeptide fragments, and complexes isolated with 
glutathione-agarose beads. Bound proteins were visualised by SDS-PAGE and 
audioradiography. This figure is representative of three independent experiments. 
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Figure.3.9. Establishing the CtIP binding sites for TopBP1. a), [35S]TopBP1 full 
length or b), [35S]TopBP1 2-591aa was incubated with various GST-CtIP polypeptide 
fragments, and complexes isolated with glutathione-agarose beads. Bound proteins 
were visualised by SDS-PAGE and audioradiography, c) Coomassie Brilliant Blue 
stained gel representing the GST-CtIP fragments used in the experiment. This figure is 
representative of three independent experiments. 
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Figure.3.10. The possible interaction sites of CtIP with TopBP1.
interacts with CtIP via its first two BRCT domains, b) TopBP1 (aa 2-591) in
CtIP via regions within residues 133-463aa and 775-897aa. 
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the BRCA1-binding domain and the second one includes two major phosphorylation 
sites reported to be phosphorylated upon DNA damage by ATM (Li S. et al., 2000).  
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination, Figure.3.9.c. 
3.1.2.4. The interaction of CtIP with NBS1. 
The final protein containing the BRCT domains to be examined in this study was NBS1, 
a modulator of DNA damage sensing and signalling, a cell cycle checkpoint controller 
and a telomere stabiliser (Zhang et al., 2006). The N-terminus of the protein contains 
an FHA domain (Durocher & Jackson, 2002) followed by a tandem repeat of BRCT 
domains (Becker E. et al., 2006), the middle region contains two ATM phosphorylation 
sites (Kurz & Lees-Miller, 2004) and two nuclear localisation signals (NLS) and the C-
terminal region contains the Mre11-binding domain (Desai-Mehta et al., 2001), an NLS 
and an ATM-binding domain (Falk et al., 2005). Human NBS1 protein was arbitrarily 
divided into six fragments and the corresponding cDNAs, as well as the full length 
cDNA, were cloned into a pcDNA3 vector, which has a T7 promoter site for in vitro 
transcription/translation as described in the section 2.2.8. Figure.3.11. shows the 
domain localization and distribution of amino acids in pcDNA3 -NBS1 fragments. 
To investigate the CtIP and NBS1 interaction in vivo a co-immunoprecipitation assay 
was performed. HeLa cell lysate was incubated with a rabbit CtIP antibody and protein 
complexes were isolated with protein G-Sepharose beads. As seen in Figure.3.12. 
associated NBS1 was visualised by Western blotting. Co-immunoprecipitation of the 
proteins is consistent with data presented by Sartori et al. (Sartori et al., 2007). 
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Figure.3.11. The amino acid distribution in NBS1 fragments and the domain 
structure of human NBS1. 
In order to establish CtIP binding sites on NBS1 a GST-pull down assay was performed 
(see section 2.3.5). The equivalent of 10 µg of non-degraded GST-tagged CtIP 
fragments, assessed on the basis of previously stained Coomassie Brilliant Blue stained 
gel was used in each reaction. Radioactively labelled full length NBS1 and six 
overlapping NBS1 fragments were incubated with a GST-CtIP fragment and a full 
length protein. Complexes were separated using glutathione-Sepharose beads, 
fractionated by SDS-PAGE and visualized by autoradiography. Figure.3.13.a. shows 
direct interaction of the GST-CtIP fragments with full length [35S]NBS1 and two 
[35S]NBS1 fragments: 1-116aa, containing the FHA domain and 613-754aa, containing 
the Mre11-binding domain and the ATM binding site (Figure.3.15.). 
Additional bands on both of the Coomassie Brilliant Blue stained gel, not marked by the 
red circles, are most likely a product of degradation of the originally GST-tagged 
protein or bacterial-protein contamination (Figure.3.13.c). 
To confirm these results another GST-pull down assay was performed utilizing 
[35S]CtIP and three overlapping GST-NBS1 fragments covering the whole protein. The 
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equivalent of 10 µg of non-degraded GST-tagged NBS1 fragments, assessed on the 
basis of previously stained Coomassie Brilliant Blue stained gel was used in each 
reaction. Complexes were isolated with glutathione-agarose beads, fractionated by 
SDS-PAGE and bound radioactive protein was detected by autoradiography. As seen in 
Figure.3.13.b. the C-terminal region of NBS1 binds to radioactively labelled CtIP. The 
N-terminal region, however, in this experiment does not interact; this may be caused 
either by degradation of the GST-NBS1 fragment or improper folding of the protein 
which could inhibit the binding. There was a problem with this GST-polypeptide 
fragment during the purification procedure (section 2.2.7) as it could only be isolated 
in very small amounts suggesting an inherent instability. It is also shown in 
Figure.3.13.c., right panel, that this fragment contains a lot of degradation products 
which is seen as a large low molecular weight band that is smeared at the bottom of 
that track. Other bands, not marked by red circles, are most likely degradation 
products of the GST-tagged protein or bacterial-protein contamination (Figure.3.13.c.). 
A GST-pull down assay (section 2.3.5) was also performed to determine NBS1 binding 
sites on CtIP. Radioactively labelled NBS1 fragments containing amino acids 1-116 and 
613-754 and the full length protein, previously found to bind GST-CtIP fragments, were 
incubated with five different, overlapping GST-CtIP fragments. The equivalent of 10 µg 
of non-degraded GST-tagged CtIP fragments, assessed on the basis of previously 
stained Coomassie Brilliant Blue stained gel was used in each reaction. Complexes 
were isolated with glutathione-agarose beads, fractionated by SDS-PAGE and visualized 
by autoradiography. As shown in Figure.3.14.a. the N-terminal NBS1 fragment binds 
most GST-CtIP fragments although with different avidity. The fragment composed of 
amino acid residues 371-620 does not show any interaction. On the basis of the 
binding to N-terminal region of CtIP we propose a binding region stretching from 
amino acid residues 133-371 and another one comprising amino acid residues 775-897 
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Figure.3.12. CtIP associates with NBS1 in vivo. Hela cell lysates were 
immunoprecipitated with an antibody against CtIP. Coimmunoprecipitating NBS1 was 
identified by Western blotting. This figure is representative of three independent 
experiments. 
a) 
 
Figure.3.13. CtIP binds directly to NBS1. a) [35S] labelled full length NBS1 as well 
as six NBS1 polypeptide fragments were incubated with GST-CtIP (full length, aa45-
371 and aa324-897). Complexes were isolated with glutathione beads and bound 
proteins visualized by SDS-PAGE and autoradiography; 
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Figure.3.13. CtIP binds directly to NBS1. b) [35S] labelled full length CtIP was 
incubated with three GST-NBS1 fragments (1-230 aa, 226-578 aa and 572-754 aa). 
Complexes were isolated and visualized as described above, c) Coomassie Brilliant Blue 
stained gels representing GST-CtIP fragments used in the experiments shown in a) 
and b). This figure is representative of three independent experiments. 
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as one could argue that weaker binding to the fragment comprising 620-897aa is due 
to an overlap of residues 775-897aa; thus we could conclude that it is the 775-897aa 
region of CtIP that shows interaction with N-terminal region of NBS1. As seen in 
Figure.3.14.b. the C-terminal fragment of NBS1 shows strong binding to the CtIP 
fragments containing amino acids 133-463, 620-897 and 324-897 and weaker binding 
to a fragment composed of residues 371-620.  
On the basis of this result we can conclude that one of the two binding sites for NBS1 
is located within the 133-463aa region of CtIP as we can argue that the weak binding 
to the fragment containing amino acid residues 371-620 is due to the fact that it 
overlaps the fragment composed of 133-463aa, and therefore contains the C-terminal 
region of that fragment, which is a part of the binding site. The C-terminal fragment of 
NBS1 also interacts with a GST-CtIP fragment containing residues 620-897 but as it 
does not bind to fragment 775-897aa we can conclude that the second binding site is 
located between amino acids 620- 775. The binding of full length NBS1 mainly to the 
three GST-CtIP fragments comprising amino acid residues 133-463, 620-897 and 324-
897 confirms the previous result obtained with the N-terminal and C-terminal region of 
NBS1 and establishes the previously recognized binding sites for both of the fragments 
(Figure.3.16.). Taking into consideration the result shown in Figure.3.13.a. with the full 
length NBS1 binding to the full length CtIP it strongly enhances the importance of both 
of the binding sites on CtIP, as the full length protein associates with the full length 
NBS1 to a greater extent than the N-terminally truncated version.  
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination (Figure.3.14.d.). 
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c)       d) 
    
 
Figure.3.14. CtIP binding sites for NBS1. a), [35S]NBS1 1-116aa or b), [35S]NBS1 
613-754aa polypeptide fragments or c) [35S]NBS1 full length were incubated with five 
GST-CtIP polypeptide fragments, and complexes isolated with glutathione beads. 
Bound proteins were visualised by SDS-PAGE and audioradiography; d) Coomassie 
Brilliant Blue stained gel representing the GST-CtIP fragments used in the experiment. 
This figure is representative of three independent experiments. 
45kDa 
66kDa 
77kDa 
 
 116 
 
 
 
 
 
Figure.3.15. The possible interaction sites of CtIP on NBS1. NBS1 interacts with 
CtIP via its FHA domain and the region comprising Mre11 and ATM binding sites.  
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Figure.3.16. The interaction sites on CtIP for NBS1. a) NBS1 FHA domain 
interacts with CtIP via a region that is located in between the residues 133-371aa and 
620-775aa, b) NBS1 C-terminal region interacts with CtIP via regions located in the 
residues 133-463aa and 775-897aa. 
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Some of those results have been confirmed by Chen et al. In that publication they 
reported binding of full length NBS1 mainly to the N-terminal (1-220aa) and C-terminal 
region of CtIP (631-897aa) and to a smaller extent to a GST-CtIP fragment comprising 
439-649aa. It has also been shown that the C-terminal fragment of NBS1 does not 
bind to CtIP in the case of absence of the Mre11-binding domain (Chen et al., 2008).  
A lot of work on CtIP’s interaction with the MRN complex was started at the same time 
as this work and has been published already. Thus some of the results overlap 
published data however confirming it.  
3.2. Nuclear localization of CtIP and the BRCT-domain containing proteins 
before and after DNA damage. 
3.2.1. Introduction. 
Eukaryotic cells, upon DNA damage, activate a signalling network that coordinates a 
rapid detection of the DNA lesions and activation of the repair machinery with a 
temporary delay in cell cycle progression (Zhou & Elledge, 2000). The effectiveness of 
genome surveillance pathways is dependent on carefully organized redistribution of 
their components to nuclear regions that contain and surround the damaged DNA 
(Lucas et al., 2004). Those rearrangements, in response to ionizing radiation (IR), on 
the cellular level are manifested by the appearance of nuclear foci, so-called IR-
induced foci (IRIF; Shiloh, 2003). 
IRIF are microscopically visible, dynamic structures containing vast numbers of 
proteins that are involved in various aspects of double-strand break (DSB) repair. Thus 
IRIF are widely used as a convenient marker of DSB location.  
γ-H2AX is a phosphorylated form of the histone H2AX. H2AX in turn makes up 2-25% 
of the whole pool of the histone H2A variant, depending on the cell line and tissue 
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examined (Kinner et al., 2008). H2AX phosphorylation at Ser139 occurs just minutes 
after DNA damage and reaches its peak around 30 minutes later. It spreads 
approximately 2Mbp around the DNA lesion and the modification consists of ~2000 γ-
H2AX molecules (Rogakou et al., 1999). Thus γ-H2AX staining is a very useful tool in 
DSBs recognition. 
IRIF, apart from comprising various DNA repair-associated proteins, participate in 
restructuring large segments of chromatin in the vicinity of the DNA lesion (van 
Attikum & Gasser, 2005). This increases the accessibility of the damaged DNA for 
proteins that are engaged in DNA repair (Murr et al., 2006). IRIF formation is an 
important step in cellular protection against DNA lesions but not all proteins are readily 
located there. One of the key components of DNA damage surveillance machinery, 
Chk2, interacts with DSBs only transiently, without forming cytologically visible foci 
(Bekker-Jensen et al., 2006). Thus it has been concluded that it is not necessary for all 
proteins participating in the DNA damage repair to concentrate at the very site of the 
lesion as they may play a role in micro-compartments associated with the lesion. Also it 
has been suggested that not all damage induced foci are structurally similar which 
would reflect different roles of different proteins in the repair process (Bekker-Jensen 
et al., 2006). 
3.2.2. Results. 
The BRCT domain containing proteins, as part of the DNA damage surveillance 
mechanism, are known to form foci. Temporal studies of foci formation has revealed 
the sequence of events involving the recruitment of the MRN complex to the site of 
lesion and acetylation of ATM followed by its autophosphorylation at S1981 (Bakkenist 
& Kastan, 2003; Sun et al., 2007; Williams et al., 2007) Activated ATM phosphorylates 
histone H2AX forming so called γ-H2AX (Rogakou et al., 1999). γ-H2AX recruits MDC1 
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which in turn recruits another pool of the MRN complex and RNF8 (Ring Finger Protein 
8), which is a E3 ubiquitin ligase (Goldberg et al., 2003; Mailand et al., 2007; Stewart 
et al., 2003). Further events are either NBS1- or RNF8-dependent (Mohammad & 
Yaffe, 2009).  
Here, using immunofluorescence microscopy, we examined the localization of 53BP1, 
MDC1, TopBP1 and NBS1 IRIF in comparison with CtIP’s nuclear localization before 
and after DNA damage caused by 9Gy of irradiation. The influence of CtIP’s depletion 
on formation of 53BP1 and MDC1 IRIF occurring after irradiation with -rays was also 
tested. 
3.2.2.1. The nuclear localization of CtIP and 53BP1. 
HeLa cells were seeded on 12 well slides at 1-2 x 104cells/well. The following day the 
slides were mock-irradiated or irradiated with 9Gy and incubated for 1 h. Cells were 
fixed and co-stained with a rabbit 53BP1 antibody and a mouse γ-H2AX antibody as 
described in section 2.4.5. The secondary antibodies used in this experiment are listed 
in Table 2.8 and were a green anti-rabbit for 53BP1 and a red anti-mouse for γ-H2AX. 
The nucleus is stained in blue using 4’,6-diamidino-2-phenylindole (DAPI). Figure.3.17. 
shows the γ-H2AX and the 53BP1 staining in mock-irradiated cells and in cells 
irradiated with 9Gy. In cells treated with IR focal staining of 53BP1 and γ-H2AX is seen 
indicating localization of 53BP1 and phosphorylation of the histone H2AX at the sites of 
DNA DSBs. In the merged picture in the lower panel the yellow staining shows sites in 
the nucleus where both of the proteins co-localize.  
In Figure.3.18. co-staining with a rabbit antibody against 53BP1 and a mouse antibody 
against CtIP is shown. In the first panel HeLa cells were mock-irradiated with CtIP 
staining, in red, being slightly granular and 53BP1 staining, in green, is evenly spread 
throughout the whole nucleus apart from the nucleoli. After irradiation, as seen in the 
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Figure.3.17. The localization of γ-H2AX and 53BP1 in the cell nucleus before 
and after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against γ-
H2AX (red) and 53BP1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of the γ-H2AX staining versus the 53BP1 
staining and yellow indicates the sites where they co-localize. This figure is 
representative of three independent experiments. 
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Figure.3.18. The localization of CtIP and 53BP1 in the cell nucleus before 
and after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against 
CtIP (red) and 53BP1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of the CtIP staining versus the 53BP1 
staining and yellow indicates the sites where they co-localize. This figure is 
representative of three independent experiments. 
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lower panel, CtIP’s staining becomes more defined and granular and 53BP1 forms 
discrete foci – IRIF. In the right-hand the yellow staining indicates that the two 
proteins co-localize at the site of DSB. 
3.2.2.2. The nuclear localization of CtIP and MDC1. 
HeLa cells were seeded on 12 well slides at 1-2 x 104cells/well. The following day the 
slides were mock-irradiated or irradiated with 9Gy and incubated for 1 h. Cells were 
fixed and co-stained with a rabbit MDC1 antibody and a mouse γ-H2AX antibody 
(section 2.4.5.). The secondary antibodies used in this experiment are listed in the 
Table 2.8 and were a green anti-rabbit for MDC1 and a red anti-mouse for γ-H2AX. The 
nucleus is stained in blue using 4’,6-diamidino-2-phenylindole (DAPI). In Figure.3.19. in 
the top panel staining of both of these proteins is shown in mock-irradiated cells. In 
the absence of DNA damage histone H2AX is not phosphorylated thus there is no 
staining with the γ-H2AX antibody. MDC1’s green staining is present in the nucleus at 
all times. The lower panel shows formation of IRIF in the HeLa cells treated with 9Gy. 
Both of the proteins localize to the sites of DSBs and as seen in yellow in the merged 
picture at several sites of damaged DNA γ-H2AX and MDC1 co-localize.  
Figure.3.20. shows localization of CtIP and MDC1 staining before and after DNA 
damage caused by 9Gy of irradiation. In the top panel the mock-irradiated cells are 
shown. The CtIP staining is again not well-defined and with granular proprieties and 
the MDC1 staining is evenly distributed throughout the nucleus with the exception of 
nucleoli regions. In the lower panel, after DNA damage, both of the proteins seem to 
aggregate and CtIP’s staining becomes distinctively granular and MDC1 forms IRIF. In 
the last picture the yellow staining indicates sites at which both of the proteins localize 
together. 
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Figure.3.19. The localization of γ-H2AX and MDC1 in the cell nucleus before 
and after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against γ-
H2AX (red) and MDC1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of the γ-H2AX staining versus the MDC1 
staining and yellow indicates the sites where they co-localize. This figure is 
representative of three independent experiments. 
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Figure.3.20. The localization of CtIP and MDC1 in the cell nucleus before and 
after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against 
CtIP (red) and MDC1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of the CtIP staining versus the MDC1 
staining and yellow indicates the sites where they co-localize. This figure represents is 
representative of three independent experiments. 
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3.2.2.3. The nuclear localization of CtIP and NBS1. 
HeLa cells were seeded at a density of 1-2 x 104cells/well on 12 well microscope slides. 
The following day the slides were mock-irradiated or irradiated with 9Gy and incubated 
for 1 h. Cells were fixed and co-stained with a rabbit NBS1 antibody and a mouse γ-
H2AX antibody as described in section 2.4.5. The secondary antibodies used in this 
experiment are listed in Table 2.8 and were a green anti-rabbit for NBS1 and a red 
anti-mouse for γ-H2AX. The nucleus is stained in blue using 4’,6-diamidino-2-
phenylindole (DAPI). As shown in Figure.3.21. γ-H2AX staining is not present in the 
mock-irradiated cells (in the top panel) and NBS1 staining is ill-defined and the two 
bright dots are possibly stained centrosomes. In the lower panel IRIF staining is 
observed indicating that γ-H2AX and NBS1 localized at the sites of DSBs. In the right-
hand panel the yellow staining indicates that these two proteins localize at the same 
sites of DNA lesions. 
Figure.3.22. shows CtIP and NBS1 localization in the cell’s nucleus before and after 
DNA damage. In the top panel the distribution of the two proteins is demonstrated as 
an ill-defined nuclear staining. In the bottom panel CtIP shows more defined granular 
staining indicating the involvement in DNA lesion repair and the NBS1 staining is typical 
for a DNA damage repair protein. In the right-hand panel in yellow the overlap of the 
two staining patterns can be observed illustrating sites where CtIP and NBS1 co-
localize. 
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Figure3.21. The localization of γ-H2AX and NBS1 in the cell nucleus before 
and after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against γ-
H2AX (red) and NBS1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of the γ-H2AX staining versus the NBS1 
staining and yellow indicates the sites where they co-localize. This figure is 
representative of three independent experiments. 
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Figure.3.22. The localization of CtIP and NBS1 in the cell nucleus before and 
after DNA damage. HeLa cells were grown on slides and subsequently mock-
irradiated or irradiated with 9Gy. Cells were fixed and stained with antibodies against 
CtIP (red) and NBS1 (green) and the nucleus was visualised using DAPI staining 
(blue). Merge picture shows the positioning of CtIP staining versus the NBS1 staining 
and yellow indicates the sites where they co-localize. This figure is representative of 
three independent experiments. 
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3.2.2.4. The lack of disruption of 53BP1 and MDC1 IRIF formation upon CtIP 
depletion. 
In order to establish whether CtIP depletion influences 53BP1 and MDC1 IRIF 
formation a CtIP knock-down was performed (section 2.1.7.) followed by 
immunofluorescence staining (section 2.4.5.). HeLa cells were mock-treated or treated 
with the CtIP siRNA and after 48h they were seeded at a density of 1-2 x 104cells/well 
on 12 well microscopic slides. The following day the slides were irradiated with 3Gy 
and incubated for 1h (see section 2.1.6.2.). Cells were fixed and stained with a rabbit 
53BP1 antibody or a rabbit MDC1 antibody as described in section 2.4.5. The 
secondary antibody used in this experiment is listed in the Table 2.8 and was a green 
anti-rabbit for both 53BP1 and MDC1. The nucleus is stained in blue using 4’,6-
diamidino-2-phenylindole (DAPI). 
As shown in the Figure.3.23. the top panel represents 53BP1 IRIF formation in the 
presence of CtIP and the bottom panel represents 53BP1 IRIF formation in the 
absence of CtIP. The focal distribution of 53BP1 in both cases is similar; thus we can 
conclude that CtIP does not influence 53BP1 foci formation. This is consistent with 
other findings presented in this thesis and suggests that CtIP is a bridging protein in 
cellular protein-protein interactions. 
Figure.3.24. shows the MDC1 IRIF formation in the presence and absence of CtIP 
expression, again showing that CtIP does not influence MDC1 focal redistribution. 
Given the fact that CtIP does not influence the formation of 53BP1 and MDC1 IRIF in 
the presence of γ-H2AX we could conclude that CtIP might orchestrate the DNA repair 
processes that those proteins are involved in, such as HR in the case of MDC1, rather 
than their retention at the DSBs sites. 
               
Figure.3.23. The formation of 53BP1 IRIF is not
depletion. HeLa cells were mock-treated (a) or treated 
subsequently irradiated with 3Gy and fixed an hour post IR
represents 53BP1 IRIF and the blue staining depicts the n
Western blot showing CtIP knock-down in the HeLa cells u
actin indicates equal loading. This figure is representat
experiments. 
b) c) a)  130 
 
 disrupted upon CtIP 
with CtIP siRNA (b) and 
. The green focal staining 
ucleus (DAPI staining), c) 
sed in the experiment; β-
ive of three independent 
              
Figure.3.24. The formation of MDC1 IRIF is not
depletion. HeLa cells were mock-treated (a) or treated 
subsequently irradiated with 3Gy and fixed an hour post IR
represents MDC1 IRIF and the blue staining depicts the nu
Western blot showing CtIP knock-down in the HeLa cells u
actin indicates equal loading. This figure is representati
experiments. c) b) a)  131 
  
 disrupted upon CtIP 
with CtIP siRNA (b) and 
. The green focal staining 
cleus (DAPI staining). c) 
sed in the experiment; β-
ve of three independent 
 
 132 
3.3. Discussion.  
In previous studies CtIP has been shown to interact with the BRCT domains of BRCA1 
and this interaction has been shown to be phosphorylation-dependent in vivo 
(Table.3.1; Yu et al., 1998; Yu & Chen, 2004). We have now shown that CtIP interacts 
in vivo and in vitro with the BRCT domains of other DNA damage proteins such as 
53BP1, MDC1 and TopBP1. However, the direct interaction shown occurs with 
unphosphorylated CtIP protein. On the other hand we cannot rule out the fact that the 
in vitro translated protein could be post-translationally modified by the components of 
the in vitro transcription/translation reaction mixture as it consists of total rabbit 
reticulocyte lysate.  
Table.3.1. Proteins containing BRCT domains interacting with CtIP. 
protein binding CtIP domains involved in interaction with CtIP 
BRCA1 
BRCT domains (aa 1602-1863);  
Yu et al., 1998; Yu & Chen, 2004 
53BP1 Tudor/BRCT domains (aa 1309-1972) 
MDC1 PST/BRCT domains (aa 1052-1720) 
TopBP1 BRCT domains (aa 2-253) 
NBS1 FHA/C-terminus (aa 1-116/aa 613-754) 
 
To confirm 53BP1 and CtIP’s association in vivo a co-immunoprecipitation assay was 
performed. As shown in Figure.3.2.a. 53BP1 and CtIP exist in a complex in HeLa cell 
lysates. In order to investigate whether it is a direct or an indirect interaction a GST-
pull down assay was carried out. As seen in Figure.3.2.b. two GST-53BP1 fragments 
interact with the radioactively labelled full length CtIP and it seems likely there are two 
binding sites on 53BP1 for CtIP as shown in Figure.3.3.a., Table.3.1. The binding of 
[35S]CtIP to the GST-53BP1 fragment that contains the BRCT domains is not very 
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strong; this could be caused by its dephosphorylated nature as the BRCT domains are 
known to be phospho-binding sites (Yu et al., 2003). However, 53BP1’s BRCT 
domains have not been proven to bind specifically to phosphopeptides (Mohammad & 
Yaffe, 2009). Thus it is very likely that the GST-53BP1 fragment containing the G-A rich 
stretch and the Tudor domain is the main binding site for CtIP. The Tudor domain is 
known to bind to methylated proteins such as when 53BP1 interacts with methylated 
H3 and H4 (Huyen et al., 2004; Sanders et al., 2004). However, CtIP up to now has 
not been reported to be methylated, thus it is possible that the CtIP binding site is 
located in the C-terminal region of the fragment containing the Tudor domain and ends 
before the BRCT domains (Figure.3.3.b.).  
53BP1 is most likely involved in the NHEJ pathway of DSB repair; however, total NHEJ 
is reported to be not influenced by the depletion of CtIP (Bennardo et al., 2008). Thus 
the process in which those two proteins take part together remains to be elucidated. 
However, as 53BP1 together with NBS1 and MDC1 is known to be involved in the G2/M 
replication independent cell cycle arrest orchestrated by ATR, we could hypothesise 
that CtIP could take part in that process (Stiff et al., 2008).  
To establish the MDC1 and CtIP association in vivo a co-immunoprecipitation assay 
was carried out. As seen in Figure.3.5.a. they associate in vivo which may implicate 
either a direct interaction or involvement of a third, intermediary protein. To address 
that question a GST-pull down assay was performed. As shown in Figure.3.5.b. MDC1 
and CtIP interact directly. The MDC1-CtIP binding is well defined with two of the GST-
MDC1 fragments interacting with [35S]CtIP (Figure.3.5.b, Table.3.1.). The interaction of 
[35S]CtIP with the GST-MDC1 fragment containing the PST domain may implicate the 
PST domain as a stabilizing binding site for the CtIP-MDC1 complex in vivo, whereas 
[35S]CtIP’s binding to the GST-MDC1 fragment comprising the BRCT domains could be 
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phosphorylation dependent and have a higher affinity with a phosphorylated CtIP 
protein. The MDC1 BRCT domains have been reported to specifically bind to phopho-
proteins phosphorylated in the C-terminal region (Mohammad & Yaffe, 2009). Thus we 
could hypothesise that CtIP binds to MDC1 constitutively through the PST domain and 
the binding through the BRCT domains may occur after the DNA damage when CtIP is 
phosphorylated on either the S664 or S745 (Figure.3.6.a). 
An attempt to reveal which region of CtIP binds to either 53BP1 and MDC1 was made. 
In vitro translatable C-terminal regions of 53BP1 and MDC1 were cloned into 
pcDNA4/His vector, however the efficiency of radioactive labelling was not high 
enough to perform an informative GST-pull down with the available GST-CtIP 
fragments. 
MDC1 is known to be involved in the homologous recombination pathway by which the 
broken DNA ends are repaired during S and G2 phases of the cell cycle (Zhang et al., 
2005). This pathway is independent of and parallel to, the BRCA1-dependent HR 
pathway (Xie et al., 2007). CtIP has been shown to be involved in DSB repair and in 
the choice of the repair pathway depending on its phosphorylation status on S327 and 
subsequent interaction with BRCA1. Thus we can speculate that CtIP could engage 
MDC1 via a similar mechanism. We could hypothesise that CtIP could stimulate MDC1’s 
involvement in the HR during S/G2 cell cycle phase after DNA damage (Yun & Hiom, 
2009). 
In order to investigate the in vivo association of TopBP1 and CtIP a co-
immunoprecipitation assay was performed. As shown in Figure.3.8.a. the proteins form 
a complex in HeLa cell lysates. To assess the direct interaction a GST-pull down assay 
was carried out. The results in Figure3.8.b. indicate that [35S]TopBP1 binds to GST-
CtIP. The binding site on TopBP1 can be mapped to the N-terminal 19 amino acid 
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fragment followed by first two BRCT domains and a 56 amino acid fragment at the C-
terminal region (Figure.3.10.a., Table.3.1.). To investigate further the direct binding of 
TopBP1 and CtIP a GST-pull down assay was performed, to establish which regions of 
the CtIP bind directly to the TopBP1. As Figure.3.9. shows several GST-CtIP fragments 
bind to the radioactively labelled TopBP1. On the basis of their amino acid composition 
it could be established that the CtIP regions that bind to TopBP1 encompass the 
previously determined BRCA1 binding site and the region that includes CtIP’s two main 
phosphorylation sites, Ser664 and Ser745 (Figure.3.10.b.). We conclude further, that it 
is possible it is the BRCA1 binding site on CtIP that binds to the BRCT domains of 
TopBP1. We also hypothesise that as CtIP associates with TopBP1 in normal cells it 
constitutively binds to CtIP through one of the binding sites and the other binding site 
is utilized after DNA damage when both of the proteins are involved in DNA repair. We 
also conclude, that this would implicate two mechanisms of TopBP1 and CtIP 
interaction that rely on the cell cycle stage and absence or presence of DNA damage. 
As TopBP1 is an ATR activator in response to DNA damage we suggest that CtIP’s 
interaction with TopBP1 enhances ATR kinase activity. And indeed the depletion of CtIP 
decreases phosphorylation of the two best known ATR substrates, RPA32 and Chk1, in 
response to SSBs (Sartori et al., 2007). TopBP1 is also known to be involved in HR 
together with NBS1, thus it is possible that CtIP engages TopBP1 in HR in a similar 
manner to BRCA1 and MDC1. On the other hand the N-terminal region of NBS1 has 
been shown to bind to TopBP1 and enable it to form foci (Morishima et al., 2007).  
As NBS1 and TopBP1 have two binding sites on CtIP we could hypothesise that each of 
these proteins binds to CtIP at a different site depending on the process that CtIP and 
NBS1 or CtIP andTopBP1 are taking part together in. Whether it is HR, MMEJ, ATR 
activation or end resectioning. 
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The association of NBS1 and CtIP was established by a co-immunoprecipitation assay 
as seen in Figure.3.12. To confirm their direct interaction a GST-pull down assay was 
performed. Figure.3.13.a. shows the direct interaction of radioactively labelled NBS1 
and GST-CtIP fragments (Table.3.1.). The fragment containing the FHA domain and 
the fragment containing Mre11-binding domain and ATM-binding site interact with CtIP 
(Figure.3.15). To confirm this result another GST-pull down assay was performed using 
three GST-NBS1 fragments and [35S]CtIP. As seen in Figure.3.13.b. [35S]CtIP interacts 
with the C-terminal region of NBS1. However, the interaction with the N-terminal 
region was not seen in this experiment, which is possibly due to the degradation of the 
GST-NBS1 fragment and its low starting concentration or the conformation of that 
fragment that would inhibit the binding to the [35S]CtIP. To assay which regions of CtIP 
bind to NBS1 a GST-pull down was performed. As shown in Figure.3.14.a&b. the N-
terminal and the C-terminal regions of NBS1 were radioactively labelled and incubated 
with various, overlapping GST-CtIP fragments. On the basis of this experiment we can 
conclude that the N-terminal region of NBS1 containing the FHA domain binds to two 
regions on CtIP comprising amino acid residues 133-371 containing the C-terminal 
region of the coiled-coiled region with the Rb-binding motif and the BRCA1-binding site 
and 775-897aa comprising the second zinc-binding motif. The C-terminal region of 
NBS1 shows strong binding to the CtIP amino acid residues 133-463 which include the 
BRCA1 binding domain and 620-775aa region comprising the two major 
phosphorylation sites, Ser664 and Ser745. 
NBS1 has been reported to take part in DSB sensing as a component of the MRN 
complex. It has also been shown to be involved in the MMEJ repair pathway, like CtIP 
(Deriano et al., 2009). Thus we could hypothesise that NBS1 could be CtIP’s partner 
while redirecting the DNA damage repair from homologous recombination in S/G2 into 
microhomology-mediated end-joining in G1/G0 (Yun & Hiom, 2009). This observation 
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is supported by the observation that CtIP binds to NBS1 via the FHA domain and the C-
terminal region thus the binding is not mediated by CtIP’s phosphorylation on S327 by 
CDK during the cell cycle. On the other hand the C-terminal region of NBS1 binds to 
CtIP through the C-terminal region of CtIP that comprises the two phosphorylation 
sites known to be phosphorylated by ATM in response to DNA damage 
(Figure.3.16.b.), thus this interaction could be induced in damaged cells. However it is 
worth noting that CtIP interacts in vivo with NBS1 in normal cells as well and the 
overall interaction is not induced by DNA damage (Figure.4.1.). However as CtIP binds 
to NBS1 through two sites it is possible that in normal cells it binds through one motif 
and in damaged cell by the other and thus the overall level of interaction remains the 
same.  
Taking into consideration all previously described results one can conclude that the 
BRCA1-binding region of CtIP must be highly active in protein-protein interactions. This 
region has been shown to be phosphorylated by CDKs in the S/G2 cell cycle stage thus 
this event may modulate CtIP’s binding affinity for different protein partners 
(Chinnadurai, 2006). However in the course of the work described here we did not 
look at the influence of CtIP’s phosphorylation at S327.  
It has also been shown that the phosphorylation status of Ser327 in this region 
impacts the choice between the homologous recombination (HR) and the 
microhomology-mediated end-joining (MMEJ), favouring the HR in S/G2 and the MMEJ 
in G1/G0 (Yun & Hiom, 2009). This would suggest that as 53BP1, MDC1, TopBP1 and 
NBS1 take part in DNA damage repair through different pathways, CtIP could be 
orchestrating them for an efficient DNA repair process.  
The modulation of CtIP’s interaction with the different binding partners may also 
depend upon its phosphorylation by ATM in response to DNA damage. The fact that 
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one of CtIP’s binding sites for TopBP1 and NBS1 encompasses the two serine residues 
known to be phosphorylated in response to the DSBs, S664 and S745, suggests that 
the interaction might have higher affinity in the presence of the DNA lesions. This 
implies that these sites are involved in the DNA damage response possibly transducing 
the signal together with TopBP1 and NBS1 to the ATR signalling cascade (Morishima et 
al., 2007). 
To assess CtIP’s localization in the cell before and after DNA damage a series of 
immunofluorescence  microscopy experiments were carried out. HeLa cells were mock-
irradiated or irradiated with 9Gy of γ-irradiation. Fixed cells were stained using different 
sets of antibodies and the results show that CtIP localizes in the nucleus of the cell and 
in unirradiated cells the staining pattern is diffuse with signs of granularity. In 
irradiated cells CtIP’s staining becomes more granular, showing that it concentrates in 
the microcompartments that partially overlap with the irradiation induced foci (IRIF) of 
proteins that were previously reported to form IRIF, such as 53BP1, MDC1 and NBS1. 
This supports the idea that CtIP forms complexes with these proteins and that they 
aggregate in the vicinity of the DNA lesions. However, it was impossible to asses 
directly CtIP’s localization at the DSBs using γ-H2AX as a marker of the DNA double 
lesions as both available antibodies against those proteins were of the same serotype. 
Nevertheless, we could deduce, that as 53BP1, MDC1 and NBS1 are known to co-
localize with the γ-H2AX at DSBs and CtIP’s staining partially overlaps the foci 
attributable to those proteins, that CtIP is likely to relocalize in the proximity of DNA 
lesions and therefore participates in the repair process. 
CtIP remains at the DSBs for over 24h (data not shown) thus we could speculate that 
it dissociates from them only after they are repaired, and during the time it is 
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concentrated in the IRIF it orchestrates the repair processes carried out by a variety of 
nuclear factors. 
As shown in Figure.3.23&24 the association of DNA damage proteins such as 53BP1 or 
MDC1 does not depend upon CtIP’s presence. However those proteins have already 
been shown to be the ‘recruiting factors’ for proteins to concentrate in IRIF (Bekker-
Jensen et al., 2006). Thus, as mentioned before CtIP could stimulate the change of 
active repair pathway depending on the stage of repair of a particular lesion as well as 
direct the repair towards a particular pathway depending on the cell cycle (Yun & 
Hiom, 2009). Thus it would behave as a ‘repair manager’ in the repair pathways. 
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4. The in vivo association of CtIP with the DNA damage response proteins 
and the influence of CtIP siRNA depletion on phosphorylation events in 
response to DNA damage. 
4.1. Introduction 
As shown in section 3.1.2. CtIP interacts in vivo and in vitro with proteins involved in 
the DNA damage response such as 53BP1, MDC1, TopBP1 and NBS1. In this chapter 
CtIP’s association with DNA damage response proteins was studied, focusing on the 
changes that occur after DNA damage. I have also examined how CtIP’s siRNA 
depletion affects phosphorylation events after inflicting DSBs, SSBs and collapse of the 
replication fork.  
Proteins associate into multicomplexes in vivo; thus it was of interest to examine how 
these complexes behave in response to DNA lesions. Following damage the first 
proteins to be engaged are sensor proteins. They have to recognize the problem and 
recruit transducer proteins which in turn spread the signal to mediator proteins and 
effector proteins. In the DNA damage response, proteins that are classified as sensor 
proteins are mainly the MRN complex consisting of Mre11, Rad50 and NBS1 for 
recognizing double stranded breaks (DSBs) and RPA70/32/14 complex involved in 
sensing single stranded breaks (SSBs). They activate transducer proteins such as the 
members of the PIKK family, namely ATM and ATR respectively. The kinases initiate a 
phosphorylation cascade which activates the downstream targets which take part in 
repairing the lesions. One of the classes of proteins to be activated by ATM and ATR 
are mediator proteins which orchestrate their downstream targets towards resolving 
the lesions and activating the cell cycle progression, 53BP1 and MDC1 are examples 
and have been examined in this chapter.  
As CtIP was shown to interact with NBS1 and as NBS1 is a member of the MRN 
complex it was interesting to investigate this association in genetically impaired 
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backgrounds, such as the ataxia-telangiectasia-like disease (ATLD; Stewart et al., 
1999) and Nijmegen breakage syndrome (NBS; Carney et al., 1998; Weemaes et al., 
1981).  
ATLD is caused by mutation in the Mre11 gene which produces either a truncated 
protein (homozygote) or full length and mutated protein (heterozygote). At the clinical 
level ATLD is characterized by progressive cerebellar ataxia and an onset of 
neurological features (Taylor et al., 2004). In the course of this study LCLs derived 
from a homozygote patient with a truncating mutation were used.  
NBS is caused by a gene mutation, most commonly 657del5 (Varon et al, 1998), 
causing a premature truncation of the protein and expression of two smaller proteins 
(Maser et al., 2001). It is characterized by microcephaly, growth retardation, 
immunodeficiency and predisposition to tumourogenesis. Both disorders display an 
increased level of chromosome translocations and hypersensitivity to γ-irradiation. They 
fail to induce DNA damage-activated protein kinases (Taylor et al., 2004). Using cells 
derived from patients with ATLD and NBS has facilitated the study of CtIP’s association 
with the MRN complex components in physiological backgrounds.  
In this study, considerable use was made of CtIP-depleted cells following siRNA 
treatment. CtIP has been reported to be involved in facilitating the phosphorylation of 
Chk1 kinase and RPA32 in response to stalled replication forks (Sartori et al., 2007). 
Thus we examined the influence of CtIP’s depletion on phosphorylation events in 
response to ionizing irradiation, UV irradiation and replication fork stalling.  
As ATM is the main kinase involved in the DNA double stranded break response we 
examined its substrates such as NBS1, ATM, SMC1, 53BP1 and γ-H2AX. These proteins 
are known to be phosphorylated by ATM. As ATR belongs to the same family of 
proteins as ATM and shares a consensus phosphorylation motif, it was interesting to 
investigate how the phosphorylation cascade spreads in response to SSBs and fork 
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stalling, influencing the phosphorylation status of those proteins. It was also of my 
interest to investigate whether the depletion of CtIP has an effect on the 
phosphorylation events in response to UV and replication fork stalling. On the other 
hand, as it was reported that ATR activates ATM in response to SSBs and replication 
fork stalling (Stiff et al., 2006), it was of interest to investigate the role of ATR 
phosphorylation of established ATM targets. Thus, we also investigated whether the 
depletion of CtIP influences ATR activation and subsequent ATM activation in response 
to SSBs and replication fork stalling. In addition ATM is responsible for ATR activation 
in response to DSBs (Yoo et al., 2007) thus it was important to establish whether CtIP 
also plays role in this process. 
4.2. Results. 
4.2.1. The in vivo association of CtIP with the DNA damage response 
proteins before and after DNA damage. 
4.2.1.1. The association of CtIP with the DNA damage sensor proteins. 
In order to establish CtIP’s association in vivo with the DNA damage sensor proteins, 
before and after DNA damage, a co-immunoprecipitation assay was performed. HeLa 
cells were mock-irradiated, irradiated with 5Gy or with 30J (section 2.1.6.2.) and left 
for 1 h before harvesting. The co-immunoprecipitation assay was performed as 
described in the section 2.4.2. A rabbit antibody was used to immunoprecipitate CtIP 
and the complexes were isolated with protein G-Sepharose beads; the associated 
proteins were fractionated by the SDS-PAGE and visualized by Western blotting. As 
shown in the Figure.4.1. CtIP associates with the MRN (Mre11, Rad50, NBS1) complex, 
which is the main sensor of the double stranded DNA break recognition system. As 
shown in Figure.4.1. CtIP also associates with RPA70, a main sensor of the single 
stranded break recognition pathway. Furthermore, none of those interactions are 
influenced by DNA damage. This may account for CtIP being one of the key 
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components of these complexes thus co-existing with them despite the damage caused 
to the DNA.  
As shown previously in section 3.1.2.4. CtIP interacts directly with NBS1, which is one 
of the components of the MRN complex. Here we decided to investigate CtIP’s direct 
interaction with the other components of the MRN complex, namely with Mre11 and 
Rad50. A GST-pull down assay was performed (section 2.3.5.) using three overlapping 
GST-CtIP fragments and radioactively labelled (section 2.2.8.) full-length Mre11 and 
Rad50. Full-length Mre11 or Rad50 were cloned into a pRS314 vector containing a T7 
promoter site which enables the expression in vitro transcription/translation reaction 
(section 2.2.8.). Complexes were isolated with glutathione-agarose beads and 
fractionated by SDS-PAGE. The autoradiographs in Figure.4.2. show the lack of the 
direct interaction of CtIP with either Mre11 or Rad50. 
On the basis of these and previous results we could hypothesise that CtIP forms a 
complex with the MRN complex via direct interaction with NBS1. It has also been 
reported that RPA70 binds to Mre11 (Robison et al., 2004) thus we could hypothesise 
that CtIP-RPA complex formation may be mediated by CtIP-NBS1 direct interaction 
(Figure.4.3.). On the other hand RPA is known to bind to ATRIP and mediate 
ATR/ATRIP recruitment to ssDNA (Zou & Elledge, 2003) thus CtIP’s association with 
RPA complex could be mediated via the association of CtIP with TopBP1 which in 
turn binds to ATR/ATRIP (Figure.4.3.). 
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Figure.4.1. The association of CtIP with the DNA damage sensor proteins. 
HeLa cell lysates were mock-irradiated, irradiated with 5Gy or 30J and harvested 1h 
post irradiation. CtIP was immunoprecipitated with a rabbit antibody and associated 
NBS1, Mre11, Rad50 and RPA70 were visualized by Western blotting. In the right hand 
panel CtIP’s basal level is shown before IP and β-actin indicates equal levels of total 
protein in lysates before IP. This figure is representative of three independent 
experiments. 
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a) 
 
b) 
 
Figure.4.2. CtIP does not interact directly with Mre11 nor Rad50. GST-CtIP 
polypeptides were incubated with a) [35S]Mre11 or b) [35S]Rad50 and complexes 
isolated with the glutathione-agarose beads. Bound proteins were fractionated by SDS-
PAGE and visualized by autoradiography. This figure is representative of three 
independent experiments. 
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e)          f) 
         
Figure.4.3. Interaction of CtIP with the MRN complex and the RPA complex. 
a) MRN complex, b) possible interaction of CtIP with the MRN complex, c) MRN and 
RPA complex, d) possible interaction of CtIP with MRN and RPA complexes, e) RPA 
interaction with ATR/ATRIP/TopBP1, f) possible interaction of CtIP with RPA and 
ATR/ATRIP/TopBP1. 
a) b) 
c) d) 
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4.2.1.2. The association of CtIP with DNA damage transducer proteins. 
To assess the in vivo interaction of CtIP and DNA damage transducer proteins 
immunoprecipitation assays were carried out. HeLa cells were mock-irradiated or 
irradiated with 5Gy or 30J and harvested 1 h post-irradiation. CtIP was 
immunoprecipitated with a rabbit polyclonal antibody and associated proteins were 
isolated using protein G-Sepharose beads. Complexes were fractionated by SDS-PAGE 
and visualized by Western blotting. As shown in Figure.4.4. CtIP associates with the 
ATM and ATR kinases, the main two kinases transducing the phosphorylation signal to 
the downstream targets in response to double and single-stranded DNA lesions. The 
association is not dependent upon DNA damage and occurs with a similar efficiency in 
irradiated and non-irradiated cells. This result may again suggest that CtIP is a basal 
component of the complexes formed by ATM and ATR and exists in them on a 
physiological basis in undamaged cells and that the association is not altered upon the 
DNA damage. 
As shown previously in section 3.1.2.4. CtIP interacts directly with NBS1 which in turn 
interacts directly with ATM (Falck et al., 2005) thus we could hypothesise that CtIP-
ATM interaction in mediated via NBS1 (Figure.4.5.a.). 
In section 3.1.2.3. CtIP has been shown to interact directly with TopBP1 which is an 
activator of ATR. TopBP1 binds to ATR via the PRD domain (Mordes et al., 2008), thus 
we could hypothesise that association of ATR with CtIP could be mediated by it 
(Figure.4.5.b.). 
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Figure.4.4. The association of CtIP with DNA damage transducer proteins. 
HeLa cell lysates were mock-irradiated, irradiated with 5Gy or 30J and harvested 1h 
post irradiation. CtIP was immunoprecipitated with a rabbit antibody and associated 
ATM and ATR were visualized by Western blotting. In the right hand panel CtIP’s basal 
level is shown before IP and β-actin indicates equal levels of total protein in lysates 
before IP. This figure is representative of three independent experiments. 
 
 
       
Figure.4.5. Possible CtIP association with ATM and ATR. a) CtIP can associate 
with ATM via its direct interaction with NBS1, b) CtIP can associate with ATR via its 
direct interaction with TopBP1. 
a) b) 
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4.2.1.3. The association of CtIP with the DNA damage mediator proteins. 
It was shown previously in sections 3.1.2.1. and 3.1.2.2. that CtIP interacts with 53BP1 
and MDC1 in vivo and in vitro. In this section we investigated the influence of DNA 
damage on those interactions. A co-immunoprecipitation assay was performed (section 
2.4.2.) using HeLa cell lysates that were previously mock-irradiated or irradiated with 
5Gy or 30J and harvested one hour after irradiation. Rabbit polyclonal antibodies 
against 53BP1 or MDC1 were used to immunoprecipitate 53BP1 and MDC1 
respectively. Complexes were isolated with protein G-Sepharose beads and 
fractionated with SDS-PAGE. Associated CtIP was detected by Western blotting. As 
shown in Figure.4.6. CtIP associates with 53BP1 and this interaction is not influenced 
by the DNA damage as is the case of CtIP’s association with MDC1 before and after 
DNA damage (Figure.4.7.). This result may suggest that those complexes form in 
normal cells and that the occurrence of the double- or single-stranded DNA lesions 
does not change them.  
As CtIP interacts directly with both 53BP1 and MDC1 and 53BP1 and MDC1 have been 
reported to interact directly as well (Eliezer et al., 2009) it is possible that CtIP forms a 
complex involving both of those proteins (Figure.4.8.). MDC1 is also thought to be an 
indispensible component of the MRN complex thus MDC1, MRN, 53BP1 and CtIP could 
be involved in a multiprotein complex together with ATM which is known to bind to 
NBS1 and MDC1 (Stucki & Jackson, 2006). 
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Figure.4.6. The association of CtIP with the DNA damage transducer protein 
53BP1. HeLa cell lysates were mock-irradiated, irradiated with 5Gy or 30J and 
harvested 1h post irradiation. CtIP was immunoprecipitated with a rabbit antibody and 
associated proteins visualized by Western blotting. In the right hand panel 53BP1’s 
basal level is shown before IP and β-actin indicates equal levels of total protein in 
lysates before IP. This figure is representative of three independent experiments. 
               
Figure.4.7. The association of CtIP with the DNA damage transducer protein 
MDC1. HeLa cell lysates were mock-irradiated, irradiated with 5Gy or 30J and 
harvested 1h post irradiation. CtIP was immunoprecipitated with a rabbit antibody and 
associated proteins visualized by Western blotting. In the right hand panel MDC1’s 
basal level is shown before IP and β-actin indicates equal levels of total protein in 
lysates before IP. This figure is representative of three independent experiments. 
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4.2.2. The interaction of CtIP with ATM and the MRN complex components in 
patients with ATLD and NBS syndromes. 
In order to establish whether CtIP’s in vivo association with the key factors of the 
double-stranded DNA damage response pathway differs in genetically pathological 
backgrounds, a series of co-immunoprecipitation assays (section 2.4.2.) was 
performed, using LCL cells derived from a healthy donor, ATLD LCLs and NBS LCLs.  
The ATLD patient-derived LCLs harbour a truncating mutation, which causes C > T 
transition at nucleotide 1897, creating an in-frame stop codon and resulting in a 
premature termination at 571aa instead of 680aa, producing a 65kDa protein in place 
of a 81kDa one (Figure.4.9; Stewart et al., 1999).  
 
Figure.4.9. The Mre11 protein expressed by the ATLD patient used in this 
study. 
The NBS patient-derived LCLs contain a typical truncation in the NBS gene, the 
657del5 mutation in exon 6, splitting the protein into a 26K (p26, 1-218aa) and a 70K 
(p70, 221-754aa) polypeptide (Figure.4.10; Matsura et al., 1998).  
CtIP was immunoprecipitated with a rabbit polyclonal antibody from the cell lysates 
prepared from normal LCL cells, ATLD LCLs and NBS LCLs which were mock-irradiated 
or irradiated with 5Gy. The complexes were fractionated by SDS-PAGE and associated 
proteins were visualized by Western blotting. As shown in the Figure.4.11.a. 
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Figure.4.11. The association of CtIP with Mre11, Rad50 and ATM in ATLD 
and NBS patient derived LCLs and NBS1 in ATLD patient derived LCLs. a) 
normal LCLs, ATLD LCLs and NBS LCLs or b) normal LCLs and ATLD LCLs were mock-
irradiated or irradiated with 5Gy and harvested 1 h post irradiation. CtIP was 
immunoprecipitated with a rabbit antibody and associated a) Mre11, Rad50, ATM or b) 
NBS1 were visualized by Western blotting. In the right hand panel CtIP’s basal level is 
shown before IP and β-actin indicates equal levels of total protein in lysates before IP. 
This figure is representative of three independent experiments. 
a) 
b) 
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Rad50 is detected in the CtIP immunoprecipitates as well (Figure.4.11.a.). The 
interaction in all cell lines appears to be stable and not dependent either upon intact 
Mre11 nor NBS1. In the ATLD LCLs the association with CtIP is decreased but not 
abrogated as all of the MRN complex components have decreased levels of expression 
(Stewart et al., 1999). In the NBS LCLs the interaction is the same as in the normal 
LCLs, again either due to CtIP’s association with p70 NBS1 and Mre11 or due to 
immunoprecipitation of a complex consisting of more than just the MRN proteins. 
Rad50’s association with CtIP appears to be mediated through other proteins that were 
immunoprecipitated together with CtIP and MRN complex.  
In case of CtIP’s association with ATM in normal LCLs and ATLD LCLs the association 
again does not change after DNA damage and corresponds to the basal levels of ATM 
before immunoprecipitation (Figure.4.11.a.). However in the NBS LCLs there is a slight 
reduction in the association of CtIP and ATM in comparison to the basal level of ATM in 
NBS LCLs which would suggest the same amount of complex formation as in the 
normal LCLs if the mutation in NBS1 was not affecting the complex formation. Thus we 
hypothesise that full length NBS1 has influence on ATM and CtIP’s complex formation 
which is disrupted in NBS LCLs which carry a truncating mutation, causing the 
expression of two NBS1 protein: N-terminal p26 and C-terminal p70. Thus we 
speculate that the full length NBS1 is necessary for an efficient CtIP and ATM complex 
formation.  
CtIP and ATM’s association is also reduced in ATLD LCLs (Figure.4.11.a.) but this is 
most likely due to lower expression of NBS1 in those cells. This would imply that NBS1 
plays a role in efficient formation of CtIP-ATM complex as suggested in the previous 
section (Figure.4.5.a.). 
In order to establish whether NBS1 phosphorylation by ATM influences its association 
with CtIP a co-immunoprecipitation assay was performed (section 2.4.2.). LCL cells 
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derived from an A-T patient were mock-irradiated or irradiated with 5Gy and harvested 
1h post-irradiation. CtIP was immunoprecipitated with a rabbit antibody and complexes 
were isolated with protein G-Sepharose beads and fractionated by SDS-PAGE. The 
associated NBS1 was visualized by Western blotting. As shown in Figure.4.12. NBS1 
associates with CtIP in the absence of ATM and the interaction is not dependent upon 
DNA damage. The association is also unaffected by the phosphorylation status of 
NBS1, which is seen as a band shift in the presence of ATM following IR (Figure.4.12., 
top panel, fourth track). Thus we could conclude that association of CtIP and NBS1 is 
stable and is not affected by the phosphorylation status of NBS1 nor the absence of 
ATM. 
To examine further the interaction of CtIP with the components of the MRN complex 
an Mre11 knock-down was performed. HeLa cells were incubated twice with an Mre11 
siRNA (section 2.1.7.) and 96 h post treatment the cells were mock-irradiated or 
irradiated with 5Gy. Cell lysates were immunoprecipitated with a rabbit antibody 
against CtIP, complexes were isolated using protein G-agarose beads (section 2.4.2.), 
fractionated by SDS-PAGE and associated proteins were visualized by Western blotting.  
Figure.4.13. shows that Mre11 knock-down causes the down regulation of all of the 
components of the MRN complex, similarly to mutation in an ATLD patient derived 
LCLs (Stewart et al., 1999). However the association of CtIP with NBS1 or Rad50 is not 
abolished in knock-down cells. It is compromised by the down-regulation of expression 
of NBS1 and Rad50 but not disrupted by Mre11 knock-down. This suggests that Mre11 
is not essential for CtIP’s association with NBS1 or Rad50.  
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Figure.4.12. The influence of NBS1 phosphorylation on its association with 
CtIP. Normal LCLs and A-T LCLs were mock-irradiated or irradiated with 5Gy and 
harvested after 1 h. CtIP was immunoprecipitated with a rabbit antibody and 
associated NBS1 was visualized by Western blotting. In the lower panels ATM’s and 
CtIP’s basal level is shown before IP and β-actin indicates equal levels of total protein 
in lysates before IP. This figure is representative of three independent experiments. 
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Figure.4.13.The association of CtIP with NBS1 and Rad50 in Mre11 knock-
down HeLa cells. HeLa cells were treated with Mre11 siRNA and subsequently mock-
irradiated or irradiated with 5Gy. CtIP was immunoprecipitated with a rabbit antibody 
and associated NBS1 and Rad50 were visualized by Western blotting. In the lower 
panel Mre11’s and CtIP’s basal levels are shown and β-actin indicates equal levels of 
total protein in lysates before IP. This figure is representative of three independent 
experiments. 
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As NBS1 was previously shown to bind CtIP directly, mainly through the region 
containing the Mre11 binding domain and ATM binding site (section 3.1.2.4.), we 
investigated whether Mre11 can be competed off NBS1 by the addition of excess CtIP. 
A co-immunoprecipitation assay was performed (section 2.4.2.) using LCL cells which 
were mock-irradiated or irradiated with 5Gy. A rabbit antibody against NBS1 was used 
to immunoprecipitate NBS1 in the presence of either 10µg of full length GST-CtIP, no 
GST-tagged protein or GST protein alone. LCL cell lysates were incubated with the 
antibody, with or without GST-tagged protein, overnight at 4oC. On the following day 
complexes were isolated with protein G-Sepharose beads, fractionated by SDS-PAGE 
and the associated Mre11 was visualized by Western blotting. As shown in Figure.4.14. 
the association of NBS1 and Mre11 is slightly disrupted by addition of the GST protein 
alone but is virtually abolished by the addition of the full length GST-CtIP construct. 
DNA damage caused by 5Gy does not influence that effect.  
This result suggests that excess GST-CtIP protein could compete Mre11 off NBS1. We 
hypothesise that the in vivo association of one of the pools of Mre11-NBS1 complexes 
might be influenced by CtIP as CtIP has been shown to bind to NBS1 via its C-terminal 
region containing the Mre11-binding site (Chen et al., 2008). This would mean that 
NBS1 could be competed off Mre11 and directed for association with other proteins 
and this would be orchestrated by CtIP acting as a mediator protein. Alternatively it is 
possible that CtIP interacts with a certain pool of NBS1 preventing its binding to Mre11.  
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Figure.4.14.CtIP and Mre11 compete for the same binding site on NBS1. LCL 
cells were mock-irradiated or irradiated with 5Gy and harvested an hour post 
irradiation. NBS1 was immunoprecipitated with a rabbit antibody in the presence of 
10µg of GST-CtIP or 10µg GST protein or without GST-tagged protein. 
Coimmunoprecipitating Mre11 was identified by Western blotting. In the lower panel 
NBS1’s basal level is shown before IP and β-actin indicates equal levels of total protein 
in lysates before IP. This figure is representative of three independent experiments. 
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4.2.2.1. The influence of CtIP’s knock-down on the phosphorylation events 
in response to different DNA damaging agents. 
To establish CtIP’s influence on phosphorylation events in response to different 
damaging agents a CtIP knock-down was performed (section 2.1.7.). HeLa cells were 
mock-treated or treated with the CtIP siRNA and after 72 h they were either mock-
irradiated or irradiated with 5Gy or 30J (section 2.1.6.2.) or treated with camptothecin 
(CPT) at 1µM for 1 h (section 2.1.5.1.). Following treatment, cells were harvested at 
four time points: before treatment – 0 h and after treatment: 1 h, 5 h and 24 h. The 
cell lysates were fractionated by SDS-PAGE and proteins were visualized by Western 
blotting. 
Figure.4.15. shows the phosphorylation of five ATM targets after the DNA damage 
caused by 5Gy. ATM activation is rapid and reaches its maximum 5 min after treatment 
with 0.5Gy. It has also been shown that ATM stays in a phosphorylated state for at 
least 24h (Bakkenist & Kastan, 2003). As shown in Figure.4.15. ATM is phosphorylated 
after exposure to 5Gy at 1h and 5h time point. The absence of phosphorylation after 
24h may be due to too short exposure of the X-ray film or the fact that in this study 
instead of primary fibroblasts HeLa cells were used. However in the absence of CtIP 
phosphorylation of ATM in HeLa cells persists longer which may be due to DNA 
damage taking longer time to be repaired in the absence of CtIP. NBS1 is typically 
phosphorylated by ATM on S343 in response to the DNA double stranded breaks. As 
shown in Figure.4.15. there is no significant difference in NBS1 phosphorylation on 
S343 in CtIP-depleted cells. The same result is obtained for autophosphorylation of 
ATM on S1981, SMC1 phosphorylation on S966 and γ-H2AX on the S139.  
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Figure.4.15. The influence of CtIP knock-down on phosphorylation of ATM 
targets in response to 5Gy of ionizing radiation. HeLa cells were treated with 
CtIP siRNA and subsequently mock-irradiated or irradiated with 5Gy and harvested at 
the indicated time points. The cell lysates were fractionated by SDS-PAGE and proteins 
visualized by Western blotting. This figure represents a result of three independent 
experiments. 
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S1778 of 53BP1 has not previously been reported as an ATM phosphorylation site 
(Jowsey et al., 2007) but it is a consensus site for ATM and ATR and has been shown 
to be phosphorylated in the response to 3Gy of ionizing radiation by Stewart et al. 
(Stewart et al., 2007). As shown in Figure.4.15. it is phosphorylated in response to 5Gy 
and the depletion of CtIP has only a minor effect. As mentioned before, ATM and ATR 
have a consensus phosphorylation motif and so this phosphorylation may be a joint 
effort. Thus in CtIP depleted cells 53BP1’s phosphorylation on S1778 is not impaired in 
CtIP knock-down cells. Overall this result suggests that the siRNA depletion of CtIP has 
a minor effect on the phosphorylation events in response to double-stranded DNA 
lesions orchestrated by ATM. 
To establish if single-stranded DNA lesions and depletion of CtIP have an effect on the 
phosphorylation cascade, HeLa cells were irradiated with 30J and harvested at the 
indicated time points. As shown in Figure.4.16. phosphorylation of typical ATR targets 
such as Chk1 and RPA32 is notably impaired in the CtIP depleted cells suggesting that 
CtIP facilitates their phosphorylation in response to single-stranded DNA breaks. In 
Figure.4.17. the influence of CtIP knock-down on previously described ATM targets is 
shown. As expected there is no significant influence of CtIP depletion on the SMC1 
phosphorylation. Its phosphorylation is less in response to UV-irradiation compared 
with γ-irradiation. The lack of a marked reduction in SMC1 phosphorylation in CtIP-
depleted cells may be due to the ATR basal activity that is present in normal cells. As 
shown by Kim et al. (2002) SMC1 is a major ATM target in response to IR, but it is still 
phosphorylated in ATM-depleted cells in response to UV and replication fork stalling in 
an ATR-dependent manner. As has been reported, phosphorylation of SMC1 occurs in 
cells lacking DNA-PK, thus suggesting that phosphorylation of SMC1 is DNA-PK 
independent (Kim et al., 2002). Thus one could argue that basal activation of ATR is 
sufficient to activate a portion of ATM in response to UV and replication fork stalling.  
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Figure.4.16. The influence of CtIP knock-down on phosphorylation of ATR 
targets in response to 30J of UV radiation. HeLa cells were treated with CtIP 
siRNA and subsequently mock-irradiated or irradiated with 30J and harvested at the 
indicated time points. The cell lysates were fractionated by SDS-PAGE and proteins 
visualized by Western blotting. This figure is representative of three independent 
experiments. 
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Figure.4.17. The influence of CtIP knock-down on phosphorylation of ATM 
targets in response to 30J of UV radiation. HeLa cells were treated with CtIP 
siRNA and subsequently mock-irradiated or irradiated with 30J and harvested at the 
indicated time points. The cell lysates were fractionated by SDS-PAGE and proteins 
visualized by Western blotting. This figure is representative of three independent 
experiments. 
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However in cells depleted of CtIP, ATR kinase, as it only shows its basal activity, 
cannot efficiently cooperate with ATM in phosphorylation of such targets as NBS1, ATM 
itself and 53BP1. This is confirmed by the delayed H2AX phosphorylation 
(Figure.4.17.). We could speculate, that the basal activity of ATR, observed in cells 
depleted of CtIP, is sufficient enough to activate only a portion of ATM. This in turn 
would mean that at the beginning of the ATM phosphorylation cascade H2AX is not 
phosphorylated efficiently, due to only partial activation of ATM. Which in turn results 
in prolonged activation of ATM which eventually results in full phosphorylation of H2AX. 
The process is delayed, however, and it does reach its full potential until 5h post 
irradiation (Figure.4.17.).  
We could hypothesise that ATM in CtIP-depleted cells is active for longer to complete 
all of its normal tasks and this is seen as prolonged phosphorylation of H2AX and 
SMC1. On the other hand depletion of CtIP using siRNA seems to create a basal 
response to DSBs which is seen as appearance of γ-H2AX foci in unirradiated cells 
treated with CtIP siRNA (data not shown). This could also contribute to ATM’s basal 
activation and its prolonged activity. 
However, NBS1 and ATM phosphorylation is impaired in the CtIP knock-down cells, 
implying its ATR-dependence as reported by Stiff et al. (Stiff et al., 2005 & 2006) who 
showed that autophosphorylation of ATM in response to SSBs and replication fork 
stalling is ATR-dependent. 53BP1 phosphorylation is markedly reduced in the CtIP 
knock-down HeLa cells suggesting that it is mainly phosphorylated by ATR on S1778 
and this process is mediated by CtIP.  
To investigate further the ATR-dependent phosphorylation events similar experiment 
was performed using CPT as the DNA damaging agent. CPT is a cytotoxic quinoline 
alkaloid drug which inhibits DNA topoisomerase I (topo I) and causes replication fork 
stalling. An acute (1h) drug treatment was applied to previously CtIP siRNA-depleted 
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cells which were harvested at the indicated time points. As seen in Figure.4.16. 
phosphorylation of the ATR targets Chk1 and RPA32 is appreciably decreased in CtIP 
deficient cells as reported previously by Sartori et al. (2007). This suggests CtIP 
involvement in targeting Chk1 and RPA32 for ATR phosphorylation. Furthermore, 
phosphorylation of NBS1, ATM, SMC1, 53BP1 and H2XA are considerably reduced 
suggesting that CtIP plays a major role in ATR signalling in the event of replication 
fork stalling (Figure.4.19.). 
Cells treated with CPT and depleted of CtIP show a greater reduction in 
phosphorylation of NBS1, ATM, 53BP1 and to lesser extent SMC1, than the cells 
irradiated with 30J and depleted of CtIP. It may be due to different kinase activation 
mechanisms. As Yoo et al. report TopBP1 driven activation of ATR has a different 
route depending on the type of DNA damage (Yoo et al., 2007). In the presence of 
DSBs ATM phosphorylates TopBP1 on S1131 and this event is required for 
subsequent ATR activation. But in the case of replication fork stalling that 
phosphorylation is not necessary and the precise mechanism of the upstream events 
of that activation remains to be elucidated. The evidence emerging from the CtIP 
siRNA experiments suggests the existence of three pathways of ATR activation in 
response to DSBs, SSBs and fork stalling. CtIP would be involved in all three 
pathways but to different extents and at different levels: post ATR-activation in DSBs 
and during activation and post activation in SSBs and fork stalling, possibly 
employing different sets of proteins.  
In the response to DSBs, as it is ATM that activates ATR by phosphorylating TopBP1, 
the impairment of phosphorylation of the downstream targets appears to be minor 
(Figure.4.15.). Therefore impairment of the actual ATR activation event might be 
causing phophorylation to be reduced in response to 30J and fork stalling by CPT and 
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it could be that CtIP has a role in activating ATR in response to the SSBs and the fork 
stalling.  
What is also important to note is that when we compare the difference in 
phosphorylation of ATR and ATM targets in cells depleted of CtIP in response to UV 
(Figure.4.16. & 4.17.) and to CPT treatment (Figure.4.18. & 4.19.), CtIP has a major 
influence on phosphorylation events carried out by ATR alone. And using Chk1 
phosphorylation as an example (Figure.4.18.) we can argue that CtIP-depletion 
causes the most major disruptions in processes carried out by ATR in response to the 
replication fork stalling. 
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Figure.4.18.The influence of CtIP knock-down on phosphorylation of ATR 
targets in response to camptothecin (CPT) treatment. HeLa cells were treated 
with CtIP siRNA and subsequently mock-treated or treated with CPT at 1µM and 
harvested at the indicated time points. The cell lysates were fractionated by SDS-PAGE 
and proteins visualized by Western blotting. This figure represents a result of three 
independent experiments. 
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Figure.4.19.The influence of CtIP knock-down on phosphorylation of ATM 
targets in response to camptothecin (CPT) treatment. HeLa cells were treated 
with CtIP siRNA and subsequently mock-treated or treated with CPT at 1µM and 
harvested at the indicated time points. The cell lysates were fractionated by SDS-PAGE 
and proteins visualized by Western blotting. This figure represents a result of three 
independent experiments. 
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4.2.2.2. ATR phosphorylation of 53BP1 in vitro and the influence of CtIP 
depletion on ATR-53BP1 association in vivo. 
To investigate further 53BP1 phosphorylation by ATR a kinase assay was performed 
(section 2.4.4.). A mouse antibody against ATR was used to immunoprecipitate ATR 
from HeLa cell lysates. The kinase was isolated with protein G-Sepharose beads and 
resuspended in kinase buffer. The beads with bound ATR were incubated with either 
20µg GST-53BP1 fragment (1584-1972aa) containing the tandem repeats of the BRCT 
domain and the S1778 site or 20µg GST protein alone and with 1µl of [32P]γ-ATP. As 
an additional control protein G-Sepharose beads were incubated with the cell lysates 
alone and then incubated with 1µl of [32P]γ-ATP. The reaction was stopped by 
addition of Laemmli Sample Buffer, complexes were fractionated by SDS-PAGE, the 
gel was stained with Coommassie Brilliant Blue, dried and the phosphorylation of the 
GST-53BP1 fragment was visualized by autoradiography. As shown in Figure.4.20. 
the GST-53BP1 fragment containing the S1778 site is efficiently phosphorylated by 
ATR suggesting that this site may be an ATR phosphorylation site in response to DNA 
damage. This is consistent with previous results where 53BP1 phosphorylation on 
S1778 is impaired in CtIP siRNA-depleted cells in response to the DNA damage 
caused by 30J of UV irradiation or the replication fork stalling caused by CPT (Figure. 
4.17. & 4.19.). However the GST-53BP1 (1584-1972aa) fragment may contain other, 
unreported phosphorylation sites that could be potentially phosphorylated by ATR. 
The non-specific bands in both of the tracks containing the GST-tagged proteins are 
a possible phosphorylation product of bacterial proteins that are present in the GST-
tagged protein eluates. 
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Figure.4.20. The in vitro phosphorylation of 53BP1 S1778 by ATR. ATR was 
immunoprecipitated from HeLa cell lysates and incubated with GST-53BP1 1584-
1971aa or with GST alone and with [32P]γ-ATP. Complexes were fractionated by SDS-
PAGE and the phosphorylation of the GST-53BP1 fragment was visualized by 
autoradiography. This figure is representative of three independent experiments. 
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In order to establish whether the depletion of CtIP has an effect on ATR and 53BP1 
association in vivo an immunoprecipitation assay was performed. A rabbit antibody 
against 53BP1 was used to immunoprecipitate 53BP1 from HeLa cell lysates. 
Complexes were isolated with protein G-Sepharose beads as described in section 
2.4.2., fractionated with SDS-PAGE and the associated ATR was visualized by Western 
blotting. As shown in the Figure.4.21. the 53BP1 and ATR in vivo association is 
impaired in CtIP depleted HeLa cells. This could suggest that CtIP is an important 
factor in ATR and 53BP1 association and that this association facilitates 53BP1’s 
phosphorylation in response to DNA damage. 
4.2.2.3. Association of ATR with 53BP1 in cells depleted of CtIP and CtIP 
association with BLM after replication stress. 
CtIP is a known factor taking part in DNA end resectioning after DNA double strand 
breaks. This process prepares the DNA ends to be coated with RPA complex and 
subsequently ATR/ATRIP/TopBP1 complexes are recruited (Figure.1.13.; Sartori et al., 
2007). To examine this in more detail, we decided to investigate whether CtIP 
associates in vivo with BLM, a RecQ helicase, which also takes part in DNA end 
resectioning at DSBs (Gravel et al., 2008).  
A co-immunoprecipitation assay was performed (section 2.4.2.). HeLa cell lysates were 
mock-treated or treated with 1mM Hydroxyurea (HU) as described in section 2.1.5.1. 
and a goat BLM antibody was used to immunoprecipitate BLM. Complexes were 
isolated with protein G-Sepharose beads, fractionated with SDS-PAGE and the 
associated CtIP was visualized by Western blotting. As shown in Figure. 4.22. CtIP and 
BLM interact in vivo in HeLa cells treated with HU. HU is an anti-neoplastic drug and 
DNA replication inhibitor causing ribonucleotide depletion which results in  
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Figure.4.21. The association of 53BP1 and ATR is impaired in CtIP siRNA 
depleted HeLa cells. HeLa cell lysates were immunoprecipitated with a rabbit 53BP1 
antibody and coimmunoprecipitating ATR was visualized by Western blotting. 53BP1’s 
and CtIP’s basal level is shown before IP and β-actin indicates equal levels of total 
protein in lysates before IP. This figure is representative of three independent 
experiments. 
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DNA double-stranded breaks near replication forks. CtIP and BLM associated in vivo 
only in the presence of DNA damage. Thus we can speculate that they exist in a 
complex that assembles to facilitate DNA end resection and subsequent repair of 
collapsed replication forks.  
BLM has been reported to associate with 53BP1 after HU treatment (Sengupta et al., 
2004). Thus as a positive control for the previous experiment another co-
immunoprecipitation assay was performed using HU-treated HeLa cells. A rabbit 
antibody against 53BP1 was used to immunoprecipitate 53BP1 and protein G-
Sepharose beads were used to isolate formed complexes which were fractionated with 
SDS-PAGE. Associated BLM was visualized by Western blotting. As shown in 
Figure.4.23. 53BP1 associates with BLM only after treatment with HU which again 
suggests its involvement in repairing the collapsed replication fork thus possibly this 
complex involves amongst other proteins also CtIP, BML and 53BP1.  
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Figure.4.22. The in vivo association of CtIP and BLM after hydroxyurea (HU) 
treatment. HeLa cells were mock-treated or treated with 1mM HU and subsequently a 
goat antibody against BLM was used to immunoprecipitate BLM. Associated CtIP was 
visualized by Western blotting. In the right hand panel BLM’s basal level is shown and 
β-actin indicates equal levels of total protein in lysates before IP. This figure is 
representative of three independent experiments. 
           
Figure.4.23. The in vivo association of BLM and 53BP1 after hydroxyurea 
(HU) treatment. HeLa cells were mock-treated or treated with 1mM HU and 
subsequently a rabbit antibody against 53BP1 was used to immunoprecipitate 53BP1. 
Associated BLM was visualized by Western blotting. In the right hand panel 53BP1’s 
basal level is shown and β-actin indicates equal levels of total protein in lysates before 
IP. This figure is representative of three independent experiments. 
 
 178 
4.3. Discussion. 
In the previous chapter, I showed that CtIP binds BRCT domain containing proteins. In 
this chapter I investigated the influence of γ-irradiation and UV-irradiation on CtIP’s 
ability to interact in vivo with these and other proteins involved in DNA damage 
signalling pathways.  
As shown in section 4.2.1.1. CtIP interacts with the components of the MRN complex 
and with RPA70 (Figure.4.1.) which are sensor proteins of DNA double-stranded breaks 
and single-stranded breaks, respectively. It also interacts with transducer proteins ATM 
and ATR (Figure.4.4.) and with mediator proteins 53BP1 (Figure.4.6.) and MDC1 
(Figure.4.7.). None of those interactions appear to be influenced by the damage 
caused to the DNA either in the form of double-stranded breaks nor single-stranded 
ones. This observation suggests that CtIP is a crucial component of those complexes in 
normal cells (Figure.4.2., Figure.4.5., Figure.4.8.) It would also imply that for efficient 
functioning of a viable cell all of these proteins have to stay in close contact. As CtIP 
interacts with all of these proteins it is likely that it is involved in a multiprotein 
complex. This hypothesis is based on the findings from the previous chapter, where 
CtIP interacts directly with 53BP1, MDC1, TopBP1 and NBS1.  
On the other hand, BRCA1 is known to form a multicomplex with DNA damage 
response proteins termed BASC (BRCA1-associated genome surveillance complex; 
Wang et al., 2000). Amongst the proteins involved in the formation of that complex are 
ATM, BLM, MRN complex and the mismatch repair genes (MMR): MHS2, MHS6 and 
MLH1 (Figure.4.24.a.). In the results shown in this chapter CtIP is recognized as an 
associate of ATM, MRN complex and BLM. CtIP has been also reported to bind directly 
to the BRCT domains of BRCA1 (Wong et al., 1998).  
One CtIP allele is found to be frequently mutated in colon cancer with microsatellite 
instability and MMR genes are found to be mutated in hereditary colon cancer (Vilkki et 
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al., 2002). Apart from that finding, genes involved in MMR are frequently mutated in 
hereditary colon cancer. Thus the hypothesis would suggest that CtIP would take part 
in MMR, but during malfunctioning MMR it would undergo mutation as well, which 
would impede its function, which in a feedback loop would cause errors in MMR and 
consequently lead to the development of the microstability in those cancer tissues. 
Exo1 has been reported to play a key role in MMR together with the RPA complex 
(Modrich, 2006). In recent findings Mre11/Sgs1(BLM)/Sae2(CtIP)/Exo1 have been 
reported to be involved in DNA end-resectioning in yeast (Mimitou & Symington, 
2008). Thus one could hypothesise that CtIP, since it interacts with BRCT domain 
containing proteins such as 53BP1, MDC1, TopBP1, NBS1 and BRCA1 and associates in 
vivo with a plethora of other DNA damage response proteins and could be a part of the 
BASC complex (Figure.4.24.a.). The BASC complex could possibly consist of more than 
just BRCA1 and eight associated proteins and might gather all the proteins necessary 
to sense DNA damage, to perform the repair processes and modulate their activity by 
phosphorylation events performed by the PIKK kinases and checkpoint kinases. 
By formation of the multi-protein complex CtIP would manage the crucial proteins in a 
‘ready to react’ state in the case of any disruptions caused by internal or external 
factors. The existence of this multi-protein complex would facilitate a rapid diagnosis 
followed by response and repair of the damage as soon as it occurs. However CtIP’s 
exact role in the activities of the complex remains to be elucidated (Figure.4.24.b&c). 
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Figure.4.24. The formation of possible multiprotein complex mediated by 
CtIP. a) the BASC complex, b) CtIP’s possible association with the BASC complex, c) 
formation of possible multiprotein complex by CtIP. 
a) 
b) 
c) 
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CtIP’s association with the MRN complex and ATM in the inherited disorder 
backgrounds was also examined. As shown in the Figure.4.11.a. ATM’s association with 
CtIP is not affected by the Mre11 truncating mutation but there is a possibility that the 
interaction is modified by mutation in NBS1. CtIP’s association with ATM appears to be 
weaker in NBS patient LCLs judged by basal levels of ATM in the cell lysates before IP. 
Similar weaker association of ATM with CtIP occurs in ATLD LCLs. That would suggest 
that the interaction, if it was as efficient, should be the same as the CtIP-ATM 
association in normal LCLs. Thus we could speculate that intact NBS1 is necessary for 
CtIP-ATM association in the case of NBS LCLs. And the lower level of 
immunoprecipitated ATM in ATLD LCLs is influenced by lower levels of NBS1 in those 
cells (Figure.4.11.a.; Stewart et al., 1999).  
It appears that truncating mutations in either Mre11 (Figure.4.8.) or NBS1 (Figure.4.9.) 
do not have a major influence on CtIP’s ability to associate with other components of 
the complex that are intact. Mre11’s association with CtIP in the ATLD and NBS cells 
still appears to be normal (Figure.4.11.a.). There are several possibilities why this may 
be happening. In the case of ATLD cells, CtIP still associates with Mre11 and this 
interaction is most likely mediated by NBS1. As described in section 3.1.2.4. NBS1 
binds CtIP directly but Mre11 does not. NBS1 also binds Mre11 directly (Carney et al., 
1998) and the Mre11 truncating mutation does not affect that interaction (Stewart et 
al., 1999). The Mre11 and NBS1 association occurs through the N-terminal region of 
Mre11 (Desai-Mehta et al., 2001) that is left intact by the mutation. As shown in 
Figure.4.2.a. CtIP does not bind Mre11 directly thus CtIP and Mre11 association must 
be mediated by NBS1.  
As for the CtIP-Rad50 association in ATLD cells, it is compromised by reduced 
expression levels of Rad50 due to the Mre11 mutation (Stewart et al., 1999) but is not 
abolished. Rad50 has been reported to bind to Mre11 directly (Dolganov et al., 1996), 
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although no direct binding to NBS1 has been shown. Thus we suggest that CtIP-Rad50 
association again is mediated by NBS1 binding to CtIP such that the whole complex is 
immunoprecipitated with the CtIP antibody.  
The NBS LCLs express two variants of NBS1: p26 and p70 (Maser et al., 2001). CtIP is 
most likely associated with both of them as the results in the section 3.1.2.4. suggest. 
The p70 variant and Mre11 would be associated with CtIP so that the whole MRN 
complex could be immunoprecipitated from the LCL NBS cell lysates using the CtIP 
antibody. Sartori et al. report the direct binding of CtIP to Mre11 and Rad50 when they 
are expressed together in a baculovirus system (Sartori et al., 2007). However our 
results show that CtIP does not interact directly with Mre11 nor Rad50 when they are 
expressed singly. This difference possibly arises from differences in experimental 
protocol. Additionally the proteins may fold differently, depending on whether they are 
expressed together or in isolation. Although CtIP does not bind to Mre11 or Rad50 
when they are expressed separately (Figure.4.3.) it may associate with them when 
they form a complex. As mentioned before this may be due to different folding of the 
proteins forming a complex. By the way Mre11 and Rad50 associate they may form a 
binding site for CtIP. Another hypothesis would presume the existence of other 
proteins in the immunoprecipitated complex such that CtIP could be associated with 
them and they in turn would bind to Mre11 or Rad50; in which case functional NBS1 
would not be necessary for this interaction. Similar explanations could be proposed for 
the association of CtIP and NBS1 or Rad50 in Mre11 knock-down cells (Figure.4.13.). 
Another possibility in this case is that the Mre11 depletion is not complete. Thus it 
could still be expressed in the cell although at lower levels, in that case the MRN 
complex could still form.  
An interesting observation has arisen from the competition experiment where, as 
shown in the Figure.4.14., the addition of GST-CtIP to the NBS1 immunoprecipitation 
 
 183 
reaction abolishes its association with Mre11. This suggests that CtIP and Mre11 may 
compete in vivo for the same binding region on NBS1. Nevertheless, in vivo, the 
affinity of Mre11 for NBS1 must be appreciably greater than that of CtIP or perhaps 
only a small pool of NBS1 is bound to CtIP and utilized by the cell differently than 
when it is associated in the MRN complex. 
To study the effect of CtIP on phosphorylation events after DNA damage, CtIP knock-
down experiments were performed. CtIP-depleted cells were mock-irradiated or 
irradiated with 5Gy or 30J or treated with CPT and harvested at four different time 
points. As shown in the Figure.4.15. the depletion of CtIP does not impair the 
phosphorylation events initiated by DNA DSBs caused by 5Gy. Those phosphorylation 
events are normally regulated by ATM which has not been reported to be influenced by 
CtIP. The phosphorylation of the main targets of ATM such as NBS1, ATM, SMC1 or 
H2AX is not affected by CtIP depletion suggesting a minor role for CtIP in ATM 
activation. S1778 on 53BP1 has not been reported as an ATM phosphorylation site 
(Jowsey et al., 2007) and could, thus, be phosphorylated by ATR. As shown in 
Figure.4.15. the phosphorylation of 53BP1 is only slightly impaired which suggests two 
possibilities. The first is that ATR is being activated by ATM (as Yoo et al., 2007 report) 
and in an activated form does not need CtIP as much for the subsequent 
phosphorylation events. The second option is that in the presence of DSBs the 53BP1 
S1778 is phosphorylated by ATM, which in the absence of an ATR activating signal 
from CtIP, assumes ATR’s functions in transducing the signal. In the case of SSBs and 
replication fork stalling ATR is the activator of ATM (Stiff et al., 2006). If ATR is not 
activated efficiently, like in the case of CtIP depletion, it cannot efficiently activate 
ATM. In the Figure.4.17. we can observe an impairment of the phosphorylation of ATM 
targets, namely NBS1 and ATM, in the absence of CtIP. This suggests that in the cells 
depleted of CtIP ATR is not effectively activated and in the presence of SSBs caused by 
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UV irradiation or replication fork stalling ATR is unable to activate ATM efficiently. The 
same effect, but even more pronounced, could be observed in Figure.4.19. where 
phosphorylation of these proteins is severely impaired in CtIP-depleted cells. This 
suggests that CtIP, apart from facilitating phosphorylation performed by ATR, could be 
an activator of ATR’s kinase activity in the presence of SSBs and collapsed replication 
forks. 
Sartori et al. reported that in response to SSBs or replication fork stalling, 
phosphorylation of RPA32 and Chk1 is impaired in cells lacking CtIP (Sartori et al., 
2007). The same results are shown in Figure.4.16. and 4.18., providing confirmation 
that CtIP is required for efficient phosphorylation of ATR targets.  
To assess whether S1778 of 53BP1 is an ATR target a kinase assay was performed. As 
shown in Figure.4.20. ATR phosphorylates a GST-53BP1 fragment containing that site. 
We could speculate that it could actually be an ATR dependant phosphorylation site, 
but that GST-53BP1 fragment may contain other SQ/TQ motifs that could be 
phosphorylated by ATR. We also established that CtIP depletion reduces the ability of 
ATR to associate with 53BP1 in vivo (Figure.4.21.). One could hypothesise that 
impaired 53BP1 phosphorylation is due to an inability of ATR to associate with 53BP1 
and subsequently efficiently phosphorylate it in the absence of CtIP. 
CtIP emerges as an important co-activator and partner of ATR. As CtIP also associates 
with BLM it could be playing a role in BLM’s phosphorylation by ATR but this remains to 
be elucidated as the antibody that we acquired for pT99 for BLM from Dr. Y. Pommier 
did not give a clear answer.  
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5. The phosphorylation of CtIP by members of the PIKK kinase family. 
5.1. Introduction. 
Complex organisms have developed many ways to respond to internal and external 
stimuli. One of the responses is phosphorylation of proteins and lipids. Enzymes that 
transfer the phosphate group are classed as kinases. At any given time in the cell cycle 
it has been estimated that one-third of all the proteins exists in a phosphorylated state. 
The great majority of kinases are serine/threonine kinases that phosphorylate their 
targets on serine residues and less often on threonine residues. Another, less 
numerous class, are tyrosine kinases phosphorylating their targets at tyrosine residues 
(Stryer, 1995). Human genome sequencing has revealed that kinases represent around 
2% of the genome (Amit et al., 2007). Phosphorylation is the most wide spread 
reversible post-translational modification. The process is carried out by hydrolyzing an 
ATP molecule to transfer its γ phosphate group onto serine, threonine or tyrosine 
residue. Only intracellular proteins are eligible for phosphorylation unlike extracellular 
ones (Stryer, 1995). 
The kinases involved in the initiation of the DNA damage response are members of the 
superfamily of PIKK kinases (phosphoinositide 3-kinase (PI3K) – related kinase) 
including ATM (ataxia telangiectasia-mutated), ATR (ATM and Rad3-related), DNA-PKcs 
(DNA-dependent protein kinase catalytic subunit), SMG1 (suppressor with 
morfogenetic effect on genitalia 1, also referred to as ATX), mTOR (mammalian target 
of rapamycin) and TRRAP (transformation/transcription domain-associated protein) 
which does not possess kinase activity. They are all large proteins whose domain 
structure shares similarities (Figure.5.1.).  
The N-terminal regions of the PIKK proteins contain HEAT (Huntingtin, Elongation 
factor 3, A subunit of protein phosphatase 2A and TOR1) repeats that are not very 
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conserved between these proteins. The C-terminal part contains the kinase domain or 
kinase-like domain in case of TRRAP. This domain is flanked by two conserved regions, 
FAT (FRAP, ATM, TRRAP) and FATC (FAT C-terminus). The FATC domain is necessary 
for the kinase activity of all PIKK family members apart from TRRAP and the precise 
function of the FAT domain remains to be elucidated (Lovejoy et al., 2009). The 
members of the family that possess the kinase activity share a common 
phosphorylation motif: SQ/TQ. The C-terminus of the PIKK kinases also contains the 
PRD region (PIKK regulatory domain) which is responsible for interaction with 
activating proteins: ATM-MRN, ATR-TopBP1 and DNA-PKcs-Ku70/80. The PRD region in 
case of SMG1 is atypically long and the activating protein for SMG1 has not been 
identified. 
 
Figure.5.1. The domain structure of the PIKK family members. HEAT repeats - 
Huntingtin, Elongation factor 3, A subunit of protein phosphatase 2A and TOR1; FAT - 
FRAP, ATM, TRRAP; PRD - PIKK regulatory domain; FATC - FAT C-terminus. 
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SMG1 is an essential component of the nonsense-mediated mRNA decay (NMD) 
pathway which is a surveillance mechanism for malfunctioning mRNAs. In this process 
mRNAs are checked for premature termination codons (PTCs) and if they are found to 
possess one, are directed for degradation. This process is orchestrated by SMG1. It has 
been suggested that SMG1, although involved in NMD, is able to respond to other 
external stimuli such as growth factors and environmental stress, such as IR or UV. 
Indeed, Abraham (2004) suggests that SMG1 function developed during metazoan 
evolution, from a protein with a main function in NMD into a protein that is an integral 
component of vertebrate stress-response pathways. SMG1 was shown to be activated 
by IR and UV irradiation (Brumbaugh et al., 2004). The siRNA depletion of SMG1 
causes constitutive activation of the Chk2 kinase and appearance of γ-H2AX foci in the 
absence of DNA damage. These observations suggest that the loss of SMG1 causes an 
inappropriate detection of genotoxic stress. SMG1 depleted cells also lose the potential 
to divide which resembles the loss of ATR kinase. These observations suggest a strong 
involvement of SMG1 in the maintenance of genome stability (Abraham, 2004). 
In this chapter I focused on CtIP and its ability to associate with kinases in multiprotein 
complexes. As shown in this chapter CtIP, when immunoprecipitated from cell lysates, 
pulls down kinase activity. This suggests that it plays a ‘scaffold role’ in 
phosphorylation processes carried out by those kinases. It is also revealed that CtIP 
associates with SMG1. CtIP’s sequence analysis showed two regions of homology with 
NBS1 C-terminal region, that is found to be responsible for interaction with ATM. This 
region has also been shown to be conserved among proteins that are activator proteins 
for other PIKK family members, namely ATRIP for ATR and Ku70/80 for DNA-PKcs 
(Falk et al., 2005). I suggest that CtIP might be a possible activator protein for the 
SMG1 kinase although further experiments are required to establish direct binding 
between CtIP and SMG1. 
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5.2. Results. 
5.2.1. Co-immunoprecipitation of active caffeine-sensitive kinases with CtIP. 
To investigate whether CtIP can co-immunoprecipitate with an active kinase and 
whether that kinase is caffeine sensitive, kinase assays were performed (section 
2.4.4.). LCLs were irradiated with 5Gy and harvested 30 min post irradiation or treated 
with 5mM caffeine for 30 min, subsequently irradiated with 5Gy and harvested 30 min 
post irradiation. A rabbit antibody was used to immunoprecipitate CtIP and associated 
kinases. Complexes were isolated with protein G-Sepharose beads which were 
resuspended in the kinase buffer after the last wash. GST-p53 (aa 1-73), GST-RPA32 
(aa 1-270) and GST were used as substrates for the kinase reaction. When GST-CtIP 
fragments were used as substrates sufficient protein equivalent to 10 µg of non-
degraded GST-tagged protein, assessed on the basis of a stained Coomassie blue 
stained gel (Figure.5.2.b.), was incubated with the protein G-Sepharose beads. 
For the kinase assay the protein G-sepharose beads were resuspended, after the last 
wash, in the kinase buffer with the addition of [32P]γ-ATP and incubated with the GST-
tagged protein at 37oC for 15 min. As an additional control protein G-Sepharose beads 
were incubated with the cell lysates alone, washed and then incubated with [32P]γ-ATP 
as described previously. The reaction was stopped by addition of Laemmli Sample 
Buffer, proteins were fractionated by SDS-PAGE and visualized by autoradiography. As 
shown in red in the Figure.5.2.a. CtIP has the ability to immunoprecipitate active 
kinases which are caffeine sensitive suggesting that it could be one or more PIKK 
kinases such as ATM and ATR. The bands in GST-p53 and GST-RPA tracks that are  
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Figure.5.2. CtIP immunoprecipitates kinase activity which is caffeine 
sensitive. a) LCLs were irradiated with 5Gy and a rabbit antibody was used to 
immunoprecipitate CtIP. Associated kinase activity was used to phosphorylate GST-
p53, GST-RPA32 or GST without or with addition of caffeine. Complexes were 
fractionated by SDS-PAGE and phosphorylation of the GST-tagged proteins was 
visualized by audioradiography, b) The SDS-PAGE gel stained with Coommassie 
Brilliant Blue showing the GST-tagged proteins used in this experiment. This figure is 
representative of three independent experiments. 
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phosphorylated in the reaction inhibited with caffeine as well as without caffeine are a 
possible product of nonspecific phosphorylation. The phosphorylation could also be 
carried out by other kinases, that are not caffeine sensitive, that could be potentially 
immunoprecipitated with the CtIP antibody. A potential substrate for those kinases 
could be the differentially spliced variants of GST-p53 and GST-RPA or bacterial 
proteins. 
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination (Figure 5.2.b.). 
In order to establish whether it is a pool of kinases or just ATM that is the active kinase 
associated with CtIP, another kinase assay was performed. HeLa cells depleted of ATM 
(established by stable transfection of shATM construct in a retroviral system resulting 
in ATM expression silencing, a generous gift from Grant Stewart) were lysed in TGN 
buffer (section 2.4.4.). A rabbit CtIP antibody was used to immunoprecipitate CtIP and 
associated kinases. Complexes were isolated with protein G-Sepharose beads and 
resuspended in the kinase buffer after the last wash. The equivalent of 10 µg of non-
degraded GST-tagged protein, assessed on the basis of previously stained Coomassie 
blue stained gel was used in each reaction. The GST-tagged protein used in the 
experiment was either GST-p53 (aa 1-73) or GST-RPA32 (aa 1-270) or GST-CtIP (aa 
327-897) or GST . As an additional control, protein G-Sepharose beads were incubated 
with the cell lysates alone and then incubated with [32P]γ-ATP. The kinase reaction was 
performed at 37oC for 15 min and stopped by addition of the Laemmli Sample Buffer. 
Complexes were fractionated by SDS-PAGE and the phosphorylation of GST-p53, GST-
RPA32 and GST-CtIP was visualized by autoradiography. As shown by the red circles in 
Figure.5.3.a. CtIP co-immunoprecipitates with active kinases apart from ATM as  
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indicated by still visible phosphorylation of CtIP as well as p53 and RPA32. Four bands 
marked with orange dots are results of nonspecific phosphorylation carried out by 
kinases that bind directly to the protein G-sepharose beads and phosphorylate proteins 
present in cell lysates used in the experiment.  
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination (Figure 5.3.b.). 
5.2.2. The phosphorylation of CtIP by kinases from the PIKK family and the 
association of CtIP with SMG1. 
To establish whether ATR and ATM phosphorylate CtIP in vitro a kinase assay was 
performed. LCLs were irradiated with 5Gy for the ATM kinase assay and harvested 30 
min post irradiation to allow for full ATM activation. LCLs for ATR kinase assay were 
harvested without irradiation. Mouse anti ATR or ATM antibodies were used to 
immunoprecipitate ATR or ATM respectively and the kinases were isolated with protein 
G-Sepharose beads. After the last wash the beads with associated kinase were 
resuspended in the kinase buffer and for each kinase, ATR or ATM, four different 
reactions were performed. As positive controls GST-p53 and GST-RPA32 were used as 
substrates. In each reaction the equivalent of 10 µg of non-degraded GST-tagged 
protein, assessed on the basis of previously stained Coomassie Brilliant Blue stained gel 
was used. The GST-tagged proteins used in the experiment were either GST-p53 (aa 
1-73), GST-RPA32 (aa 1-270), GST-CtIP (aa 327-897) or GST protein. Each reaction 
was supplemented with 1µl of [32P]γ-ATP. As an additional control protein G-Sepharose 
beads were incubated with the cell lysates alone and then incubated with 1µl of [32P]γ-
ATP. The kinase reaction was performed at 37oC for 15 min and was stopped with 
Laemmli Sample Buffer. Proteins were fractionated by SDS-PAGE and visualized by  
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Figure.5.4. ATR and ATM phosphorylate CtIP in vitro. a) LCLs were mock-
irradiated for ATR kinase assay and irradiated with 5Gy for ATM kinase assay and 
harvested 30 mins post irradiation. A mouse antibody against ATR or ATM was used to 
immunoprecipitate ATR or ATM respectively. Each kinase was used to phosphorylate 
GST-p53, GST-RPA32, GST-CtIP or GST alone. Complexes were fractionated by SDS-
PAGE and phosphorylation of GST-tagged proteins was visualized by audioradiography, 
b) The SDS-PAGE gel stained with Coommassie Billiant Blue showing the GST-tagged 
proteins used in the experiment. This figure is representative of three independent 
experiments. 
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autoradiography. As shown in the Figure.5.4.a. ATR and ATM kinases phoshorylate 
GST-CtIP protein as well as the positive controls: GST-p53 and GST-RPA32. CtIP is 
phosphorylated more efficiently by ATM rather than ATR, as well as p53. RPA32 is 
phosphorylated to a greater extent by ATR kinase. 
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein, 
alternatively spliced variants or bacterial-protein contamination (Figure 5.3.b.). 
5.2.2.1. CtIP binding to SMG1. 
In the previous chapter (section 4.2.1.2.) CtIP was shown to associate in vivo with two 
members of the PIKK kinase family: ATM and ATR (Figure.4.4.). In this section it was 
decided to establish whether CtIP associates with another member of that family, 
namely SMG1 also known as ATX.  
To establish the possible interaction, co-immunoprecipitation was performed (section 
2.4.2.). HeLa cells were mock-irradiated, irradiated with 5Gy or irradiated with 30J and 
harvested one hour post irradiation. A rabbit antibody was used to immunoprecipitate 
SMG1. Complexes were isolated with protein G-Sepharose beads, fractionated with 
SDS-PAGE and associated CtIP or RPA70 was visualized by Western blotting. As shown 
in the Figure.5.5. SMG1 associates with CtIP and RPA70 before and after DNA damage. 
The CtIP-SMG1 association appears to be enhanced by single stranded DNA lesions 
and the RPA70-SMG1 association is enhanced by DNA damage generally. As shown 
previously CtIP associates with RPA70 before and after DNA damage (Figure.4.1.). This 
could suggest that a SMG1-CtIP-RPA70 complex is involved in DNA damage sensing 
and repair alongside ATM and ATR.  
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Figure.5.5. The in vivo association of SMG1 with CtIP and RPA70. Hela cells 
were mock-irradiated or irradiated with 5Gy or 30J and harvested at the indicated time 
points. SMG1 was immunoprecipitated with a rabbit antibody and associated CtIP or 
RPA70 were visualized by Western blotting. In the right hand panel SMG1’s basal level 
is shown and β-actin indicates equal levels of total protein. This figure is representative 
of three consecutive repeats. 
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In order to investigate whether SMG1 phosphorylates CtIP, and whether that process is 
caffeine sensitive, a kinase assay was performed. LCLs were irradiated with 5Gy and 
harvested 30 min post irradiation or treated with 5mM caffeine for 30 min, 
subsequently irradiated with 5Gy and harvested 30 min post irradiation. A rabbit 
antibody was used to immunoprecipitate SMG1 and the kinase was isolated using 
protein G-Sepharose beads. The equivalent of 10 µg of non-degraded GST-tagged 
protein, assessed on the basis of previously stained Coomassie Brilliant Blue stained gel 
was used in each reaction. The GST-tagged proteins used in the experiment were 
either GST-p53 (aa 1-73), GST-RPA32 (aa 1-270), or GST-CtIP (aa 327-897).Each 
reaction was supplemented with 1µl of [32P] γ-ATP. As an additional control protein G-
Sepharose beads were incubated with the cell lysates alone and then incubated with 
1µl of [32P]γ-ATP. The reactions were stopped after 15 min by addition of Leamelli 
Sample Buffer. Complexes were fractionated by SDS-PAGE and phosphorylation of the 
GST-tagged proteins was visualized by autoradiography. As shown in red ovals in 
Figure.5.6.a. CtIP is phosphorylated by SMG1 to a limited extent compared to p53 and 
this process is caffeine sensitive. RPA32 does not appear to be an SMG1 
phosphorylation substrate. The pronounced band marked by the orange dot is possibly 
a product of a different kinase than SMG1 binding nonspecifically to the protein G-
Sepharose beads and phosphorylating a protein present in the cell lysates used in the 
experiment. 
Additional bands on the Coomassie Brilliant Blue stained gel, not marked by the red 
circles, are most likely a product of degradation of the originally GST-tagged protein or 
bacterial-protein contamination (Figure 5.6.b.). 
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Figure.5.6. CtIP is phosphorylated by SMG1 and the proccess is caffeine 
sensitive. a) LCLs were mock-treated or treated with 5mM caffeine and harvested 1 h 
post treatment. A rabbit antibody was used to immunoprecipitate SMG1 and the kinase 
was used to phosphorylate GST-p53, GST-RPA32, GST-CtIP and GST. Complexes were 
fractionated by SDS-PAGE and the phosphorylation of GST-tagged proteins was 
visualized by audioradiography, b) The SDS-PAGE gel stained with Coommassie 
Brilliant Blue showing the GST-tagged proteins used in the experiment. This figure is 
representative of three independent repeats. 
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5.2.3. Homology between CtIP and NBS1, ATRIP and Ku80. 
It has been reported that NBS1, ATRIP and Ku80 are homologous in their C-terminal 
regions which bind to ATM, ATR or DNA-PK respectively (Falk et al., 2005). The 
homologous region and the identical amino acids are shown in the Figure.5.7. As CtIP 
associates with ATM and ATR in vivo we carried out a sequence comparison between 
CtIP and NBS1 and found that CtIP shares homology with the NBS1 C-terminal region 
at two sites in the protein. These sites are situated between residues 267 and 284aa 
and 595 and 603aa, shown in the Figure.5.8.a. The first region is located before the 
BRCA1 binding site and the second one is located before the pair of ATM 
phosphorylation sites at S664 and S745 (Figure.5.8.b.). This result raised a possibility 
that CtIP could be a binding partner for SMG1 or other PIKKs in the same way as NBS1 
is to ATM, ATRIP to ATR and Ku70/80 to DNA-PKcs. It would be a very interesting new 
link in the DNA damage response pathways thus we decided to investigate this further. 
We obtained SMG1 siRNA and tried to decrease its expression but in the system used 
the experiment was not successful. As we could not obtain GST-SMG1 constructs or 
SMG1 constructs that would translate in vitro, we could not establish whether CtIP and 
SMG1 bind directly. I also could not establish optimal phosphorylation conditions for 
SMG1 antibody in HeLa cell lysates which were used to perform a kinase assay with 
CtIP knock-down to examine whether knock-down of CtIP influences the kinase activity 
of SMG1. 
Thus the question whether CtIP and SMG1 are direct binding partners taking part in 
the DNA damage response and CtIP affects SMG1 kinase activity remains to 
determined. 
  
 
Figure.5.7. The homology between the C-terminal region of NBS1, ATRIP 
and Ku80. The sequence alignment of the homologous regions of NBS1, ATRIP and 
Ku80 that bind to ATM, ATR and DNA-PK respectively (Falk et al., 2005).  
 
 
 
 
 
 
 
a) 
b)  
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Figure.5.8. The C-terminal region of NBS1 shows homology with two regions 
of CtIP. a) The sequence alignment the of C-terminal region of NBS1 with two regions 
of CtIP; residues highlighted in red are identical and residues highlighted in yellow are 
similar. b) A CtIP diagram showing the positions of the aligned sequences. 
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5.2.4. Establishing new phosphorylation sites on CtIP. 
CtIP was reported to be phosphorylated at S664 and S745 by Li S. et al. (Li et al., 
2000). Using amino acid sequence analysis it is predicted that there are five more 
potential phosphorylation sites (Figure.5.9.), which are consensus phosphorylation 
sites for PIKK kinase family members: SQ/TQ. It was decided to investigate in detail 
four of them. The investigation was dictated by the fact, that the full length GST-CtIP 
protein is unstable and the longest GST-CtIP protein available starts at 327aa. Thus to 
examine the phosphorylation pattern in the most physiologically relevant construct 
available GST-CtIP 327-897aa was chosen.  
To establish the importance of each SQ/TQ site site-directed mutagenesis was 
performed. DNA encoding CtIP 327-897aa cloned into pGex vector was used. Each 
serine or threonine followed by a glutamine residue, namely S506, S555, S679 or T859 
was mutated into an alanine. The S664 and S745 residues were mutated separately 
and together to serve as a control for this experiment. In each PCR reaction (section 
2.2.9.1.) a set of primers with a point mutation at the appropriate position was used so 
the PCR product would express an alanine instead of serine or threonine. Each 
mutated CtIP construct was sequenced (section 2.2.9.2.) and the mutated codons are 
shown in Figure.5.10. Mutated constructs were used to transform (section 2.2.2.) 
XL10-Gold Ultracompetent bacteria for small scale DNA preparation (section 2.2.3.2.) 
and subsequently BL21-CodonPlus (DE3)-RIL bacteria were transformed for mutated 
GST-CtIP protein production and purification (section 2.2.7.).  
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Figure.5.9. The positioning of new and reported phosphorylation site
human CtIP. The CtIP cartoon showing positions of reported: S664 and S74
new: S231, S506, S555, S679 and T859 phosphorylation sites. 
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From the PIKK family ATM was chosen as a model kinase involved in DNA DSBs 
response. A kinase assay was performed (section 2.4.4.) to investigate the influence of 
mutation in each SQ/TQ site, or two mutations in the case of S664 and S745, in one 
construct, on the in vitro phosphorylation of CtIP by ATM. LCLs were irradiated with 
5Gy and harvested 30 min post irradiation to allow for ATM full activation. A mouse 
antibody was used to immunoprecipitate ATM and the kinase was isolated using 
protein G-Sepharose beads. After the last wash the beads with bound ATM were 
resuspended in kinase buffer and to each portion of beads 10 µg of wild type GST-CtIP 
324-897aa or GST-CtIP 324-897aa mutant: S506A, S555A, S664A, S679A, S745A, 
S859A or S664A and S745A mutations together or GST alone was added and 
supplemented with 1 µl of [32P]γ-ATP. As an additional control protein G-Sepharose 
beads were incubated with the cell lysates alone and then incubated with 1µl of [32P]γ-
ATP. The kinase reaction was incubated at 37oC for 3 min and stopped by the addition 
of Laemmli Sample Buffer. Samples were heated to 95 oC for 5 min, fractionated by 
SDS-PAGE and phosphorylated GST-tagged proteins were visualized by 
autoradiography. As shown in the Figure.5.11. the phosphorylation of the wild type 
GST-CtIP is much more pronounced than phosphorylation of each of the mutated 
protein. The greatest reduction in phosphorylation was observed for the two previously 
described phosphorylation sites S664 and S745 mutated together. In the case of the 
proposed phosphorylation sites mutation in residue S555 gave the greatest reduction 
in the phosphorylation efficiency.  
A greater degree of specificity has been suggested with ATM preferentially 
phosphorylating LSQE and, to a lesser extent, LTQE (O’Neill et al., 2000). On the other 
hand the presence of adjacent positively charged residues next to neutral residues 
reduces the phosphorylation efficiency when the kinase assay is performed using a  
  
 
a) 
b)  Figure.5.11. The phosphorylation of GST-CtIP 327-897aa mutants. 
a) LCLs were irradiated with 5Gy and harvested 30 min post irradiation. A 
mouse antibody was used to immunoprecipitate ATM and the kinase was 
used to phosphorylate wild type GST-CtIP, GST-CtIP point mutants and GST. 
Complexes were fractionated by SDS-PAGE and the phosphorylation of GST-
tagged proteins was visualized by audioradiography, b) The SDS-PAGE gel 
stained with Coommassie Brilliant Blue showing the GST-tagged proteins used 
in the experiment. This figure is representative of three independent 
experiments.  207 
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GST-p53 fragment (Table.5.1; Kim et al., 1999). Amino acid sequence examination of 
residues adjacent to the predicted SQ/TQ phosphorylation sites reveals that these 
regions have different charges. Table.5.1. shows the amino acid composition of the 
SQ/TQ sites in the GST-p53 fragment (Kim et al., 1999) and the GST-CtIP fragments 
(this study), their surrounding residues and their charges. 
Table.5.1. Sequence of the p53 fragment used to establish the specificity of 
ATM kinase and established and predicted SQ/TQ phosphorylation sites in 
CtIP with their adjacent residues. 
GST-protein amino acid sequence a.a. charge 
p53 P(0)P(0)L(0)S(0)Q(0)E(-)T(0)F(0) 00000-00 
CtIP residue no.   
506 Q(0)E(-)K(+)S(0)Q(0)G(0)S(0)E(-) 0-+0000- 
555 E(-)P(0)C(0)S(0)Q(0)E(-)C(0)I(0) -0000-00 
664 A(0)D(-)L(0)S(0)Q(0)Y(0)K(+)M(0) 0-0000+0 
679 K(+)D(-)G(-)S(0)Q(0)S(0)K(+)L(0) +--000+0 
745 D(-)S(0)F(0)S(0)Q(0)A(0)A(0)D(-) -000000- 
859 F(0)P(0)S(0)T(0)Q(0)T(0)C(0)M(0) 00000000 
 
When we compare the charges of the adjacent residues with the phosphorylation 
efficiency in Figure.5.11. we can hypothesise that if the S residue is adjacent to one or 
two negatively charged amino acids that are on opposite sides of the S residue we can 
observe the greatest influence of that sequence on phosphorylation of that S residue. 
This is seen in Figure.5.11. as the greatest reduction of phosphorylation of S555, S664 
and S745. However if a positively charged residue or neutral  residues surround the 
predicted phosphorylation site we do not observe such a great impairment in the 
phosphorylation. This can be caused by the conformation of the protein enabling 
efficient phosphorylation of a particular residue. However it seems to be rather 
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important that the residue before S is hydrophobic (L or F in the case of CtIP; Kim et 
al., 1999) or that a negatively charged residue should follow the Q residue. Those two 
configurations give the best possible efficiency of ATM phosphorylation. However as 
seen in the case of S664 or S745 even the presence of just one of those sequence 
factors such as a hydrophobic residue (L or F) directs the S residue for efficient ATM 
phosphorylation. Thus in the case of S555 we could hypothesise that it is the E residue 
that influences the phosphorylation of this S by ATM. In the case of S506, S679 and 
T859 the amino acids that surround the phosphorylation site do not share many 
similarities with the described LSQE/LTQE sequence. For S506 it can be the positively 
charged K that lowers the efficiency of phosphorylation, S679 is next to two negatively 
charged residues which could influence the phosphorylation efficiency and T859 would 
not only have a default lower phosphorylation rate then S residue (Kim et al., 1999; 
O’Neill et al., 2000) but the adjacent residues are not very similar to the ones in the 
p53 sequence (Kim et al., 1999). Thus we could expect a smaller reduction in 
phosphorylation in comparison to non-mutated residues or none at all. 
5.3. Discussion. 
In the previous chapters CtIP was shown to form novel complexes with proteins 
involved in the DNA damage response pathways. In this chapter we analysed whether 
the complexes formed with the PIKK family kinases possess kinase activity when 
associated with CtIP. As shown in Figure.5.2.a. CtIP antibody co-immunoprecipitates a 
kinase activity that is able to phosphorylate GST-p53 fragment 1-73 containing three 
reported PIKK kinase phosphorylation sites (Siliciano et al., 1997) and GST-RPA32 that 
has been shown to be phosphorylated at several serine and threonine residues by the 
kinases from the PIKK family (Block et al., 2004; Manthey et al.,2007). The kinase 
activity immunoprecipitated by CtIP is caffeine sensitive which suggests that it is a 
member of the PIKK family or all of them complexed together. To establish whether it 
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is a pool of kinases or just ATM, CtIP was immunoprecitipated from HeLa cells depleted 
of ATM. As shown in Figure.5.3.a. CtIP associates with other PIKK kinases apart from 
ATM. This result suggests that CtIP forms complexes with possibly one or more PIKK 
kinases, apart from ATM, and those complexes have an ability to phosphorylate 
downstream targets such as p53, RPA32 or CtIP.  
CtIP was reported to be phosphorylated on S664 and S745 by ATM (Li et al., 2000). As 
shown in Figure.5.3.a. GST-CtIP protein is still phosphorylated even in the absence of 
ATM. Thus we decided to investigate whether it is phophorylated by ATR and SMG1. In 
Figure. 5.4.a. we can clearly observe phosphorylation of GST-CtIP by ATR and we 
compare it with almost the same level of phosphorylation performed by ATM. 
Figure.5.6.a. shows SMG1 phosphorylating GST-p53 and GST-CtIP to a limited extent. 
This process, as for all other PIKK family members, is caffeine sensitive. This suggests 
that CtIP can be phosphorylated in vivo by all members of the PIKK family. There is a 
possibility that each of the kinases has a preference for a specific site but this remains 
to be established. 
Protein phosphorylation is known to change protein conformation. The change in 
conformation may expose regions of the protein previously buried, for example in 
hydrophobic areas. Phosphorylation also changes the charge of a region of a protein 
which, in turn changes its folding (secondary/tertiary structure; Krupa et al., 2004). 
Protein phosphorylation also alters the specificity of protein-protein interactions. A wide 
range of DNA damage response proteins have domains that are known to specifically 
bind to phospho-peptides such as the FHA domain or the BRCT domains (Durocher & 
Jackson, 2002; Manke et al., 2003).  
The fact that CtIP is phosphorylated by several kinases may suggest that each of those 
kinases shows a preference towards a specific site. Thus depending on the type of 
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DNA damage CtIP could be phosphorylated at different sites, by differet kinases, which 
would result in different protein folding. Differential folding could effectively enable 
CtIP to bind different partners, thus it might engage  in different cellular processes. 
As shown previously CtIP associates with ATM and ATR and the complex formation is 
not influenced by DNA damage (Figure.4.3). Figure.5.5. demonstrates CtIP’s 
association with SMG1 kinase before and after DNA damage inflicted by 5Gy or 30J. 
The interaction appears to be stronger after SSBs. However, SMG1 also interacts with 
RPA70 and this interaction is enhanced by DNA damage, Figure.5.5. As shown 
previously CtIP interacts stably with RPA70 before and after damage (Figure.4.1.) and 
we could hypothesise that the SMG1-CtIP-RPA70 complex is involved in DNA damage 
sensing and repair. It is also possible, therefore, that CtIP does not bind SMG1 directly 
in vivo. 
As CtIP associates with SMG1 and SMG1 has not been reported to possess a binding 
partner that would associate with its PRD (PIKK regulatory domain, Figure.5.1.) motif it 
was decided to investigate this further. A sequence analysis of NBS1’s C-terminal ATM 
binding region aligned with the CtIP sequence showed two regions of homology. The 
first one is located between 267 and 284aa and the second is located between 595 and 
603aa (Figure.5.7.a.). The first region is located just N-terminal to the BRCA1 binding 
site and the second is located between two pairs of ATM phosphorylation sites: S506, 
S555 and S664, S745. If the binding region of CtIP-SMG1 was located between those 
phosphorylation sites CtIP binding could be modulated depending on which site is 
phosphorylated. Phosphorylation would change the conformation of the protein thus 
enhancing or decreasing the interaction, but this remains to be elucidated, as it was 
impossible to establish the direct interaction of SMG1 and CtIP. This was due to our 
inability to obtain SMG1 constructs that would either translate in vitro or would 
produce GST-SMG1 protein fragments. Due to lack of time it was also impossible to 
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create such constructs ourselves. Thus we can only speculate on CtIP being an 
activator protein for SMG1 kinase activity and binding to its PRD motif. It must also be 
borne in mind, however, that CtIP could bind primarily to ATM and/or ATR mediating 
an, as yet, unknown function. 
CtIP has been reported to be phosphorylated by ATM on residues S664 and S745 (Li . 
et al., 2000). Sequence analysis showed that there are five other S-T/Q motifs that 
could be potentially phosphorylated by members of the PIKK family. It was decided to 
mutate four of them as the most physiological GST-CtIP construct available did not 
include the first one, S231. As shown in Figure.5.11. immunoprecipitated ATM kinase 
phosphorylates the wild type GST-CtIP most effectively and the mutated species are all 
phosphorylated less efficiently. From the newly recognized phosphorylation sites it 
appears that S555 shows the greatest decrease in the phosphorylation efficiency after 
mutation. This may be due to the fact that it is a potential ATM phosphorylation site in 
vivo. On the other hand there is a possibility that if the phosphorylation assay was 
carried out using other PIKK kinases we would be able to establish phosphorylation 
sites specific for each kinase, but this remains to be elucidated. As has been reported it 
is difficult to establish site-specific phosphorylation using a phosphorylation assay, if 
the site can be recognized by different members of the same family of kinases 
(Temporini et al., 2008). As O’Neill et al. (2000) and Kim et al. (1999) report ATM, ATR 
and DNA-PK have different preferences towards SQ/TQ sites depending on the 
adjacent residues. Thus one could hypothesise that it would be of interest to perform 
the kinase assay shown in Figure.5.11. with other members of the PIKK family as well. 
However it seems that the best way to recognize a site and a kinase that 
phosphorylates it is by carrying out in vivo experiments. Possibly introducing mutated 
proteins into cells and knocking down the kinases and then looking at the 
phosphorylation profile of the protein either by phosphospecific antibodies or mass 
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spectrophotometry (Jowsey et al., 2007). This approach was beyond available time for 
this project. 
 
 214 
 
 
CHAPTER VI 
GENERAL DISCUSSION 
 
 
Possible roles for CtIP in the cellular DNA 
damage response. 
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6.1. Research on CtIP in a historical perspective. 
CtIP was first described as a binding partner of CtBP, Rb and BRCA1 (Fusco et al., 
1998, Schaeper et al., 1998; Yu et al., 1998). Thus the initial research focused on 
exploring how CtIP and its binding partners act together to regulate transcription and 
the cell cycle. The research that we undertook was based on the observation that CtIP 
binds to the BRCT domains of BRCA1 (Wong et al., 1998, Yu et al., 1998).  
BRCA1 was known, not only to be involved in the cell cycle regulation, but also was 
recognized as a tumour suppressor gene (Hakem et al., 1996; Hall et al., 1990; Miki et 
al., 1994). It was later shown to be involved in homologous recombination together 
with Rad51 (Baumann et al. 1996; Scully et al., 1997a) and this has led to 
investigations into BRCA1’s involvement in the DNA damage response (Moynahan et 
al., 1999). As CtIP was a BRCA1 binding partner investigation was initiated into CtIP’s 
involvement in the DNA damage response and this work has been presented here.  
In a review in 2006 Chinnadurai described CtIP as a ‘team player with luminaries’ such 
as tumour supressors BRCA1 and Rb. By the middle of 2006 Wu & Lee had described 
CtIP as a ‘multivalent adaptor’ taking part in transcriptional regulation, DNA damage 
response and cell cycle checkpoint regulation. Previous studies had concentrated on 
the regulation of Rb activity by CtIP. However, also in 2006, a different report 
appeared, showing BRCA1/BARD1 DNA damage-induced association with the MRN 
complex and TopBP1 (Greenberg et al., 2006). It was possibly a milestone in the 
research into CtIP function.  
In late 2007 Jackson’s lab published a first paper on CtIP’s function in the DNA end 
resectioning (Sartori et al., 2007) and CtIP’s importance became apparent to a larger 
audience. Now CtIP is thought to be indispensible in ssDNA end creation, DSBR, HR 
and MMEJ.  
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6.2. CtIP involvement in the initiation of DNA damage response by the MRN 
complex. 
In the course of this study we established, at the same time as Jackson’s lab, that CtIP 
forms a complex and binds directly to the MRN complex. However, our data indicate 
that CtIP binds directly to NBS1 rather than Mre11 or Rad50 when they are expressed 
separately (Figure.3.13., Figure.3.14., Figure.4.2.). As Sartori et al. (2007) show, CtIP 
binds directly to a complex formed by Mre11 and Rad50, which does not exclude the 
possibility that it does not bind to them separately as they may form a binding site for 
CtIP by their complex formation. However, considering our data and Sartori’s et al. 
results one could postulate that CtIP is an integral part of the MRN complex. To 
investigate this matter further, we performed co-immunoprecipitation assays from cells 
that are defective either in Mre11 (ATLD patient-derived LCLs) or NBS1 (NBS patient-
derived LCLs). The ATLD patient-derived LCLs express a truncated version of Mre11, 
lacking the second DNA binding motif (DNA binding B, Figure.1.6. & Figure.4.9). The 
NBS patient-derived LCLs express two NBS1 proteins: p26, containing the FHA domain 
and the first BRCT domain and p70, comprising the C-terminal region of the protein 
starting with the second BRCT domain (Figure.4.10). The results revealed that CtIP 
associates with the members of the complex despite mutations in either Mre11 or 
NBS1, although the level of association of CtIP with NBS1 and Rad50 is compromised 
by the mutation of Mre11 in ATLD LCLs (Figure.4.11.).  
An interesting observation was also made, showing that CtIP’s association with ATM is 
compromised in NBS1 mutated cells and in ATLD cells, which show a lower level of 
NBS1 expression due to the Mre11 mutation (Figure.4.11.a.; Stewart et al., 1999). This 
would suggest that ATM associates with CtIP via NBS1 indicating that CtIP would not 
be necessary for ATM activation by the MRN complex. 
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In a recent article, Yuan & Chen (2009) demonstrated that the MRN complex is one of 
the first sensors of DNA damage. They report that, in cells depleted of H2AX, 53BP1 
IRIF formation is still present upon DNA damage although retention of those foci is not 
longer than 120 mins. Further, they have shown that 53BP1 and BRCA1 transient foci 
formation in H2AX-depleted cells depends on the presence of NBS1 and Mre11.  
Yuan & Chen (2009) also point out, that cells depleted of ATM (Barlow et al., 1996), 
MDC1 (Lou et al., 2006), 53BP1 (Manis et al., 2004; Ward et al., 2004) or H2AX 
(Celeste  et al., 2002) are still viable whereas mice knock-outs of the MRN complex 
(Luo et al., 1999; Zhu J. et al., 2001; Xiao Y.& Weaver D. T., 1997), CtIP (Chen et al., 
2005), ATR (Brown & Baltimore, 2000; de Klein et al., 2000), BRCA1 (Ludwig et al., 
1997), BRCA2 (Sharan et al., 1997) and Rad51 (Tsuzuki et al., 1996) show embryonic 
lethality. However, the key finding in this article is the transient formation of IRIF in 
the absence of H2AX that is stimulated by the MRN complex. This suggests that the 
DNA damage response is initiated by the MRN complex protein-protein interaction 
resulting in foci formation. Yuan & Chen also suggest that NBS1 could be a binding 
partner for 53BP1 but I would hypothesise that CtIP is the missing link in the transient 
formation of IRIF at the sites of DNA damage preformed by MRN.  
CtIP seems to be a scaffold that binds to a variety of factors and interacts in vivo with 
an even larger number of proteins. It seems reasonable to propose that Mre11 and 
Rad50 are the factors that bind broken DNA ends. Mre11 also binds to NBS1 which 
could facilitate complex protein-protein interactions. To enlarge the spectrum of 
possible interactions NBS1 would bind CtIP, which in this setting, would mainly serve 
as a docking station for other proteins, that are involved in the DNA damage repair. 
This transient complex could repair the damage that would arise from low doses of UV 
before the phosphorylation of H2AX would occur and before ATM or ATR would be 
recruited to the repair process. Thus we could speculate, on the basis of the Yuan & 
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Chen (2009) report, that low level DNA damage is readily repaired by MRN/CtIP 
transient IRIF formation and formation of γ-H2AX/MDC1 dependent foci is the next 
step in the repair process, that is activated in the case of more severe damage. Those 
foci are long-lived and also contain 53BP1 and BRCA1 and other proteins that are 
involved in the transient foci formation. On the basis of this deduction it would be 
interesting to look at TopBP1 transient foci formation as well as the efficiency of their 
formation in CtIP-depleted cells. 
6.3. Implication of CtIP interaction with the BRCT domain containing 
proteins in transient IRIF formation. 
In support of the hypothesis described above, in chapter III I have shown that CtIP 
binds directly to a number of BRCT domain-containing proteins involved in the DNA 
damage response such as MDC1, 53BP1, TopBP1 and NBS1. Thus the model of the 
transient IRIF formation I would propose is the recruitment of MRN/CtIP to the sites of 
damage and subsequent concentration of 53BP1, BRCA1 and possibly MDC1 and 
TopBP1. In the case of more severe damage ATM would be recruited and subsequently 
phosphorylate H2AX which in turn recruits MDC1 which forms a firm, anchored scaffold 
with γ-H2AX and MRN/CtIP. This scaffold recruits other DNA repair proteins. The latter 
process is not CtIP dependent as MDC1 anchors itself to chromatin mainly via γ-H2AX. 
As shown in Figure.3.24. depletion of CtIP does not interfere with MDC1 γ-H2AX-
dependent foci formation and their retention. It is also indicated by normal formation 
of 53BP1 foci in CtIP-depleted cells (Figure.3.23.). 
However, CtIP has been reported to be ubiquitylated by BRCA1/BARD E3 Ub-protein 
ligase (Yu et al., 2006). This results in CtIP’s relocalization to the sites of DNA damage; 
however further investigations are needed to resolve this pathway of DNA damage 
recognition and repair (Figure.1.19.). 
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Furthermore, CtIP in the later stages of the DNA damage response, after the 
engagement of γ-H2AX and its dependent foci formation, could orchestrate the repair 
events due to its ability to form protein multicomplexes by its wide range of protein-
protein interactions. As it binds directly to TopBP1 we could propose that by this 
interaction it engages ATR in DSBR. We could also hypothesise that CtIP-TopBP1 
interaction could be involved in TopBP1 transient foci formation but this remains to be 
investigated. 
As shown in Figures: 3.18, 3.20 and 3.22. CtIP is a nuclear protein that in normal cells 
shows a slightly granular distribution which changes after DNA damage caused by IR 
into distinct structures resembling foci. In those Figures we can observe, in yellow, the 
overlap of CtIP staining with foci formed by 53BP1, MDC1 and NBS1. We can also 
conclude that as 53BP1, MDC1 and NBS1 foci colocalize with γ-H2AX (Figures: 3.17, 
3.19 and 3.21) CtIP’s staining would also overlap γ-H2AX foci. Thus it is possible that 
CtIP concentrates at the sites of DSBs to facilitate formation of protein complexes by 
proteins that are involved in the DNA damage repair response. Thus CtIP could be 
potentially involved in transient foci assembly with the MRN complex as well as 
facilitating DNA damage repair triggered by phosphorylation of γ-H2AX. 
6.4. CtIP involvement in the DNA repair pathway choice. 
CtIP has been also shown to be involved in the selection of the appropriate DNA 
damage repair pathway together with BRCA1 (Yun & Hiom, 2009). That report reveals 
that CtIP, by interaction with BRCA1 in G2/M, redirects DNA repair towards HR. As CtIP 
interacts with MDC1, Figure.3.5.b., we could argue that this interaction may favour HR 
in G2/M as MDC1 is involved in controlling HR, although this pathway is distinct from 
the BRCA1 pathway. Thus CtIP could redirect repair in G2/M towards HR by two 
different mechanisms involving either BRCA1 or MDC1. In case of failure one of the 
pathways the other would still be able to repair the damage. 
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As mentioned before, CtIP’s interaction with both NBS1 and 53BP1 could be involved in 
the formation of the temporary foci. Furthermore, CtIP could be involved in the DNA 
damage pathway that those proteins take part in. In the case of NBS1 it could be the 
MMEJ (Deriano et al., 2009), thus CtIP could potentially redirect the repair in G1 
towards MMEJ. NBS1 has also been reported to be involved in phosphorylation events 
orchestrated by ATR such as phosphorylation of RPA32 (Manthey et al., 2007). As CtIP 
is involved in phosphorylation events directed by ATR (Figure.4.14, Figure.4.16), NBS1 
and CtIP could be potentially cooperating in that repair mechanism.  
NBS1 has also been reported to interact with TopBP1 via its N-terminal region 
containing the FHA and the BRCT domain. This interaction in vivo has an irradiation 
dose-dependent character (Morishima et al., 2007). This would agree with the previous 
hypothesis that CtIP/MRN could involve TopBP1 in the repair processes, in the 
transient foci formation, in the case of local DNA damage cause by a low doses of UV. 
In the case of γ-H2AX foci formation and subsequent IRIF formation of other DNA 
damage response proteins, like 53BP1, CtIP/MRN would be engaged in the retention of 
those foci occurring in the presence of severe DNA damage. Secondly, Morishima et al. 
(2007) report that NBS1 and TopBP1 are involved in HR which would imply that the 
ATR pathway together with CtIP could be involved in HR as well.  
6.5. Influence of CtIP depletion on phosphorylation events caused by DNA 
damage. 
As shown in the Figure.4.16.and Figure.4.18., CtIP is involved in ATR signaling. A 
major impairment of the phosphorylation of proteins such as RPA32 or Chk1 in 
response to DNA damage caused by 30J or CPT in CtIP-depleted cells shows that CtIP 
is either involved in enabling the interaction between ATR and its substrates or it 
stimulates ATR kinase activity together with TopBP1.  
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The effect of CtIP depletion on phosphorylation events following DNA damage caused 
by 5Gy, 30J or CPT is shown in Figures:4.15. to 4.19. As expected CtIP depletion has a 
minor effect on phosphorylation of such proteins as NBS1, ATM, SMC1 or H2AX which 
in response to 5Gy of γ-irradiation are regulated by ATM kinase activity initiated by the 
MRN complex (Lee & Paull, 2005). As mentioned before, CtIP-ATM association is most 
likely mediated by NBS1 (Figure.4.11.a.), thus we could conclude that CtIP has virtually 
no effect on ATM’s activation and subsequent phosphorylation of ATM targets. In the 
case of 53BP1 phosphorylation on S1778, which has not been reported as an ATM 
phosphorylation site (Jowsey et al., 2007), we suggest that it is phosphorylated by 
ATR. As Yoo et al. (2007) report, ATR is activated in response to IR (but not replication 
stress) by ATM phosphorylation of S1131 on TopBP1 thus it would not need CtIP for 
the activation process. If 53BP1 S1778 was a true ATR phosphorylation site it could still 
be phosphorylated even in the absence of CtIP as ATR would be activated by ATM. The 
other possibility is that S1778 on 53BP1, in response to IR, is phosphorylated by ATM 
as ATR and ATM belong to the same kinase family thus share a consensus 
phosphorylation site. Furthermore ATM is recognized as a main kinase in DSB response 
thus there is a likelihood that ATM would phosphorylate ATR targets in response to 
DSBs. 
Stiff et al. (2006) report that ATR activates ATM after SSBs and replication fork stalling. 
If ATR is not activated efficiently in response to UV irradiation, as in the case of CtIP 
depletion, it cannot efficiently activate ATM. Figure.4.17. shows an impairment of the 
phosphorylation of ATM targets, namely NBS1 and ATM, in the absence of CtIP. This 
suggests that in cells depleted of CtIP ATR is not effectively activated, thus in the 
presence of SSBs caused by UV irradiation or replication fork stalling ATR is unable to 
activate ATM efficiently. The same effect, but even more pronounced, is observed in 
Figure.4.19. where those proteins’ phosphorylation is severely impaired in CtIP-
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depleted cells treated with CPT. This suggests that CtIP, apart from facilitating 
phosphorylation performed by ATR, could be an enhancer of ATR’s kinase activity in 
the presence of SSBs and collapsed replication forks. Sartori et al., report that after 
SSBs or replication fork stalling in cells lacking CtIP the phosphorylation of RPA32 and 
Chk1 is impaired (Sartori et al., 2007). Figure.4.16.&4.18. show the same result. This 
confirms that CtIP is required for efficient phosphorylation of ATR targets.  
Figure.4.17.shows no significant influence of CtIP depletion on SMC1 phosphorylation 
after UV, which is the target of ATM. SMC1 is also phosphorylated less in response to 
UV-irradiation as compared to γ-irradiation. We could hypothesise that there is no 
significant reduction of SMC1 phosphorylation in CtIP-depleted cells and this may be 
due to ATR’s basal activity present in normal cells and in cells depleted of CtIP which 
would be the major factor phosphorylating SMC1 in response to UV. Kim et al. (2002) 
show SMC1 as a major ATM target in response to IR (Kim et al., 2002). On the other 
hand, it is still phosphorylated in ATM-depleted cells in response to UV and replication 
fork stalling in an ATR-dependent manner. These authors also report that SMC1 is 
phosphorylated in cells lacking DNA-PK thus suggesting that phosphorylation of SMC1 
is DNA-PK independent (Kim et al., 2002). On the basis of this report we suggest that 
basal activity of ATR is sufficient to activate a portion of ATM in response to UV and 
replication fork stalling. This would also explain the lack of reduction in H2AX 
phosphorylation following DNA damage caused by IR, UV and CPT in CtIP depleted 
cells. 
6.6. ATR phosphorylation of the BRCT region of 53BP1 containing S1778. 
Figure.4.20. shows that ATR phosphorylates (in vitro) a GST-53BP1 fragment 
containing the S1778 site - thus we could speculate that it actually is an ATR 
dependent phosphorylation site. On the other hand, that GST-53BP1 fragment contains 
one more SQ motif, S1943, that could be phosphorylated by ATR. Furthermore I also 
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established that CtIP depletion reduces the ability of ATR to associate with 53BP1 in 
vivo, Figure.4.21. Thus we could hypothesise that impaired phosphorylation of 53BP1 
in cells lacking CtIP is due to a reduced ability of ATR to associate with 53BP1 and 
subsequently efficiently phosphorylate it in the absence of CtIP. 
6.7. CtIP’s multiprotein complex formation. 
As shown in chapter IV, CtIP associates in vivo with the MRN complex, RPA70 
(Figure.4.1.), ATM, ATR (Figure.4.4.), 53BP1 (Figure.4.6.) and MDC1 (Figure.4.7.). The 
interactions are not influenced either by DSBs or SSBs. We conclude that CtIP forms a 
stable complex with these proteins similarly to BRCA1, which forms a BASC complex 
(Wang et al., 2000). Alternatively, as CtIP binds directly to BRCA1 (Wong et al., 1998) 
it is possible that CtIP could broaden the spectrum of activity of the BASC complex by 
recruiting its other binding partners to it (Figure.4.22.). However further investigation 
into CtIP’s complex formation ability is needed to establish an exact role for CtIP in 
mediating protein interactions.  
Another aspect of this issue is that CtIP is able to form complexes with the MRN 
complex components even in the case of either NBS1 or Mre11 mutation, Figure.4.11. 
Furthermore, in excess, CtIP has the ability to compete Mre11 off NBS1, Figure.4.14. 
This would suggest that this interaction has a dynamic nature and that, depending on 
the metabolic circumstances of the cell, could change to perform different activities.  
CtIP is associated with the MRN complex and appears to be involved in different 
processes such as DNA end resectioning in DSBR or removing covalently bound Top1 
and Top2 from ssDNA ends in SSBR (Hartsuiker et al., 2009; Sartori et al., 2007). 
Engagement in two such distinct processes suggests that the MRN/CtIP may impinge 
on both DSBR and SSBR. Thus it could lead us to a conclusion that CtIP could be 
closely associated with the MRN complex and could be involved in modulating its 
protein-protein binding ability. 
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As mentioned before, this could also apply to the MRN transient foci formation and 
recruitment of 53BP1 or BRCA1 that would be potentially recruited by direct interaction 
with CtIP (Hartsuiker et al., 2009). 
We also investigated CtIP’s association with BLM helicase. BLM is known to associate 
with 53BP1 in response to replication fork collapse caused by HU treatment (Tripathi et 
al., 2007). BLM is thought to regulate HR by modulating the functions of proteins that 
are involved in that process as well as being a component of the BASC complex (Wang 
et al., 2000; Wu et al., 2001). Thus, the fact that it associates with CtIP after HU 
treatment (Figure.4.20) may suggest another possible mechanism in which CtIP is 
engaged in HR. Thus, we might speculate, that CtIP takes part in homologous 
recombination events on several different levels. Firstly being involved in redirecting 
the repair towards HR together with BRCA1 in S/G2 (Yun & Hiom, 2009) and possibly 
by similar mechanism with MDC1, as discussed previously. Secondly it could be 
involved in HR together with BLM enlarging its spectrum of protein-protein interactions. 
CtIP forms complexes with PIKK kinases as described in chapter V. This suggests that 
it possibly could orchestrate phosphorylation events by its binding ability with other 
proteins that are substrates for those kinases. Perhaps by choosing a binding partner 
and directing it for phosphorylation CtIP would orchestrate the sequence of events 
during the DNA damage response. However, it seems more likely that CtIP organizes 
the phosphorylation cascade in response to SSB or replication fork collapse which is 
indicated by the impairment of the phosphorylation of such proteins as ATM, NBS1 and 
53BP1 in response to 30J of UV or CPT treatment (Figure.4.15.&4.16). 
6.8. Recognition of new ATM phosphorylation sites on CtIP. 
CtIP itself undergoes phosphorylation by members of the PIKK family, namely by ATM, 
ATR and to less extent, SMG1. Each of those kinases can potentially have a preference 
for specific SQ/TQ sites on CtIP. If that was the case, CtIP could be phosphorylated by 
 
 225 
each of them at a different residue or each of the kinases could phosphorylate a 
different set of sites at each time. Depending on which residue would be 
phosphorylated it would differentially change the conformation of CtIP protein. The 
different folding of the CtIP protein could enable it to interact with a different set of 
binding partners in response to different genotoxic insults. This ability would be very 
useful taking into consideration the spectrum of activities that CtIP is involved in. Thus 
CtIP’s activity would depend on the type of damage and the kinase activated by it. 
6.9. CtIP sequence homology with the conserved C-terminal region of NBS1. 
The C-terminal region of NBS1 that is responsible for interaction with the ATM kinase 
and its subsequent activation (Falk et al., 2005) has two regions of homology with 
CtIP, Figure.5.7. Thus it is possible that CtIP might be an activator of SMG1 kinase 
activity, by binding to its PRD motif, however this remains to be investigated as the 
kinase assay with CtIP knock-down cells was not optimized to obtain any significant 
results. 
The interplay between the DNA damage response proteins reveals a very complicated 
network. It seems that most of the proteins involved in the DNA damage response are 
somehow interlinked with each other. This forms a very sophisticated web of 
connections where protein posttranslational modifications play a key role.  
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